{"4ea6fc2ea38f9ae6e1791645a1761d7f996149a2": [["IntroductionCoronaviruses are a large family of viruses that can cause severe illness to the human being.", [["illness", "DISEASE", 78, 85], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 12, 25], ["human", "ORGANISM", 93, 98], ["human", "SPECIES", 93, 98], ["human", "SPECIES", 93, 98], ["severe illness", "PROBLEM", 71, 85]]], ["The first known severe epidemic is Severe Acute Respiratory Syndrome (SARS) occurred in 2003, whereas the second outbreak of severe illness began in 2012 in Saudi Arabia with the Middle East Respiratory Syndrome (MERS).", [["Acute Respiratory Syndrome", "DISEASE", 42, 68], ["SARS", "DISEASE", 70, 74], ["illness", "DISEASE", 132, 139], ["Respiratory Syndrome", "DISEASE", 191, 211], ["Severe Acute Respiratory Syndrome", "PROBLEM", 35, 68], ["SARS", "PROBLEM", 70, 74], ["severe illness", "PROBLEM", 125, 139], ["the Middle East Respiratory Syndrome", "PROBLEM", 175, 211], ["severe", "OBSERVATION_MODIFIER", 16, 22], ["epidemic", "OBSERVATION_MODIFIER", 23, 31], ["Severe", "OBSERVATION_MODIFIER", 35, 41], ["Acute", "OBSERVATION_MODIFIER", 42, 47], ["Respiratory Syndrome", "OBSERVATION", 48, 68], ["severe", "OBSERVATION_MODIFIER", 125, 131], ["illness", "OBSERVATION", 132, 139], ["Middle", "ANATOMY_MODIFIER", 179, 185], ["Respiratory Syndrome", "OBSERVATION", 191, 211]]], ["The current outbreak of illness due to coronavirus is reported in late December 2019.", [["illness", "DISEASE", 24, 31], ["coronavirus", "DISEASE", 39, 50], ["coronavirus", "ORGANISM", 39, 50], ["illness", "PROBLEM", 24, 31], ["coronavirus", "PROBLEM", 39, 50]]], ["This new virus is very contagious and has quickly spread globally.", [["This new virus", "PROBLEM", 0, 14], ["new", "OBSERVATION_MODIFIER", 5, 8], ["virus", "OBSERVATION", 9, 14], ["very", "OBSERVATION_MODIFIER", 18, 22], ["contagious", "OBSERVATION_MODIFIER", 23, 33], ["quickly", "OBSERVATION_MODIFIER", 42, 49], ["spread", "OBSERVATION_MODIFIER", 50, 56], ["globally", "OBSERVATION_MODIFIER", 57, 65]]], ["On March 11, as the number of COVID-19 cases has increased thirteen times apart from China with more than 118,000 cases in 114 countries and over 4,000 deaths, WHO declared this a pandemic.IntroductionAs the outbreak of the COVID-19 has become a worldwide pandemic, the real-time analyses of epidemiological data are needed to prepare the society with better action plans against the disease.", [["deaths", "DISEASE", 152, 158], ["COVID-19", "CHEMICAL", 224, 232], ["COVID", "TEST", 30, 35], ["the COVID", "TEST", 220, 229], ["a worldwide pandemic", "PROBLEM", 244, 264], ["epidemiological data", "TEST", 292, 312], ["the disease", "PROBLEM", 380, 391]]], ["Since the birth of novel COVID-19 [1] , the world is restlessly fighting with its cause.", [["novel COVID", "TEST", 19, 30]]], ["COVID-19 belongs to the family of the SARS-CoV and MERS-CoV, where it begins with the initial level symptoms of the common cold to severe level of respiratory diseases causing difficulty in breathing, tiredness, fever, and dry cough [3] .", [["respiratory", "ANATOMY", 147, 158], ["SARS", "DISEASE", 38, 42], ["respiratory diseases", "DISEASE", 147, 167], ["difficulty in breathing", "DISEASE", 176, 199], ["tiredness", "DISEASE", 201, 210], ["fever", "DISEASE", 212, 217], ["dry cough", "DISEASE", 223, 232], ["COVID-19", "GENE_OR_GENE_PRODUCT", 0, 8], ["SARS-CoV", "ORGANISM", 38, 46], ["MERS-CoV", "ORGANISM", 51, 59], ["COVID-19", "DNA", 0, 8], ["SARS-CoV", "SPECIES", 38, 46], ["MERS-CoV", "SPECIES", 51, 59], ["the initial level symptoms", "PROBLEM", 82, 108], ["respiratory diseases", "PROBLEM", 147, 167], ["difficulty in breathing", "PROBLEM", 176, 199], ["tiredness", "PROBLEM", 201, 210], ["fever", "PROBLEM", 212, 217], ["dry cough", "PROBLEM", 223, 232], ["respiratory diseases", "OBSERVATION", 147, 167]]], ["Prasad et al. [4] observed that the identification of the virus can be improved by imaging using immunoelectron microscopy techniques [5] .", [["the virus", "PROBLEM", 54, 63], ["imaging", "TEST", 83, 90], ["immunoelectron microscopy techniques", "TEST", 97, 133]]], ["Figure 1 shows the typical structure of COVID-19 virus, from the throat swab of the first Indian laboratory-confirmed case, captured using sample electron microscopy imaging.", [["throat swab", "ANATOMY", 65, 76], ["COVID-19 virus", "ORGANISM", 40, 54], ["COVID-19 virus", "SPECIES", 40, 54], ["COVID", "TEST", 40, 45], ["the throat swab", "TEST", 61, 76], ["sample electron microscopy imaging", "TEST", 139, 173], ["throat", "ANATOMY", 65, 71]]], ["Till date, detailed morphology and ultrastructure of this virus remain incompletely understood, and there are no specific vaccines or treatments for COVID-19.", [["this virus", "PROBLEM", 53, 63], ["specific vaccines", "TREATMENT", 113, 130], ["treatments", "TREATMENT", 134, 144], ["COVID", "TEST", 149, 154]]], ["However, many ongoing clinical trials are evaluating potential treatments.COVID-19 transmission stagesAs per the WHO reports [5] , the pandemic situation is classified into four stages.", [["potential treatments", "TREATMENT", 53, 73]]], ["The first stage begins with the cases reported for the people who travelled in already affected regions, whereas in the second stage, cases are reported locally among family, friends and others who came into contact with the person arriving from the affected regions.", [["people", "ORGANISM", 55, 61], ["people", "SPECIES", 55, 61], ["person", "SPECIES", 225, 231]]], ["At this point the affected people are traceable.", [["people", "ORGANISM", 27, 33], ["people", "SPECIES", 27, 33], ["traceable", "OBSERVATION", 38, 47]]], ["Later, the third stage makes the situation even worse as the transmission source becomes untraceable and spreads across the individuals who neither have any travel history nor came into contact with the affected person.", [["person", "SPECIES", 212, 218]]], ["Figure 2 , presents the outbreak of COVID-19 across the nations with the high number of confirmed cases such as US, Italy, Spain, and China based on the WHO reports [3] , whereas figure 3 illustrates the rising characteristic of the number of confirmed, death, and recovered cases in these nations between the period January 22, 2020, to April 1, 2020, taken from Johns Hopkins live dashboard.", [["death", "DISEASE", 254, 259], ["COVID", "TEST", 36, 41]]], ["The worst of all, stage 4 beings when the transmission becomes endemic and uncontrollable.", [["endemic", "PROBLEM", 63, 70], ["uncontrollable", "PROBLEM", 75, 89], ["endemic", "OBSERVATION_MODIFIER", 63, 70], ["uncontrollable", "OBSERVATION", 75, 89]]], ["Figure 4 presents the complete stages of the COVID-19 epidemic.", [["the COVID", "TEST", 41, 50], ["epidemic", "PROBLEM", 54, 62]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.COVID-19 transmission stages(which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.08.20057679 doi: medRxiv preprint it is claimed that the origin of the virus is Wuhan, China [6] ; it affects the other developed countries (USA, Italy, Spain, Britain, etc.).", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["COVID", "TEST", 161, 166], ["The copyright holder", "TREATMENT", 219, 239], ["this preprint", "TREATMENT", 244, 257], ["medRxiv", "TREATMENT", 309, 316], ["med", "ANATOMY", 105, 108], ["virus", "OBSERVATION", 363, 368]]], ["These countries are now in stage 4 of the transmission and facing more number of infections and deaths compared to China.", [["infections", "DISEASE", 81, 91], ["deaths", "DISEASE", 96, 102], ["infections", "PROBLEM", 81, 91], ["infections", "OBSERVATION", 81, 91]]], ["In the case of China, it is observed that exponential growth of the confirmed cases reaches the saturation stage where the number of cases stopped growing.", [["exponential", "OBSERVATION_MODIFIER", 42, 53], ["growth", "OBSERVATION_MODIFIER", 54, 60]]], ["This follows from the fact that the number of susceptible people, which are exposed to virus, are dramatically reduced.", [["people", "ORGANISM", 58, 64], ["people", "SPECIES", 58, 64], ["virus", "PROBLEM", 87, 92], ["virus", "OBSERVATION", 87, 92], ["dramatically", "OBSERVATION_MODIFIER", 98, 110], ["reduced", "OBSERVATION_MODIFIER", 111, 118]]], ["This was made possible due to the reduced social contact among people by segregating the infected individuals in quarantine and a complete lockdown period was initiated by the Chinese government, thereby reducing the possibility of further spread.COVID-19 transmission stagesMachine learning algorithms play an important role in epidemic analysis and forecasting [7] , [8] .", [["people", "ORGANISM", 63, 69], ["people", "SPECIES", 63, 69], ["further spread", "PROBLEM", 232, 246], ["COVID", "TEST", 247, 252], ["epidemic analysis", "TEST", 329, 346]]], ["In the presence of massive epidemic data, the machine learning techniques help to find the epidemic patterns so that the early action can be planned to stop the spread of the virus.", [["massive epidemic data", "PROBLEM", 19, 40], ["the machine learning techniques", "TREATMENT", 42, 73], ["the virus", "PROBLEM", 171, 180], ["massive", "OBSERVATION_MODIFIER", 19, 26], ["epidemic", "OBSERVATION", 27, 35]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not peer-reviewed)The copyright holder for this preprint . https://doi.org/10.1101/2020.04.08.20057679 doi: medRxiv preprint ing and deep learning models are used to observe everyday behaviour along with the prediction of future reachability of the COVID-2019 across the nation by utilizing the real-time information from the Johns Hopkins dashboard.(which was not peer-reviewed)Rest of the paper is organised as follows: section 2 contains a brief discussion on existing machine learning based approaches, whereas section 3 talks about the dataset used for experiments.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 190, 210], ["this preprint", "TREATMENT", 215, 228], ["medRxiv preprint ing", "TREATMENT", 280, 300], ["deep learning models", "TREATMENT", 305, 325], ["existing machine", "TREATMENT", 635, 651], ["med", "ANATOMY", 105, 108], ["deep", "ANATOMY_MODIFIER", 305, 309]]], ["Epidemic analysis and experimental strategy are discussed in section 4 and 5 respectively, whereas results are discussed in section 6.", [["Epidemic analysis", "TEST", 0, 17], ["experimental strategy", "TREATMENT", 22, 43]]], ["Concluding remarks and future work are discussed in section 6.Related workSince the last decade, digital technologies are playing critical roles in major health sector problems including disease prevention, the present worldwide health emergency also seeking technological support to tackle COVID-2019.", [["disease prevention", "TREATMENT", 187, 205]]], ["In a paper, authors highlighted the possible applications of trending digital technologies such as internet of things (IoT), big-data analytics, artificial intelligence (AI), deep learning and blockchain technology to develop strategies for monitoring, detection and prevention of epidemic; and also to identify the impact of the epidemic to the healthcare sector [9] .", [["trending digital technologies", "TREATMENT", 61, 90], ["artificial intelligence (AI)", "PROBLEM", 145, 173], ["blockchain technology", "TREATMENT", 193, 214], ["monitoring", "TEST", 241, 251], ["epidemic", "PROBLEM", 281, 289]]], ["In this paper, the author forecasted the various parameters for the next 2 days based on the study about the prevalence and incidence of the COVID-2019.", [["the study", "TEST", 89, 98], ["the COVID", "TEST", 137, 146]]], ["This research work also demonstrates the correlogram and ARIMA forecast graph for the epidemic incidence and prevalence.Related workDeb et al. [11] proposed a time series method to analyze incidence pattern and the estimated reproduction number of COVID-19 outbreak.", [["a time series method", "TREATMENT", 157, 177], ["incidence pattern", "PROBLEM", 189, 206], ["COVID", "TEST", 248, 253]]], ["They performed statistical analysis to explore the trends of the outbreak to highlight the present epidemiological stage of a region so that various policies can be identified to address COVID-19 pandemic in different countries cite11.", [["COVID-19", "ORGANISM", 187, 195], ["statistical analysis", "TEST", 15, 35], ["COVID", "TEST", 187, 192]]], ["As per the present situation, it is essential to understand the early spread patterns of the infection to plan and control the effective safety measures.", [["infection", "DISEASE", 93, 102], ["the infection", "PROBLEM", 89, 102], ["infection", "OBSERVATION", 93, 102]]], ["In this direction, Kucharski et al. proposed a scientific model of critical SARS-CoV-2 transmission by using different datasets to study the COVID-19 outbreak inside and outside Wuhan.", [["CoV-2", "ORGANISM", 81, 86], ["critical SARS", "PROBLEM", 67, 80], ["the COVID", "TEST", 137, 146]]], ["With this, they explored the possible spread of disease outbreak outside Wuhan [12] .Related workRecently there are several studies conducted on the epidemiological outbreak of COVID-19 using exploratory data analysis (EDA) based on various available datasets.", [["several studies", "TEST", 116, 131], ["COVID", "TEST", 177, 182], ["exploratory data analysis", "TEST", 192, 217]]], ["The studies mainly focus on the occurrence of confirmed, death, and recovered cases in Wuhan and the rest of the world to understand the suspected threats and subsequent planning of containment activities [13] .", [["death", "DISEASE", 57, 62], ["The studies", "TEST", 0, 11]]], ["Lauer et al., in their research work raised the issue of the criticality of the incubation period for COVID-19.", [["COVID-19", "CHEMICAL", 102, 110], ["COVID", "TEST", 102, 107]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not peer-reviewed)The copyright holder for this preprint . https://doi.org/10.1101/2020.04.08.20057679 doi: medRxiv preprint on this better surveillance and control activities can be planned [14] .", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 190, 210], ["this preprint", "TREATMENT", 215, 228], ["medRxiv", "TREATMENT", 280, 287], ["med", "ANATOMY", 105, 108]]], ["The research highlighted that the location-specific rate of disease spread follows either steady or explosive power-law growth with different scaling exponents.", [["disease spread", "PROBLEM", 60, 74], ["different scaling exponents", "PROBLEM", 132, 159], ["disease", "OBSERVATION", 60, 67], ["law growth", "OBSERVATION_MODIFIER", 116, 126], ["different", "OBSERVATION_MODIFIER", 132, 141], ["scaling", "OBSERVATION_MODIFIER", 142, 149], ["exponents", "OBSERVATION_MODIFIER", 150, 159]]], ["Based on the above literature, it is evident that sufficient work is available on exploratory data analysis to understand the existing trend of the epidemic but still there is a lot of scopes to develop and test efficient machine learning based prediction models so that proactive strategies could be identified to cater the immediate needs.Dataset descriptionThe day to day prevalence data of COVID-2019 from January 22, 2020, to April 1, 2020, were retrieved from the official repository of Johns Hopkins University.", [["exploratory data analysis", "TEST", 82, 107], ["proactive strategies", "TREATMENT", 271, 291]]], ["In the present study, we have taken time-series summary tables in CSV format having three tables for confirmed, death and recovered cases of COVID-2019 with six attributes i.e. province/state, country/region, last update, confirmed, death and recovered cases, where the update frequency of the dataset is once in a day [2] .", [["death", "DISEASE", 112, 117], ["death", "DISEASE", 233, 238]]], ["Figure 5 presents the COVID-19 confirmed, recovered, and death cases distribution across the world since the time data was recorded.", [["death", "DISEASE", 57, 62], ["the COVID", "TEST", 18, 27], ["the time data", "TEST", 105, 118]]], ["It is easy to observe the exponential growth of the spread which needs to be controlled.Epidemic AnalysisThe COVID-19 spread has brought the world under the brink of loss of human lives due to which it is of utmost importance to analyze the transmission growth at the earliest and forecast the forthcoming possibilities of the transmission.", [["loss of human lives", "DISEASE", 166, 185], ["human", "ORGANISM", 174, 179], ["human", "SPECIES", 174, 179], ["human", "SPECIES", 174, 179], ["the spread", "PROBLEM", 48, 58], ["Epidemic Analysis", "TEST", 88, 105], ["The COVID", "TEST", 105, 114], ["exponential", "OBSERVATION_MODIFIER", 26, 37], ["growth", "OBSERVATION_MODIFIER", 38, 44]]], ["With this objective, state-of-the-art mathematical models are adopted based on machine learning such as support vector regression (SVR) [16] and polynomial regression (PR) [17] , and deep learning regression models such as a standard deep neural network (DNN) and recurrent neural networks (RNN) using long short-term memory (LSTM) cells [18] .", [["neural networks", "ANATOMY", 274, 289], ["LSTM) cells", "ANATOMY", 326, 337], ["neural network", "MULTI-TISSUE_STRUCTURE", 239, 253], ["neural networks", "MULTI-TISSUE_STRUCTURE", 274, 289], ["LSTM) cells", "CELL", 326, 337], ["RNN", "CELL_LINE", 291, 294], ["long short-term memory (LSTM) cells", "CELL_LINE", 302, 337], ["the-art mathematical models", "TREATMENT", 30, 57], ["support vector regression", "TREATMENT", 104, 129], ["SVR", "TEST", 131, 134], ["polynomial regression (PR)", "PROBLEM", 145, 171], ["deep learning regression models", "PROBLEM", 183, 214], ["a standard deep neural network", "TREATMENT", 223, 253], ["recurrent neural networks", "PROBLEM", 264, 289], ["deep", "ANATOMY_MODIFIER", 183, 187], ["neural networks", "OBSERVATION", 274, 289]]], ["Machine learning and deep learning approaches are implemented using the python library \"sklearn\" and \"keras\" respectively, to predict the total number of confirmed, recovered, and death cases worldwide.", [["death", "DISEASE", 180, 185]]], ["The prediction will allow undertaking the necessary decisions based on transmission growth such as increasing the lockdown period, executing the sanitation procedure, providing the everyday resources, etc.Epidemic Analysis.", [["the sanitation procedure", "TREATMENT", 141, 165], ["Epidemic Analysis", "TEST", 205, 222]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not peer-reviewed)The copyright holder for this preprint . https://doi.org/10.1101/2020.04.08.20057679 doi: medRxiv preprintTraining and testingThe regression approaches for epidemic analysis are trained and tested on realtime data [2] using the number of confirmed, recovered, and death cases as the label for the corresponding day.", [["CC", "CHEMICAL", 0, 2], ["death", "DISEASE", 454, 459], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 190, 210], ["this preprint", "TREATMENT", 215, 228], ["medRxiv", "TREATMENT", 280, 287], ["epidemic analysis", "TEST", 346, 363], ["realtime data", "TEST", 390, 403], ["med", "ANATOMY", 105, 108]]], ["With extensive experiments, machine learning approaches are implemented with the polynomial kernel of degree 6 and other coefficient values as gamma=0.01, epsilon=1, and C=0.1.", [["machine learning approaches", "TREATMENT", 28, 55], ["other coefficient values", "TEST", 115, 139], ["gamma", "TEST", 143, 148], ["epsilon", "TEST", 155, 162], ["C", "TEST", 170, 171]]], ["The standard DNN consists of a dense input layer with 128 neurons, three hidden dense layers with 256 neurons and output layer is consists of a single neuron whereas the RNN, consists of three stacks of LSTM layers having 64 neurons combined with 10% dropout to avoid the overfitting problem and final output layer with a single neuron.", [["neurons", "ANATOMY", 58, 65], ["neurons", "ANATOMY", 102, 109], ["neuron", "ANATOMY", 151, 157], ["RNN", "ANATOMY", 170, 173], ["neurons", "ANATOMY", 225, 232], ["neuron", "ANATOMY", 329, 335], ["neurons", "CELL", 58, 65], ["layers", "TISSUE", 86, 92], ["neurons", "CELL", 102, 109], ["LSTM layers", "TISSUE", 203, 214], ["neurons", "CELL", 225, 232], ["DNN", "DNA", 13, 16], ["RNN", "PROTEIN", 170, 173], ["a dense input layer", "PROBLEM", 29, 48], ["the overfitting problem", "PROBLEM", 268, 291], ["dense", "OBSERVATION_MODIFIER", 31, 36], ["input", "OBSERVATION_MODIFIER", 37, 42], ["layer", "OBSERVATION_MODIFIER", 43, 48], ["dense", "OBSERVATION_MODIFIER", 80, 85], ["layers", "OBSERVATION_MODIFIER", 86, 92], ["output", "OBSERVATION_MODIFIER", 114, 120], ["layer", "OBSERVATION_MODIFIER", 121, 126], ["overfitting", "OBSERVATION", 272, 283]]], ["The mean squared error (MSE) is the most widely used objective function and root mean square error (RMSE) as a metric function for evaluating the regression models.", [["a metric function", "TEST", 109, 126], ["the regression models", "TEST", 142, 163]]], ["The MSE loss can be computed by using equation 1.Training and testingwhere y indicates the original value,\u0177 indicates the predicted value, and N is the number of samples predicted.Training and testingDue to the limited availability of the data, the trained models are validated against the training data and then utilized to forecast the number of confirmed, recovered, and death cases for the next 10 days.Results and discussionThe discussed machine learning and deep learning approaches output the possible number of cases for the next 10 days across the world.", [["death", "DISEASE", 374, 379], ["The MSE loss", "PROBLEM", 0, 12], ["Training and testing", "TEST", 180, 200], ["the training data", "TEST", 286, 303], ["MSE loss", "OBSERVATION", 4, 12]]], ["Figure 6 illustrates the predicted trend of the COVID-19 using SVR, PR, DNN, and LSTM with worldwide data.", [["COVID-19", "DNA", 48, 56], ["PR", "PROTEIN", 68, 70], ["the COVID", "TEST", 44, 53], ["SVR", "TEST", 63, 66], ["PR", "TEST", 68, 70], ["worldwide data", "TEST", 91, 105]]], ["Table 1 indicates the RMSE score of the approaches computed against the available number of COVID-19 cases.", [["COVID", "TEST", 92, 97]]], ["It is also observed that training of LSTM model is heavily dependent on the deviation in the values, with the fact that larger the deviation more the time it takes to train.", [["heavily dependent", "PROBLEM", 51, 68], ["larger the deviation", "PROBLEM", 120, 140], ["heavily", "OBSERVATION_MODIFIER", 51, 58], ["dependent", "OBSERVATION_MODIFIER", 59, 68], ["larger", "OBSERVATION_MODIFIER", 120, 126]]], ["Hence, the number of cases were scaled using minmax scaler to fit the LSTM model and later the predicted cases were rescaled to the original range using invert minmax transform from \"sklearn\" python library.", [["minmax scaler", "TREATMENT", 45, 58], ["the LSTM model", "TEST", 66, 80], ["invert minmax transform", "TREATMENT", 153, 176]]], ["Among these approaches, the visual representation of the prediction from figure 6 and RMSE score as highlighted in table 1 confirms the PR approach as the best fit to follow the growing trend.ConclusionThe world is under the grasp of SARS-CoV2 (COVID-19) virus.", [["SARS", "DISEASE", 234, 238], ["SARS-CoV2", "ORGANISM", 234, 243], ["COVID-19) virus", "ORGANISM", 245, 260], ["PR", "PROTEIN", 136, 138], ["SARS-CoV2 (COVID-19) virus", "SPECIES", 234, 260], ["RMSE score", "TEST", 86, 96], ["the PR approach", "TREATMENT", 132, 147], ["SARS", "TEST", 234, 238], ["COVID", "TEST", 245, 250], ["virus", "PROBLEM", 255, 260]]], ["This article proposed to utilize the machine learning and deep learning models for epidemic analysis using data from Johns Hopkins dashboard.", [["the machine learning", "TREATMENT", 33, 53], ["epidemic analysis", "TEST", 83, 100]]], ["The results show that polynomial regression (PR) yielded a minimum root mean square error .", [["polynomial regression (PR)", "PROBLEM", 22, 48], ["root", "OBSERVATION_MODIFIER", 67, 71], ["mean square", "OBSERVATION", 72, 83], ["error", "OBSERVATION", 84, 89]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Conclusion(which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.08.20057679 doi: medRxiv preprint (RMSE) score over other approaches in forecasting the COVID-19 transmission.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["this preprint", "TREATMENT", 226, 239], ["med", "ANATOMY", 105, 108]]], ["However, if the spread follows the predicted trend of the PR model then it would lead to huge loss of lives as it presents the exponential growth of the transmission worldwide.", [["PR", "PROTEIN", 58, 60], ["huge loss of lives", "PROBLEM", 89, 107], ["exponential", "OBSERVATION_MODIFIER", 127, 138], ["growth", "OBSERVATION_MODIFIER", 139, 145]]], ["As observed from China, this growth of the COVID-19 can be reduced and quenched by reducing the number of susceptible individuals from the infected individuals.", [["COVID-19", "CHEMICAL", 43, 51], ["COVID-19", "DNA", 43, 51], ["the COVID", "TEST", 39, 48], ["susceptible individuals", "PROBLEM", 106, 129], ["the infected individuals", "PROBLEM", 135, 159], ["infected", "OBSERVATION", 139, 147]]], ["The study can further be extended to utilize other machine learning and deep learning models.Conclusion.", [["The study", "TEST", 0, 9], ["other machine learning", "TREATMENT", 45, 67], ["deep learning models", "TREATMENT", 72, 92]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Conclusion(which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.08.20057679 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["this preprint", "TREATMENT", 226, 239], ["medRxiv", "TREATMENT", 291, 298], ["med", "ANATOMY", 105, 108]]]], "PMC7442438": [], "e7886534b2fa86c414f229a3c08ec683deace134": [["IntroductionNecrotizing enterocolitis (NEC) is a devastating neonatal disease with rapid onset which affects 6% of all premature infants .'", [["Necrotizing enterocolitis", "DISEASE", 12, 37], ["NEC", "DISEASE", 39, 42], ["infants", "ORGANISM", 129, 136], ["infants", "SPECIES", 129, 136], ["Necrotizing enterocolitis", "PROBLEM", 12, 37], ["NEC", "PROBLEM", 39, 42], ["a devastating neonatal disease", "PROBLEM", 47, 77], ["Necrotizing", "OBSERVATION_MODIFIER", 12, 23], ["enterocolitis", "OBSERVATION", 24, 37], ["devastating", "OBSERVATION_MODIFIER", 49, 60], ["neonatal", "OBSERVATION_MODIFIER", 61, 69], ["disease", "OBSERVATION", 70, 77], ["rapid", "OBSERVATION_MODIFIER", 83, 88], ["onset", "OBSERVATION_MODIFIER", 89, 94]]], ["Twenty to forty per cent of these cases are fatal, representing a major contribution to the mortality of premature infants who survive early respiratory distress .", [["respiratory", "ANATOMY", 141, 152], ["respiratory distress", "DISEASE", 141, 161], ["infants", "ORGANISM", 115, 122], ["infants", "SPECIES", 115, 122], ["premature infants", "PROBLEM", 105, 122], ["early respiratory distress", "PROBLEM", 135, 161], ["fatal", "OBSERVATION", 44, 49], ["respiratory distress", "OBSERVATION", 141, 161]]], ["In addition, surviving babies with post-operative short bowel syndrome or malabsorption frequently suffer prolonged hospitalization and costly care .' 3 No single theory for the pathogenesis of NEC has been proven .", [["bowel", "ANATOMY", 56, 61], ["short bowel syndrome", "DISEASE", 50, 70], ["malabsorption", "DISEASE", 74, 87], ["NEC", "DISEASE", 194, 197], ["babies", "ORGANISM", 23, 29], ["bowel", "ORGAN", 56, 61], ["NEC", "CANCER", 194, 197], ["post-operative short bowel syndrome", "PROBLEM", 35, 70], ["malabsorption", "PROBLEM", 74, 87], ["NEC", "PROBLEM", 194, 197], ["bowel", "ANATOMY", 56, 61], ["syndrome", "OBSERVATION", 62, 70], ["NEC", "OBSERVATION", 194, 197]]], ["These include prematurity,\" enteral feeding 5 .6 and enteric bacteria .\"", [["prematurity", "DISEASE", 14, 25], ["prematurity", "PROBLEM", 14, 25], ["\" enteral feeding", "TREATMENT", 26, 43], ["enteric bacteria", "PROBLEM", 53, 69], ["prematurity", "OBSERVATION", 14, 25]]], ["There is no good experimental evidence to suggest that injury to the intestinal mucosa results primarily from a vascular insult .' 910 There is also no compelling clinical evidence that the initial intestinal injury results from ischemia, as postulated by several investigators in earlier studies .2,111 13 It also has become clear that NEC is not a single disease entity, but rather a pathophysiological syndrome with many precipitants .IntroductionNumerous outbreaks of NEC have been detected in recent years .", [["intestinal mucosa", "ANATOMY", 69, 86], ["vascular", "ANATOMY", 112, 120], ["intestinal", "ANATOMY", 198, 208], ["injury to the intestinal mucosa", "DISEASE", 55, 86], ["vascular insult", "DISEASE", 112, 127], ["intestinal injury", "DISEASE", 198, 215], ["ischemia", "DISEASE", 229, 237], ["NEC", "DISEASE", 337, 340], ["NEC", "DISEASE", 472, 475], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 69, 86], ["vascular", "MULTI-TISSUE_STRUCTURE", 112, 120], ["intestinal", "ORGAN", 198, 208], ["NEC", "PATHOLOGICAL_FORMATION", 337, 340], ["NEC", "CANCER", 472, 475], ["injury to the intestinal mucosa", "PROBLEM", 55, 86], ["a vascular insult", "PROBLEM", 110, 127], ["the initial intestinal injury", "PROBLEM", 186, 215], ["ischemia", "PROBLEM", 229, 237], ["earlier studies", "TEST", 281, 296], ["NEC", "PROBLEM", 337, 340], ["a single disease entity", "PROBLEM", 348, 371], ["a pathophysiological syndrome", "PROBLEM", 384, 413], ["NEC", "PROBLEM", 472, 475], ["no", "UNCERTAINTY", 9, 11], ["injury", "OBSERVATION", 55, 61], ["intestinal mucosa", "ANATOMY", 69, 86], ["vascular", "ANATOMY", 112, 120], ["insult", "OBSERVATION", 121, 127], ["no compelling", "UNCERTAINTY", 149, 162], ["intestinal", "ANATOMY", 198, 208], ["injury", "OBSERVATION", 209, 215], ["ischemia", "OBSERVATION", 229, 237], ["clear", "OBSERVATION", 326, 331], ["NEC", "OBSERVATION", 337, 340], ["single", "OBSERVATION_MODIFIER", 350, 356], ["disease", "OBSERVATION", 357, 364], ["pathophysiological syndrome", "OBSERVATION", 386, 413], ["Numerous", "OBSERVATION_MODIFIER", 450, 458], ["outbreaks", "OBSERVATION_MODIFIER", 459, 468], ["NEC", "OBSERVATION", 472, 475]]], ["The fact that instituting infection control measures is always effective in terminating such outbreaks strongly suggests the involvement of an infectious agent under certain conditions .\"", [["infection", "DISEASE", 26, 35], ["instituting infection control measures", "TREATMENT", 14, 52], ["an infectious agent", "PROBLEM", 140, 159], ["infection", "OBSERVATION", 26, 35], ["infectious", "OBSERVATION", 143, 153]]], ["Bacteria most often associated with the disease are Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae and Clostridia species .\"", [["Escherichia coli", "ORGANISM", 52, 68], ["Klebsiella pneumoniae", "ORGANISM", 70, 91], ["Enterobacter cloacae", "ORGANISM", 93, 113], ["Escherichia coli", "SPECIES", 52, 68], ["Klebsiella pneumoniae", "SPECIES", 70, 91], ["Enterobacter cloacae", "SPECIES", 93, 113], ["Escherichia coli", "SPECIES", 52, 68], ["Klebsiella pneumoniae", "SPECIES", 70, 91], ["Enterobacter cloacae", "SPECIES", 93, 113], ["Bacteria", "PROBLEM", 0, 8], ["the disease", "PROBLEM", 36, 47], ["Escherichia coli", "PROBLEM", 52, 68], ["Klebsiella pneumoniae", "PROBLEM", 70, 91], ["Enterobacter cloacae", "PROBLEM", 93, 113], ["Clostridia species", "PROBLEM", 118, 136], ["Escherichia coli", "OBSERVATION", 52, 68], ["Klebsiella pneumoniae", "OBSERVATION", 70, 91], ["Enterobacter cloacae", "OBSERVATION", 93, 113], ["Clostridia species", "OBSERVATION", 118, 136]]], ["\" Evidence for such association is strongest for K. pneumonia, 18 and weakest for Clostridia species .", [["pneumonia", "DISEASE", 52, 61], ["K. pneumonia", "SPECIES", 49, 61], ["K. pneumonia", "SPECIES", 49, 61], ["K. pneumonia", "PROBLEM", 49, 61], ["Clostridia species", "PROBLEM", 82, 100], ["pneumonia", "OBSERVATION", 52, 61]]], ["A possible role for Clostridium difficile toxin in NEC has been disproven .' 9 22 Other epidemiological studies have implicated viruses (e .g .", [["Clostridium difficile", "DISEASE", 20, 41], ["NEC", "DISEASE", 51, 54], ["Clostridium difficile toxin", "ORGANISM", 20, 47], ["NEC", "PATHOLOGICAL_FORMATION", 51, 54], ["Clostridium difficile toxin", "PROTEIN", 20, 47], ["Clostridium difficile", "SPECIES", 20, 41], ["Clostridium difficile", "SPECIES", 20, 41], ["Clostridium difficile toxin", "PROBLEM", 20, 47], ["NEC", "PROBLEM", 51, 54], ["Other epidemiological studies", "TEST", 82, 111], ["viruses", "PROBLEM", 128, 135], ["possible role for", "UNCERTAINTY", 2, 19], ["viruses", "OBSERVATION", 128, 135]]], ["Rotavirus, Coronavirus and Coxsackie B2 virus) .' 4 .23 ' 24 These epidemiological associations are suggestive but do not prove that the implicated organism really causes the disease .", [["Rotavirus", "DISEASE", 0, 9], ["Rotavirus", "ORGANISM", 0, 9], ["Coxsackie B2 virus", "ORGANISM", 27, 45], ["Coxsackie B2 virus", "SPECIES", 27, 45], ["Coxsackie B2 virus", "SPECIES", 27, 45], ["Rotavirus", "PROBLEM", 0, 9], ["Coronavirus", "TEST", 11, 22], ["Coxsackie B2 virus", "TEST", 27, 45], ["the implicated organism", "PROBLEM", 133, 156], ["the disease", "PROBLEM", 171, 182], ["disease", "OBSERVATION", 175, 182]]], ["The situation is further complicated by the fact that all these organisms can be part of the normal flora in neonates .", [["neonates", "ORGANISM", 109, 117], ["all these organisms", "PROBLEM", 54, 73], ["normal", "OBSERVATION_MODIFIER", 93, 99], ["flora", "OBSERVATION", 100, 105]]], ["A solid theory for infectious pathogenicity of NEC therefore awaits the identification of those special pathogenic traits which distinguish bacterial strains isolated from NEC patients from those of normal flora .IntroductionIn a recent study on the intraluminal biochemistry of neonates with NEC, the occurrence of this disease was associated with low intraluminal pH (<5) and with the presence of large amounts of undigested protein (usually casein) and carbon source (usually lactose) in the bowel .", [["intraluminal", "ANATOMY", 353, 365], ["bowel", "ANATOMY", 495, 500], ["NEC", "DISEASE", 47, 50], ["NEC", "DISEASE", 172, 175], ["NEC", "DISEASE", 293, 296], ["lactose", "CHEMICAL", 479, 486], ["carbon", "CHEMICAL", 456, 462], ["lactose", "CHEMICAL", 479, 486], ["NEC", "PATHOLOGICAL_FORMATION", 47, 50], ["patients", "ORGANISM", 176, 184], ["intraluminal", "IMMATERIAL_ANATOMICAL_ENTITY", 250, 262], ["neonates", "ORGANISM", 279, 287], ["intraluminal", "IMMATERIAL_ANATOMICAL_ENTITY", 353, 365], ["lactose", "SIMPLE_CHEMICAL", 479, 486], ["bowel", "ORGAN", 495, 500], ["undigested protein", "PROTEIN", 416, 434], ["patients", "SPECIES", 176, 184], ["NEC", "PROBLEM", 47, 50], ["those special pathogenic traits", "PROBLEM", 90, 121], ["bacterial strains", "PROBLEM", 140, 157], ["NEC patients", "PROBLEM", 172, 184], ["a recent study", "TEST", 228, 242], ["NEC", "PROBLEM", 293, 296], ["this disease", "PROBLEM", 316, 328], ["low intraluminal pH", "PROBLEM", 349, 368], ["large amounts of undigested protein", "PROBLEM", 399, 434], ["infectious", "OBSERVATION_MODIFIER", 19, 29], ["NEC", "OBSERVATION", 47, 50], ["normal flora", "OBSERVATION", 199, 211], ["NEC", "OBSERVATION", 293, 296], ["disease", "OBSERVATION", 321, 328], ["large", "OBSERVATION_MODIFIER", 399, 404], ["amounts", "OBSERVATION_MODIFIER", 405, 412], ["undigested protein", "OBSERVATION", 416, 434], ["bowel", "ANATOMY", 495, 500]]], ["25 It was further shown\" that inoculation of a rabbit ileal loop with casein and organic acids at pH 4 .0 resulted in hemorrhagic necrotic intestine .", [["ileal", "ANATOMY", 54, 59], ["necrotic intestine", "ANATOMY", 130, 148], ["casein and organic acids", "CHEMICAL", 70, 94], ["pH 4 .0", "CHEMICAL", 98, 105], ["hemorrhagic necrotic", "DISEASE", 118, 138], ["rabbit", "ORGANISM", 47, 53], ["ileal loop", "MULTI-TISSUE_STRUCTURE", 54, 64], ["casein", "SIMPLE_CHEMICAL", 70, 76], ["organic acids", "SIMPLE_CHEMICAL", 81, 94], ["necrotic intestine", "ORGAN", 130, 148], ["rabbit", "SPECIES", 47, 53], ["rabbit", "SPECIES", 47, 53], ["a rabbit ileal loop with casein", "TREATMENT", 45, 76], ["organic acids", "TEST", 81, 94], ["pH", "TEST", 98, 100], ["hemorrhagic necrotic intestine", "PROBLEM", 118, 148], ["hemorrhagic", "OBSERVATION_MODIFIER", 118, 129], ["necrotic", "OBSERVATION", 130, 138], ["intestine", "ANATOMY", 139, 148]]], ["This observation led to the conclusion that low pH, in combination with undigested casein a known chemotactic agent for polymorphonuclear leukocytes 26 may be responsible for the initial intestinal injury which triggers the disease .", [["polymorphonuclear leukocytes", "ANATOMY", 120, 148], ["intestinal", "ANATOMY", 187, 197], ["intestinal injury", "DISEASE", 187, 204], ["casein", "GENE_OR_GENE_PRODUCT", 83, 89], ["polymorphonuclear leukocytes 26", "CELL", 120, 151], ["intestinal", "ORGAN", 187, 197], ["polymorphonuclear leukocytes", "CELL_TYPE", 120, 148], ["low pH", "PROBLEM", 44, 50], ["undigested casein", "TREATMENT", 72, 89], ["polymorphonuclear leukocytes", "PROBLEM", 120, 148], ["the initial intestinal injury", "PROBLEM", 175, 204], ["the disease", "PROBLEM", 220, 231], ["low pH", "OBSERVATION_MODIFIER", 44, 50], ["may be responsible for", "UNCERTAINTY", 152, 174], ["intestinal", "ANATOMY", 187, 197], ["injury", "OBSERVATION", 198, 204]]], ["Following the initial intestinal injury, a variety of bacteria present in normal flora may contribute to the subsequent necrosis of the intestine .IntroductionTaken together, these findings suggest that bacteria with an unusual ability to rapidly ferment undigested lactose may contribute to the initial intestinal injury in NEC, by causing an abnormally low pH in the ileum and the colon .\"\"\" 18 This idea is already supported by a variety of observations : 90 to 95% of neonates developing NEC have been fed prior to the onset of the disease ;\"\"\"' there is an increased lactose concentration in stools of infants prior to the onset of NEC ; 30 intraluminal gas typical of NEC is 30% hydrogen, and enteric bacteria from these patients make hydrogen only in the presence of milk ; 31 increased D-lactate found in the urine of NEC patients is also evidence of vigorous bacterial fermentation ; 32 and excess infant formula-a breast milk substitute-is maladsorbed, passes to the colon and serves as substrate for colonic bacterial flora .", [["intestinal", "ANATOMY", 22, 32], ["flora", "ANATOMY", 81, 86], ["intestine", "ANATOMY", 136, 145], ["intestinal", "ANATOMY", 304, 314], ["NEC", "ANATOMY", 325, 328], ["ileum", "ANATOMY", 369, 374], ["colon", "ANATOMY", 383, 388], ["milk", "ANATOMY", 774, 778], ["urine", "ANATOMY", 817, 822], ["breast milk", "ANATOMY", 924, 935], ["colon", "ANATOMY", 977, 982], ["colonic", "ANATOMY", 1011, 1018], ["intestinal injury", "DISEASE", 22, 39], ["necrosis", "DISEASE", 120, 128], ["lactose", "CHEMICAL", 266, 273], ["intestinal injury", "DISEASE", 304, 321], ["NEC", "DISEASE", 325, 328], ["NEC", "DISEASE", 492, 495], ["lactose", "CHEMICAL", 572, 579], ["NEC", "DISEASE", 637, 640], ["NEC", "DISEASE", 674, 677], ["hydrogen", "CHEMICAL", 685, 693], ["hydrogen", "CHEMICAL", 741, 749], ["D-lactate", "CHEMICAL", 794, 803], ["NEC", "DISEASE", 826, 829], ["lactose", "CHEMICAL", 266, 273], ["lactose", "CHEMICAL", 572, 579], ["hydrogen", "CHEMICAL", 685, 693], ["hydrogen", "CHEMICAL", 741, 749], ["D-lactate", "CHEMICAL", 794, 803], ["intestinal", "ORGAN", 22, 32], ["intestine", "ORGAN", 136, 145], ["lactose", "SIMPLE_CHEMICAL", 266, 273], ["intestinal", "ORGAN", 304, 314], ["NEC", "PATHOLOGICAL_FORMATION", 325, 328], ["ileum", "ORGAN", 369, 374], ["colon", "ORGAN", 383, 388], ["neonates", "ORGANISM", 472, 480], ["NEC", "CANCER", 492, 495], ["lactose", "SIMPLE_CHEMICAL", 572, 579], ["stools", "ORGANISM_SUBDIVISION", 597, 603], ["hydrogen", "SIMPLE_CHEMICAL", 685, 693], ["patients", "ORGANISM", 727, 735], ["hydrogen", "SIMPLE_CHEMICAL", 741, 749], ["milk", "ORGANISM_SUBSTANCE", 774, 778], ["D-lactate", "SIMPLE_CHEMICAL", 794, 803], ["urine", "ORGANISM_SUBSTANCE", 817, 822], ["patients", "ORGANISM", 830, 838], ["breast", "ORGANISM", 924, 930], ["milk", "ORGANISM_SUBSTANCE", 931, 935], ["colon", "ORGAN", 977, 982], ["infants", "SPECIES", 607, 614], ["patients", "SPECIES", 727, 735], ["patients", "SPECIES", 830, 838], ["the initial intestinal injury", "PROBLEM", 10, 39], ["bacteria", "PROBLEM", 54, 62], ["the subsequent necrosis of the intestine", "PROBLEM", 105, 145], ["bacteria", "PROBLEM", 203, 211], ["an unusual ability", "PROBLEM", 217, 235], ["rapidly ferment undigested lactose", "PROBLEM", 239, 273], ["the initial intestinal injury in NEC", "PROBLEM", 292, 328], ["an abnormally low pH in the ileum", "PROBLEM", 341, 374], ["NEC", "PROBLEM", 492, 495], ["the disease", "PROBLEM", 532, 543], ["an increased lactose concentration", "PROBLEM", 559, 593], ["NEC", "PROBLEM", 637, 640], ["intraluminal gas", "TEST", 646, 662], ["NEC", "PROBLEM", 674, 677], ["enteric bacteria", "PROBLEM", 699, 715], ["D-lactate", "TEST", 794, 803], ["NEC", "PROBLEM", 826, 829], ["vigorous bacterial fermentation", "PROBLEM", 859, 890], ["a breast milk substitute", "TREATMENT", 922, 946], ["colonic bacterial flora", "PROBLEM", 1011, 1034], ["intestinal", "ANATOMY", 22, 32], ["injury", "OBSERVATION", 33, 39], ["variety", "OBSERVATION_MODIFIER", 43, 50], ["bacteria", "OBSERVATION", 54, 62], ["normal flora", "OBSERVATION", 74, 86], ["necrosis", "OBSERVATION", 120, 128], ["intestine", "ANATOMY", 136, 145], ["intestinal", "ANATOMY", 304, 314], ["injury", "OBSERVATION", 315, 321], ["NEC", "OBSERVATION", 325, 328], ["abnormally", "OBSERVATION_MODIFIER", 344, 354], ["low pH", "OBSERVATION_MODIFIER", 355, 361], ["ileum", "ANATOMY", 369, 374], ["colon", "ANATOMY", 383, 388], ["NEC", "OBSERVATION", 492, 495], ["increased", "OBSERVATION_MODIFIER", 562, 571], ["lactose concentration", "OBSERVATION", 572, 593], ["NEC", "OBSERVATION", 637, 640], ["enteric", "ANATOMY", 699, 706], ["bacteria", "OBSERVATION", 707, 715], ["NEC", "OBSERVATION", 826, 829], ["evidence of", "UNCERTAINTY", 847, 858], ["vigorous", "OBSERVATION_MODIFIER", 859, 867], ["bacterial fermentation", "OBSERVATION", 868, 890], ["breast", "ANATOMY", 924, 930], ["colon", "ANATOMY", 977, 982], ["colonic", "ANATOMY", 1011, 1018], ["bacterial flora", "OBSERVATION", 1019, 1034]]], ["2.s, 15, 29 To test this hypothesis predominant enteric bacteria from infants with NEC were examined for increased ability to ferment lactose, compared to normal flora controls .IntroductionHere we report that this phenotype correlated with pathogenicity with respect to NEC, using a recently developed rabbit ileal loop model .", [["ileal loop", "ANATOMY", 310, 320], ["NEC", "DISEASE", 83, 86], ["lactose", "CHEMICAL", 134, 141], ["NEC", "DISEASE", 271, 274], ["lactose", "CHEMICAL", 134, 141], ["infants", "ORGANISM", 70, 77], ["lactose", "SIMPLE_CHEMICAL", 134, 141], ["NEC", "PATHOLOGICAL_FORMATION", 271, 274], ["rabbit", "ORGANISM", 303, 309], ["ileal loop", "MULTI-TISSUE_STRUCTURE", 310, 320], ["infants", "SPECIES", 70, 77], ["rabbit", "SPECIES", 303, 309], ["rabbit", "SPECIES", 303, 309], ["enteric bacteria", "PROBLEM", 48, 64], ["NEC", "PROBLEM", 83, 86], ["increased ability to ferment lactose", "PROBLEM", 105, 141], ["this phenotype", "PROBLEM", 210, 224], ["pathogenicity", "PROBLEM", 241, 254], ["NEC", "PROBLEM", 271, 274], ["rabbit ileal loop model", "TREATMENT", 303, 326], ["predominant", "OBSERVATION_MODIFIER", 36, 47], ["enteric bacteria", "OBSERVATION", 48, 64], ["ileal loop", "OBSERVATION", 310, 320]]], ["25 A preliminary report of our findings was presented at the 1987 Meeting of the Society for Pediatric Research (Anaheim, CA) .ResultsTryptone mediated induction of the lactose operon Strains DC1 to DC6, from patients with NEC, and strains DC7 to DC12, normal flora controls (see Materials and methods), were assayed for fl-galactosidase specific activity following growth in tryptone broth in the presence and absence of inducer .ResultsResults are shown in Table 1 .", [["NEC", "ANATOMY", 223, 226], ["Tryptone", "CHEMICAL", 134, 142], ["NEC", "DISEASE", 223, 226], ["tryptone", "CHEMICAL", 376, 384], ["Tryptone", "CHEMICAL", 134, 142], ["lactose", "CHEMICAL", 169, 176], ["Tryptone", "SIMPLE_CHEMICAL", 134, 142], ["lactose", "SIMPLE_CHEMICAL", 169, 176], ["DC6", "GENE_OR_GENE_PRODUCT", 199, 202], ["patients", "ORGANISM", 209, 217], ["fl-galactosidase", "GENE_OR_GENE_PRODUCT", 321, 337], ["lactose operon", "DNA", 169, 183], ["DC1", "DNA", 192, 195], ["DC6", "DNA", 199, 202], ["patients", "SPECIES", 209, 217], ["the lactose operon Strains DC1", "TREATMENT", 165, 195], ["NEC", "PROBLEM", 223, 226], ["tryptone broth", "TREATMENT", 376, 390], ["NEC", "OBSERVATION", 223, 226]]], ["All strains, except DC4, a K. pneumoniae strain from an See Materials and methods for details .", [["K. pneumoniae", "ORGANISM", 27, 40], ["K. pneumoniae", "SPECIES", 27, 40], ["K. pneumoniae", "SPECIES", 27, 40], ["All strains", "PROBLEM", 0, 11], ["a K. pneumoniae strain", "PROBLEM", 25, 47], ["strains", "OBSERVATION", 4, 11]]], ["Reproducibility was always within 10% .ResultsRatio of induced to uninduced f/-galactosidase specific activities .", [["f/-galactosidase", "GENE_OR_GENE_PRODUCT", 76, 92]]], ["NEC patient, had normal fl-galactosidase specific activities when compared to normal flora isolates of the same species .", [["NEC", "DISEASE", 0, 3], ["patient", "ORGANISM", 4, 11], ["fl-galactosidase", "GENE_OR_GENE_PRODUCT", 24, 40], ["patient", "SPECIES", 4, 11], ["NEC", "PROBLEM", 0, 3]]], ["Partially induced synthesis of fl-galactosidase was observed in strain DC4 when grown in tryptone broth, but not when grown in minimal medium (see Table 2 , lines 1 and 2 .", [["tryptone", "CHEMICAL", 89, 97], ["fl-galactosidase", "GENE_OR_GENE_PRODUCT", 31, 47], ["DC4", "SIMPLE_CHEMICAL", 71, 74], ["fl-galactosidase", "PROTEIN", 31, 47], ["Partially induced synthesis of fl-galactosidase", "PROBLEM", 0, 47], ["tryptone broth", "TEST", 89, 103]]], ["It should be noted that strain DC4 was renamed DC4R for reasons explained below) .", [["DC4R", "PROTEIN", 47, 51], ["strain DC4", "TREATMENT", 24, 34]]], ["A similar tryptone mediated induction was observed for lactose permease synthesis ( Table 2) .", [["tryptone", "CHEMICAL", 10, 18], ["lactose", "CHEMICAL", 55, 62], ["tryptone", "CHEMICAL", 10, 18], ["lactose", "CHEMICAL", 55, 62], ["tryptone", "SIMPLE_CHEMICAL", 10, 18], ["lactose", "SIMPLE_CHEMICAL", 55, 62], ["lactose permease", "PROTEIN", 55, 71], ["A similar tryptone mediated induction", "TREATMENT", 0, 37], ["lactose permease synthesis", "TREATMENT", 55, 81]]], ["By adding back individual components of minimal medium to cultures grown in tryptone broth, and vice versa, it was shown that this is an induction effect, caused by tryptone, a pancreatic digest of casein USP (Difco) (see Table 3 ) Using dialysis it was shown that a tryptone component with a molecular weight of less than 3000 has a pronounced dose-dependent stimulatory effect (see Fig .", [["pancreatic", "ANATOMY", 177, 187], ["tryptone", "CHEMICAL", 76, 84], ["tryptone", "CHEMICAL", 165, 173], ["tryptone", "CHEMICAL", 267, 275], ["tryptone", "CHEMICAL", 267, 275], ["tryptone", "SIMPLE_CHEMICAL", 165, 173], ["pancreatic", "ORGAN", 177, 187], ["casein USP", "GENE_OR_GENE_PRODUCT", 198, 208], ["tryptone", "SIMPLE_CHEMICAL", 267, 275], ["casein USP", "PROTEIN", 198, 208], ["cultures", "TEST", 58, 66], ["tryptone broth", "TREATMENT", 76, 90], ["dialysis", "TREATMENT", 238, 246], ["a tryptone component", "PROBLEM", 265, 285], ["a molecular weight", "TEST", 291, 309], ["a pronounced dose-dependent stimulatory effect", "TREATMENT", 332, 378], ["minimal", "OBSERVATION_MODIFIER", 40, 47], ["pancreatic", "ANATOMY", 177, 187]]], ["Further characterization of the compound responsible for this effect is in progress .ResultsFurthermore, it was shown that fl-galactosidase induction starts approximately 4 min after addition of tryptone, whereas induction by the direct inducer isopropyl-fl- See Materials and methods for details .", [["tryptone", "CHEMICAL", 195, 203], ["isopropyl", "CHEMICAL", 245, 254], ["tryptone", "CHEMICAL", 195, 203], ["isopropyl", "CHEMICAL", 245, 254], ["fl-galactosidase", "GENE_OR_GENE_PRODUCT", 123, 139], ["tryptone", "SIMPLE_CHEMICAL", 195, 203], ["Further characterization", "TEST", 0, 24], ["fl-galactosidase induction", "TREATMENT", 123, 149], ["tryptone", "TREATMENT", 195, 203]]], ["Casamino acids was added to a final concentration of 1% .", [["Casamino acids", "CHEMICAL", 0, 14], ["Casamino acids", "CHEMICAL", 0, 14], ["Casamino acids", "SIMPLE_CHEMICAL", 0, 14], ["Casamino acids", "TREATMENT", 0, 14]]], ["All media were prepared from concentrated stocks so that both tryptone and minimal salts were always 1 x strength where present .", [["tryptone", "CHEMICAL", 62, 70], ["tryptone", "CHEMICAL", 62, 70], ["tryptone", "SIMPLE_CHEMICAL", 62, 70], ["All media", "TREATMENT", 0, 9], ["both tryptone", "TREATMENT", 57, 70], ["minimal salts", "TREATMENT", 75, 88]]], ["Reproducibility was always within 10% .Results3x Tryptone concentration equivalents Segregation of the lactose phenotype Strain DC4 grows as deep red colonies on MacConkey lactose agar, but at a low frequency throws off white segregants .", [["red colonies", "ANATOMY", 146, 158], ["Tryptone", "CHEMICAL", 49, 57], ["lactose", "CHEMICAL", 103, 110], ["Tryptone", "CHEMICAL", 49, 57], ["lactose", "CHEMICAL", 103, 110], ["lactose", "CHEMICAL", 172, 179], ["Tryptone", "SIMPLE_CHEMICAL", 49, 57], ["lactose", "SIMPLE_CHEMICAL", 103, 110], ["deep red colonies", "CELL_LINE", 141, 158], ["Tryptone concentration equivalents", "TREATMENT", 49, 83], ["the lactose phenotype Strain DC4", "TREATMENT", 99, 131], ["deep red colonies", "PROBLEM", 141, 158], ["MacConkey lactose agar", "TEST", 162, 184], ["white segregants", "PROBLEM", 220, 236], ["lactose phenotype", "OBSERVATION", 103, 120]]], ["Numerous sectored colonies typical of a segregation event were observed .", [["colonies", "ANATOMY", 18, 26], ["sectored colonies", "CELL_LINE", 9, 26], ["Numerous sectored colonies", "PROBLEM", 0, 26], ["a segregation event", "PROBLEM", 38, 57], ["sectored", "OBSERVATION_MODIFIER", 9, 17], ["colonies", "OBSERVATION", 18, 26], ["segregation event", "OBSERVATION", 40, 57]]], ["The parental and segregant strains were renamed DC4R (red) and DC4W (white) respectively .", [["DC4R", "GENE_OR_GENE_PRODUCT", 48, 52], ["DC4R", "PROTEIN", 48, 52], ["The parental and segregant strains", "TREATMENT", 0, 34]]], ["DC4W in turn segregated back to red on MacConkey lactose plates at low frequency .", [["DC4W", "CHEMICAL", 0, 4], ["lactose", "CHEMICAL", 49, 56], ["DC4W", "SIMPLE_CHEMICAL", 0, 4], ["DC4W", "PROTEIN", 0, 4], ["MacConkey lactose plates", "TREATMENT", 39, 63], ["low frequency", "OBSERVATION_MODIFIER", 67, 80]]], ["One such isolate was designated DC4R* .", [["DC4R*", "DNA", 32, 37]]], ["This observation suggests that the initial segregation event was not due to the irreversible loss of a plasmid .Resultsfl-galactosidase assays on DC4W revealed that lactose operon expression in this strain is no longer partially induced, and is in fact indistinguishable from that observed in a normal flora K . pneumoniae strain .", [["plasmid", "ANATOMY", 103, 110], ["lactose", "CHEMICAL", 165, 172], ["lactose", "CHEMICAL", 165, 172], ["Resultsfl-galactosidase", "GENE_OR_GENE_PRODUCT", 112, 135], ["DC4W", "SIMPLE_CHEMICAL", 146, 150], ["lactose", "SIMPLE_CHEMICAL", 165, 172], ["pneumoniae", "ORGANISM", 312, 322], ["plasmid", "DNA", 103, 110], ["DC4W", "DNA", 146, 150], ["lactose operon", "DNA", 165, 179], ["pneumoniae", "SPECIES", 312, 322], ["pneumoniae", "SPECIES", 312, 322], ["This observation", "TEST", 0, 16], ["the initial segregation event", "PROBLEM", 31, 60], ["the irreversible loss of a plasmid", "PROBLEM", 76, 110], ["galactosidase assays", "TEST", 122, 142], ["lactose operon expression", "PROBLEM", 165, 190], ["this strain", "PROBLEM", 194, 205], ["pneumoniae strain", "PROBLEM", 312, 329], ["irreversible", "OBSERVATION_MODIFIER", 80, 92], ["loss", "OBSERVATION", 93, 97], ["no longer", "UNCERTAINTY", 209, 218]]], ["The back segregant, however, was once again partially induced for lactose enzyme synthesis in the presence of tryptone, and behaved 4x 430 Carol A .", [["lactose", "CHEMICAL", 66, 73], ["tryptone", "CHEMICAL", 110, 118], ["lactose", "CHEMICAL", 66, 73], ["tryptone", "CHEMICAL", 110, 118], ["lactose enzyme", "SIMPLE_CHEMICAL", 66, 80], ["tryptone", "SIMPLE_CHEMICAL", 110, 118], ["lactose enzyme", "PROTEIN", 66, 80], ["The back segregant", "PROBLEM", 0, 18], ["lactose enzyme synthesis", "PROBLEM", 66, 90], ["back", "ANATOMY", 4, 8]]], ["Carbonaro et al . in all respects like the original DC4R strain .", [["DC4R", "GENE_OR_GENE_PRODUCT", 52, 56], ["Carbonaro et al", "TREATMENT", 0, 15]]], ["Lactose permease assays showed that expression of the lactose permease gene is similarly affected (see Table 2 ) .Partially induced synthesis of lactose enzymes and pathogenicityThe three K. pneumoniae strains DC4R, DC4W and DC4R* were tested for pathogenicity in the ileal loop rabbit model for NEC .", [["ileal loop", "ANATOMY", 268, 278], ["Lactose", "CHEMICAL", 0, 7], ["lactose", "CHEMICAL", 54, 61], ["lactose", "CHEMICAL", 145, 152], ["NEC", "DISEASE", 296, 299], ["Lactose", "CHEMICAL", 0, 7], ["lactose", "CHEMICAL", 54, 61], ["lactose", "CHEMICAL", 145, 152], ["Lactose", "SIMPLE_CHEMICAL", 0, 7], ["lactose permease", "GENE_OR_GENE_PRODUCT", 54, 70], ["lactose enzymes", "GENE_OR_GENE_PRODUCT", 145, 160], ["K. pneumoniae", "ORGANISM", 188, 201], ["DC4R", "ORGANISM", 210, 214], ["DC4W", "CELL", 216, 220], ["DC4R", "GENE_OR_GENE_PRODUCT", 225, 229], ["ileal loop", "MULTI-TISSUE_STRUCTURE", 268, 278], ["rabbit", "ORGANISM", 279, 285], ["NEC", "PATHOLOGICAL_FORMATION", 296, 299], ["lactose permease gene", "DNA", 54, 75], ["lactose enzymes", "PROTEIN", 145, 160], ["K. pneumoniae", "SPECIES", 188, 201], ["rabbit", "SPECIES", 279, 285], ["K. pneumoniae", "SPECIES", 188, 201], ["rabbit", "SPECIES", 279, 285], ["Lactose permease assays", "TEST", 0, 23], ["the lactose permease", "TEST", 50, 70], ["Partially induced synthesis of lactose enzymes", "PROBLEM", 114, 160], ["pathogenicity", "PROBLEM", 165, 178], ["DC4W", "TREATMENT", 216, 220], ["DC4R", "TREATMENT", 225, 229], ["pathogenicity", "PROBLEM", 247, 260], ["the ileal loop rabbit model", "TREATMENT", 264, 291], ["NEC", "PROBLEM", 296, 299], ["ileal loop", "ANATOMY", 268, 278], ["NEC", "OBSERVATION", 296, 299]]], ["The original DC4R strain was pathogenic, whereas the DC4W segregant had lost pathogenicity (see Fig .", [["DC4R", "GENE_OR_GENE_PRODUCT", 13, 17], ["The original DC4R strain", "PROBLEM", 0, 24], ["pathogenic", "PROBLEM", 29, 39], ["the DC4W segregant", "TREATMENT", 49, 67], ["lost pathogenicity", "PROBLEM", 72, 90]]], ["The back segregant DC4R* was as pathogenic as DC4R .", [["DC4R", "GENE_OR_GENE_PRODUCT", 19, 23], ["DC4R", "DNA", 19, 23], ["DC4R", "DNA", 46, 50], ["The back segregant DC4R", "TREATMENT", 0, 23], ["pathogenic", "PROBLEM", 32, 42]]], ["These results were reproducible and consistent in 3 independent determinations .Partially induced synthesis of lactose enzymes and pathogenicityThe observation that DC4W is neither pathogenic nor partially induced in lactose operon expression is consistent with the hypothesis that an increased ability for lactose fermentation may be a pathogenic trait with respect to NE C .", [["lactose", "CHEMICAL", 111, 118], ["lactose", "CHEMICAL", 217, 224], ["lactose", "CHEMICAL", 307, 314], ["lactose", "CHEMICAL", 111, 118], ["lactose", "CHEMICAL", 217, 224], ["lactose", "CHEMICAL", 307, 314], ["lactose enzymes", "GENE_OR_GENE_PRODUCT", 111, 126], ["DC4W", "GENE_OR_GENE_PRODUCT", 165, 169], ["lactose operon", "GENE_OR_GENE_PRODUCT", 217, 231], ["lactose", "SIMPLE_CHEMICAL", 307, 314], ["NE C", "GENE_OR_GENE_PRODUCT", 370, 374], ["lactose enzymes", "PROTEIN", 111, 126], ["DC4W", "DNA", 165, 169], ["lactose operon", "DNA", 217, 231], ["NE C", "PROTEIN", 370, 374], ["Partially induced synthesis of lactose enzymes", "PROBLEM", 80, 126], ["pathogenicity", "PROBLEM", 131, 144], ["pathogenic", "PROBLEM", 181, 191], ["an increased ability", "PROBLEM", 282, 302], ["lactose fermentation", "TREATMENT", 307, 327], ["a pathogenic trait", "PROBLEM", 335, 353], ["consistent with", "UNCERTAINTY", 246, 261]]], ["2,5 condition for pathogenicity, we tested a wild type K. pneumoniae laboratory strain (MR1) and a mutant (DC17), derived from MR1, that synthesizes lactose enzymes at a high constitutive rate in the rabbit ileal loop assay (see Table 1 and Materials and methods) .", [["ileal loop", "ANATOMY", 207, 217], ["lactose", "CHEMICAL", 149, 156], ["lactose", "CHEMICAL", 149, 156], ["K. pneumoniae", "ORGANISM", 55, 68], ["MR1", "ORGANISM", 88, 91], ["MR1", "GENE_OR_GENE_PRODUCT", 127, 130], ["lactose enzymes", "GENE_OR_GENE_PRODUCT", 149, 164], ["rabbit", "ORGANISM", 200, 206], ["ileal", "MULTI-TISSUE_STRUCTURE", 207, 212], ["DC17", "PROTEIN", 107, 111], ["MR1", "PROTEIN", 127, 130], ["lactose enzymes", "PROTEIN", 149, 164], ["K. pneumoniae", "SPECIES", 55, 68], ["rabbit", "SPECIES", 200, 206], ["K. pneumoniae", "SPECIES", 55, 68], ["rabbit", "SPECIES", 200, 206], ["pathogenicity", "PROBLEM", 18, 31], ["a wild type K. pneumoniae laboratory strain", "PROBLEM", 43, 86], ["lactose enzymes", "TEST", 149, 164], ["ileal loop", "ANATOMY", 207, 217]]], ["Results in Table 4 show that high constitutive synthesis of lactose enzyme causes a definite increase in pathogenicity grade (compare lines 4 and 6) .Partially induced synthesis of lactose enzymes and pathogenicityCloning of the gene responsible for tryptone-mediated induction and pathogenicity The genetic determinant responsible for the tryptone-mediated induction of j3galactosidase and lactose permease in DC4R, the pathogenic K. pneumoniae strain, was cloned as follows .", [["lactose", "CHEMICAL", 60, 67], ["lactose", "CHEMICAL", 181, 188], ["tryptone", "CHEMICAL", 250, 258], ["tryptone", "CHEMICAL", 340, 348], ["lactose", "CHEMICAL", 391, 398], ["DC4R", "CHEMICAL", 411, 415], ["lactose", "CHEMICAL", 60, 67], ["lactose", "CHEMICAL", 181, 188], ["tryptone", "CHEMICAL", 250, 258], ["tryptone", "CHEMICAL", 340, 348], ["j3galactosidase", "CHEMICAL", 371, 386], ["lactose", "CHEMICAL", 391, 398], ["lactose enzyme", "GENE_OR_GENE_PRODUCT", 60, 74], ["lactose enzymes", "GENE_OR_GENE_PRODUCT", 181, 196], ["tryptone", "SIMPLE_CHEMICAL", 250, 258], ["tryptone", "SIMPLE_CHEMICAL", 340, 348], ["j3galactosidase", "GENE_OR_GENE_PRODUCT", 371, 386], ["lactose", "SIMPLE_CHEMICAL", 391, 398], ["DC4R", "GENE_OR_GENE_PRODUCT", 411, 415], ["K. pneumoniae", "ORGANISM", 432, 445], ["strain", "ORGANISM", 446, 452], ["lactose enzyme", "PROTEIN", 60, 74], ["lactose enzymes", "PROTEIN", 181, 196], ["j3galactosidase", "PROTEIN", 371, 386], ["lactose permease", "PROTEIN", 391, 407], ["DC4R", "PROTEIN", 411, 415], ["K. pneumoniae", "SPECIES", 432, 445], ["K. pneumoniae", "SPECIES", 432, 445], ["high constitutive synthesis of lactose enzyme", "PROBLEM", 29, 74], ["pathogenicity grade", "PROBLEM", 105, 124], ["Partially induced synthesis of lactose enzymes", "PROBLEM", 150, 196], ["pathogenicity", "PROBLEM", 201, 214], ["tryptone-mediated induction", "TREATMENT", 250, 277], ["pathogenicity", "PROBLEM", 282, 295], ["the tryptone", "TREATMENT", 336, 348], ["j3galactosidase", "TREATMENT", 371, 386], ["lactose permease", "TREATMENT", 391, 407], ["DC4R", "TREATMENT", 411, 415], ["the pathogenic K. pneumoniae strain", "PROBLEM", 417, 452], ["definite", "UNCERTAINTY", 84, 92], ["increase", "OBSERVATION_MODIFIER", 93, 101], ["pathogenicity grade", "OBSERVATION_MODIFIER", 105, 124], ["pneumoniae strain", "OBSERVATION", 435, 452]]], ["First, a library was constructed consisting of BamH1 digested chromosomal DNA from DC4R, ligated into the BamH1 site of the plasmid pBR322 .", [["chromosomal", "ANATOMY", 62, 73], ["plasmid", "ANATOMY", 124, 131], ["BamH1", "GENE_OR_GENE_PRODUCT", 47, 52], ["chromosomal", "CELLULAR_COMPONENT", 62, 73], ["DNA", "CELLULAR_COMPONENT", 74, 77], ["DC4R", "GENE_OR_GENE_PRODUCT", 83, 87], ["BamH1", "GENE_OR_GENE_PRODUCT", 106, 111], ["pBR322", "GENE_OR_GENE_PRODUCT", 132, 138], ["BamH1 digested chromosomal DNA", "DNA", 47, 77], ["DC4R", "DNA", 83, 87], ["BamH1 site", "DNA", 106, 116], ["plasmid pBR322", "DNA", 124, 138], ["BamH1 digested chromosomal DNA", "PROBLEM", 47, 77], ["DC4R", "TREATMENT", 83, 87], ["the plasmid pBR322", "TREATMENT", 120, 138], ["chromosomal DNA", "OBSERVATION", 62, 77]]], ["39 .4' The restriction enzyme BamH1 was chosen because there are no BamH1 sites in the entire K. pneumoniae lactose operon .\"Partially induced synthesis of lactose enzymes and pathogenicityTo select the clones of interest this library was transformed 39 into the E. coli strain HB101 (hsdS20, recA13, lacYl, rpsL20), 43 deficient in host-restriction and containing a mutation conferring a deficiency in the lactose permease .", [["lactose", "CHEMICAL", 156, 163], ["lactose", "CHEMICAL", 407, 414], ["lactose", "CHEMICAL", 108, 115], ["lactose", "CHEMICAL", 156, 163], ["lactose", "CHEMICAL", 407, 414], ["BamH1", "GENE_OR_GENE_PRODUCT", 30, 35], ["BamH1", "GENE_OR_GENE_PRODUCT", 68, 73], ["K. pneumoniae", "ORGANISM", 94, 107], ["lactose", "SIMPLE_CHEMICAL", 108, 115], ["lactose enzymes", "GENE_OR_GENE_PRODUCT", 156, 171], ["E. coli", "ORGANISM", 263, 270], ["HB101", "GENE_OR_GENE_PRODUCT", 278, 283], ["hsdS20", "GENE_OR_GENE_PRODUCT", 285, 291], ["recA13", "GENE_OR_GENE_PRODUCT", 293, 299], ["lacYl", "GENE_OR_GENE_PRODUCT", 301, 306], ["rpsL20", "GENE_OR_GENE_PRODUCT", 308, 314], ["lactose", "SIMPLE_CHEMICAL", 407, 414], ["restriction enzyme BamH1", "DNA", 11, 35], ["BamH1 sites", "DNA", 68, 79], ["K. pneumoniae lactose operon", "DNA", 94, 122], ["lactose enzymes", "PROTEIN", 156, 171], ["hsdS20", "PROTEIN", 285, 291], ["recA13", "PROTEIN", 293, 299], ["lacYl", "PROTEIN", 301, 306], ["rpsL20", "PROTEIN", 308, 314], ["lactose permease", "PROTEIN", 407, 423], ["K. pneumoniae", "SPECIES", 94, 107], ["E. coli", "SPECIES", 263, 270], ["K. pneumoniae", "SPECIES", 94, 107], ["E. coli", "SPECIES", 263, 270], ["HB101", "SPECIES", 278, 283], ["The restriction enzyme BamH1", "TEST", 7, 35], ["BamH1 sites", "PROBLEM", 68, 79], ["pneumoniae lactose operon", "TREATMENT", 97, 122], ["lactose enzymes", "TEST", 156, 171], ["pathogenicity", "PROBLEM", 176, 189], ["lacYl", "TREATMENT", 301, 306], ["a mutation", "PROBLEM", 365, 375], ["a deficiency in the lactose permease", "PROBLEM", 387, 423], ["lactose permease", "OBSERVATION", 407, 423]]], ["Plasmids endowing this strain with the ability to grow on lactose as a sole carbon source were selected .", [["lactose", "CHEMICAL", 58, 65], ["lactose", "CHEMICAL", 58, 65], ["carbon", "CHEMICAL", 76, 82], ["lactose", "SIMPLE_CHEMICAL", 58, 65], ["Plasmids", "TREATMENT", 0, 8], ["this strain", "PROBLEM", 18, 29], ["lactose", "TREATMENT", 58, 65], ["a sole carbon source", "TREATMENT", 69, 89]]], ["All recombinants found contained a hybrid plasmid with a common 2 .3 kb insert in the BamH1 site of pBR322 .", [["plasmid", "ANATOMY", 42, 49], ["BamH1", "GENE_OR_GENE_PRODUCT", 86, 91], ["pBR322", "GENE_OR_GENE_PRODUCT", 100, 106], ["hybrid plasmid", "DNA", 35, 49], ["common 2 .3 kb insert", "DNA", 57, 78], ["BamH1 site", "DNA", 86, 96], ["pBR322", "DNA", 100, 106], ["a hybrid plasmid", "TREATMENT", 33, 49], ["a common 2 .3 kb insert", "TREATMENT", 55, 78], ["the BamH1 site of pBR322", "TREATMENT", 82, 106], ["hybrid plasmid", "OBSERVATION", 35, 49]]], ["One such plasmid was designated pCC1 and was retained for further study .", [["plasmid", "ANATOMY", 9, 16], ["pCC1", "DNA", 32, 36], ["further study", "TEST", 58, 71]]], ["Strain HB101 harboring the plasmid pCC1 was named DC18 .", [["plasmid", "ANATOMY", 27, 34], ["plasmid pCC1", "DNA", 27, 39], ["DC18", "DNA", 50, 54], ["HB101", "SPECIES", 7, 12], ["Strain HB101 harboring the plasmid pCC1", "TREATMENT", 0, 39]]], ["It was further shown that this plasmid confers the phenotype of interest, i .e . tryptonemediated partially induced synthesis of fl-galactosidase (see Table 1 ) .", [["fl-galactosidase", "GENE_OR_GENE_PRODUCT", 129, 145], ["see Table 1", "GENE_OR_GENE_PRODUCT", 147, 158], ["plasmid", "DNA", 31, 38], ["fl-galactosidase", "PROTEIN", 129, 145], ["this plasmid", "TREATMENT", 26, 38]]], ["This result strongly suggests that it has been possible to transfer this trait from K. pneumoniae to an E. coli background .Partially induced synthesis of lactose enzymes and pathogenicityFor southern hybridization 39 our insert was labeled with biotin-11-dUTP, using appropriate kits from Bethesda Research Labs, and hybridized to pCR100, a plasmid containing the entire K. pneumoniae lactose operon .\"", [["plasmid", "ANATOMY", 342, 349], ["lactose", "CHEMICAL", 155, 162], ["biotin-11-dUTP", "CHEMICAL", 246, 260], ["lactose", "CHEMICAL", 155, 162], ["biotin", "CHEMICAL", 246, 252], ["dUTP", "CHEMICAL", 256, 260], ["lactose", "CHEMICAL", 386, 393], ["K. pneumoniae", "ORGANISM", 84, 97], ["E. coli", "ORGANISM", 104, 111], ["lactose enzymes", "GENE_OR_GENE_PRODUCT", 155, 170], ["biotin", "SIMPLE_CHEMICAL", 246, 252], ["dUTP", "SIMPLE_CHEMICAL", 256, 260], ["pCR100", "GENE_OR_GENE_PRODUCT", 332, 338], ["K. pneumoniae", "ORGANISM", 372, 385], ["lactose", "SIMPLE_CHEMICAL", 386, 393], ["lactose enzymes", "PROTEIN", 155, 170], ["pCR100", "DNA", 332, 338], ["plasmid", "DNA", 342, 349], ["K. pneumoniae lactose operon", "DNA", 372, 400], ["K. pneumoniae", "SPECIES", 84, 97], ["E. coli", "SPECIES", 104, 111], ["K. pneumoniae", "SPECIES", 372, 385], ["K. pneumoniae", "SPECIES", 84, 97], ["E. coli", "SPECIES", 104, 111], ["K. pneumoniae", "SPECIES", 372, 385], ["pneumoniae", "PROBLEM", 87, 97], ["an E. coli background", "PROBLEM", 101, 122], ["Partially induced synthesis of lactose enzymes", "PROBLEM", 124, 170], ["pathogenicity", "PROBLEM", 175, 188], ["southern hybridization", "TEST", 192, 214], ["biotin", "TEST", 246, 252], ["Bethesda Research Labs", "TEST", 290, 312], ["a plasmid", "TREATMENT", 340, 349], ["the entire K. pneumoniae lactose operon", "TREATMENT", 361, 400], ["E. coli", "OBSERVATION", 104, 111]]], ["This experiment showed that there is no homology between the cloned fragment and any of the genes in the lactose operon (data not shown) .", [["lactose", "CHEMICAL", 105, 112], ["lactose", "SIMPLE_CHEMICAL", 105, 112], ["lactose operon", "DNA", 105, 119], ["homology between the cloned fragment", "PROBLEM", 40, 76], ["no", "UNCERTAINTY", 37, 39], ["fragment", "OBSERVATION", 68, 76]]], ["There was no homology between the cloned insert and plasmid DNA prepared from strain DC4R, 38 suggesting that the cloned fragment is of chromosomal origin .Partially induced synthesis of lactose enzymes and pathogenicityThe plasmid pCC1 was introduced into the wild type K. pneumoniae laboratory strain MR1 by transformation and the resulting strain was examined for pathogenicity in the rabbit ileal loop assay .", [["plasmid", "ANATOMY", 52, 59], ["chromosomal", "ANATOMY", 136, 147], ["plasmid", "ANATOMY", 224, 231], ["ileal loop", "ANATOMY", 395, 405], ["lactose", "CHEMICAL", 187, 194], ["pCC1", "CHEMICAL", 232, 236], ["lactose", "CHEMICAL", 187, 194], ["DNA", "CELLULAR_COMPONENT", 60, 63], ["chromosomal", "CELLULAR_COMPONENT", 136, 147], ["lactose enzymes", "GENE_OR_GENE_PRODUCT", 187, 202], ["pCC1", "GENE_OR_GENE_PRODUCT", 232, 236], ["K. pneumoniae", "ORGANISM", 271, 284], ["MR1", "GENE_OR_GENE_PRODUCT", 303, 306], ["rabbit", "ORGANISM", 388, 394], ["ileal loop", "MULTI-TISSUE_STRUCTURE", 395, 405], ["cloned insert", "DNA", 34, 47], ["plasmid DNA", "DNA", 52, 63], ["cloned fragment", "DNA", 114, 129], ["lactose enzymes", "PROTEIN", 187, 202], ["plasmid pCC1", "DNA", 224, 236], ["K. pneumoniae", "SPECIES", 271, 284], ["rabbit", "SPECIES", 388, 394], ["K. pneumoniae", "SPECIES", 271, 284], ["rabbit", "SPECIES", 388, 394], ["homology", "PROBLEM", 13, 21], ["the cloned insert", "TREATMENT", 30, 47], ["plasmid DNA", "TREATMENT", 52, 63], ["the cloned fragment", "PROBLEM", 110, 129], ["Partially induced synthesis of lactose enzymes", "PROBLEM", 156, 202], ["pathogenicity", "PROBLEM", 207, 220], ["The plasmid pCC1", "TREATMENT", 220, 236], ["the resulting strain", "PROBLEM", 329, 349], ["pathogenicity in the rabbit ileal loop assay", "PROBLEM", 367, 411], ["fragment", "OBSERVATION", 121, 129], ["chromosomal origin", "OBSERVATION", 136, 154], ["rabbit", "ANATOMY_MODIFIER", 388, 394], ["ileal loop", "ANATOMY", 395, 405]]], ["Results show ( 25 and results presented here support the hypothesis that an increased ability for lactose fermentation in certain strains of intestinal bacteria is a pathogenic trait with respect to NEC .", [["intestinal", "ANATOMY", 141, 151], ["lactose", "CHEMICAL", 98, 105], ["NEC", "DISEASE", 199, 202], ["lactose", "CHEMICAL", 98, 105], ["lactose", "SIMPLE_CHEMICAL", 98, 105], ["intestinal", "ORGAN", 141, 151], ["NEC", "PATHOLOGICAL_FORMATION", 199, 202], ["the hypothesis", "PROBLEM", 53, 67], ["an increased ability", "PROBLEM", 73, 93], ["lactose fermentation", "TREATMENT", 98, 118], ["intestinal bacteria", "PROBLEM", 141, 160], ["a pathogenic trait", "PROBLEM", 164, 182], ["NEC", "PROBLEM", 199, 202], ["intestinal", "ANATOMY", 141, 151]]], ["Previously it was shown 25 that rabbit loops inoculated with organic acid and protein (mimicking the intestinal content of neonates with NEC) develop all the gross and histological symptoms associated with the disease25 (see Materials and methods) .", [["intestinal", "ANATOMY", 101, 111], ["organic acid", "CHEMICAL", 61, 73], ["NEC", "DISEASE", 137, 140], ["rabbit", "ORGANISM", 32, 38], ["organic acid", "SIMPLE_CHEMICAL", 61, 73], ["intestinal", "ORGAN", 101, 111], ["rabbit", "SPECIES", 32, 38], ["rabbit", "SPECIES", 32, 38], ["organic acid and protein", "TEST", 61, 85], ["NEC", "PROBLEM", 137, 140], ["the gross and histological symptoms", "PROBLEM", 154, 189], ["the disease25", "PROBLEM", 206, 219], ["intestinal", "ANATOMY", 101, 111]]], ["In this work we show that inoculating rabbit loops with infant formula and appropriate bacterial strains can do the same .", [["rabbit", "ORGANISM", 38, 44], ["rabbit", "SPECIES", 38, 44], ["infant", "SPECIES", 56, 62], ["rabbit", "SPECIES", 38, 44], ["inoculating rabbit loops", "PROBLEM", 26, 50], ["infant formula", "TREATMENT", 56, 70], ["appropriate bacterial strains", "PROBLEM", 75, 104]]], ["This further strengthens our belief that the rabbit model is a valid model for NEC, and lends support to the idea that rapid bacterial fermentation of undigested carbohydrate leads to the appearance of organic acids in the intestine .", [["intestine", "ANATOMY", 223, 232], ["NEC", "DISEASE", 79, 82], ["organic acids", "CHEMICAL", 202, 215], ["carbohydrate", "CHEMICAL", 162, 174], ["rabbit", "ORGANISM", 45, 51], ["NEC", "PATHOLOGICAL_FORMATION", 79, 82], ["organic acids", "SIMPLE_CHEMICAL", 202, 215], ["intestine", "ORGAN", 223, 232], ["rabbit", "SPECIES", 45, 51], ["rabbit", "SPECIES", 45, 51], ["NEC", "PROBLEM", 79, 82], ["rapid bacterial fermentation", "PROBLEM", 119, 147], ["undigested carbohydrate", "PROBLEM", 151, 174], ["organic acids in the intestine", "PROBLEM", 202, 232], ["organic acids", "OBSERVATION", 202, 215], ["intestine", "ANATOMY", 223, 232]]], ["The proposed model for infectious pathogenicity may not explain every case of NEC, since direct evidence for increased lactose fermentation was obtained only in one out of six isolates of predominant Enterobacteriaceae studied here .", [["NEC", "DISEASE", 78, 81], ["lactose", "CHEMICAL", 119, 126], ["lactose", "CHEMICAL", 119, 126], ["NEC", "PATHOLOGICAL_FORMATION", 78, 81], ["lactose", "SIMPLE_CHEMICAL", 119, 126], ["Enterobacteriaceae", "CANCER", 200, 218], ["infectious pathogenicity", "PROBLEM", 23, 47], ["NEC", "PROBLEM", 78, 81], ["increased lactose fermentation", "PROBLEM", 109, 139], ["infectious", "OBSERVATION", 23, 33], ["NEC", "OBSERVATION", 78, 81], ["lactose fermentation", "OBSERVATION", 119, 139], ["predominant", "OBSERVATION_MODIFIER", 188, 199], ["Enterobacteriaceae", "OBSERVATION", 200, 218]]], ["On the other hand, nothing in the model requires that increased lactose fermentation be limited to the Enterobacteriaceae .", [["lactose", "CHEMICAL", 64, 71], ["lactose", "CHEMICAL", 64, 71], ["lactose", "SIMPLE_CHEMICAL", 64, 71], ["increased lactose fermentation", "TREATMENT", 54, 84], ["the Enterobacteriaceae", "PROBLEM", 99, 121], ["Enterobacteriaceae", "OBSERVATION", 103, 121]]], ["It is still possible that a number of other cases are due to increased lactose fermentation by more fastiduous bacterial species such as Clostridia or other lactose fermenting anaerobes .Partially induced synthesis of lactose enzymes and pathogenicitySeveral studies\" , \" have shown that NEC is often observed in formula-fed infants .", [["lactose", "CHEMICAL", 71, 78], ["Clostridia", "CHEMICAL", 137, 147], ["lactose", "CHEMICAL", 157, 164], ["lactose", "CHEMICAL", 218, 225], ["NEC", "DISEASE", 288, 291], ["lactose", "CHEMICAL", 71, 78], ["lactose", "CHEMICAL", 157, 164], ["lactose", "CHEMICAL", 218, 225], ["lactose", "SIMPLE_CHEMICAL", 71, 78], ["lactose fermenting anaerobes", "SIMPLE_CHEMICAL", 157, 185], ["lactose enzymes", "GENE_OR_GENE_PRODUCT", 218, 233], ["NEC", "PATHOLOGICAL_FORMATION", 288, 291], ["infants", "ORGANISM", 325, 332], ["lactose enzymes", "PROTEIN", 218, 233], ["infants", "SPECIES", 325, 332], ["increased lactose fermentation", "PROBLEM", 61, 91], ["more fastiduous bacterial species", "PROBLEM", 95, 128], ["Clostridia", "PROBLEM", 137, 147], ["other lactose fermenting anaerobes", "PROBLEM", 151, 185], ["Partially induced synthesis of lactose enzymes", "PROBLEM", 187, 233], ["Several studies", "TEST", 251, 266], ["NEC", "PROBLEM", 288, 291], ["still possible", "UNCERTAINTY", 6, 20], ["NEC", "OBSERVATION", 288, 291]]], ["Infant formula is high in lactose and protein content .", [["lactose", "CHEMICAL", 26, 33], ["lactose", "CHEMICAL", 26, 33], ["lactose", "SIMPLE_CHEMICAL", 26, 33], ["high", "OBSERVATION_MODIFIER", 18, 22], ["protein content", "OBSERVATION", 38, 53]]], ["The protein present in infant formula, casein, is similar to the tryptone-based medium used in our experiments .", [["tryptone", "CHEMICAL", 65, 73], ["tryptone", "CHEMICAL", 65, 73], ["casein", "GENE_OR_GENE_PRODUCT", 39, 45], ["tryptone", "SIMPLE_CHEMICAL", 65, 73], ["the tryptone", "TREATMENT", 61, 73]]], ["Recently we have shown that infant formula diluted up to 10 5 -fold in minimal medium also causes a 10-fold induction in lactose enzyme synthesis in DC4R but not in DC4W .", [["lactose", "CHEMICAL", 121, 128], ["lactose", "CHEMICAL", 121, 128], ["lactose enzyme", "GENE_OR_GENE_PRODUCT", 121, 135], ["DC4R", "SIMPLE_CHEMICAL", 149, 153], ["lactose enzyme", "PROTEIN", 121, 135], ["DC4R", "CELL_LINE", 149, 153], ["DC4W", "CELL_LINE", 165, 169], ["infant formula diluted", "TREATMENT", 28, 50], ["a 10-fold induction in lactose enzyme synthesis", "TREATMENT", 98, 145], ["DC4R", "TREATMENT", 149, 153], ["10-fold", "OBSERVATION_MODIFIER", 100, 107]]], ["However, we have as yet no direct proof that /3-galactosidase synthesis is also induced in the intestine nor that there is in fact increased acid production with the pathogenic strain in vivo .Partially induced synthesis of lactose enzymes and pathogenicityIf fully induced levels of /3-galactosidase are the same in strains DC4R and DC4W (see Table 2 ) why is there a color difference between these two strains on MacConkey lactose agar?", [["intestine", "ANATOMY", 95, 104], ["lactose", "CHEMICAL", 224, 231], ["lactose", "CHEMICAL", 425, 432], ["lactose", "CHEMICAL", 224, 231], ["lactose", "CHEMICAL", 425, 432], ["3-galactosidase", "SIMPLE_CHEMICAL", 46, 61], ["intestine", "ORGAN", 95, 104], ["lactose enzymes", "GENE_OR_GENE_PRODUCT", 224, 239], ["3-galactosidase", "GENE_OR_GENE_PRODUCT", 285, 300], ["DC4R", "CELL", 325, 329], ["lactose enzymes", "PROTEIN", 224, 239], ["galactosidase synthesis", "TREATMENT", 48, 71], ["increased acid production", "PROBLEM", 131, 156], ["the pathogenic strain in vivo", "PROBLEM", 162, 191], ["Partially induced synthesis of lactose enzymes", "PROBLEM", 193, 239], ["pathogenicity", "PROBLEM", 244, 257], ["galactosidase", "TREATMENT", 287, 300], ["a color difference", "PROBLEM", 367, 385], ["intestine", "ANATOMY", 95, 104], ["increased", "OBSERVATION_MODIFIER", 131, 140], ["acid production", "OBSERVATION", 141, 156]]], ["Recently we have begun experiments to try to determine the physiological basis for this color difference .", [["this color difference", "PROBLEM", 83, 104]]], ["So far we have shown (1) that DC4R is inducible by lower concentrations of lactose (0 .001%) than DC4W ; (2) that induction by 1 lactose (the concentration present in MacConkey lactose agar) is not as efficient as induction by IPTG : DC4R was induced to 27% of maximal /3-galactosidase specific activity and DC4W only to 12%; and (3) that there are differences in the kinetics of induction of strains DC4R and DC4W by lactose (data not shown) .", [["lactose", "CHEMICAL", 75, 82], ["1 lactose", "CHEMICAL", 127, 136], ["IPTG", "CHEMICAL", 227, 231], ["lactose", "CHEMICAL", 418, 425], ["lactose", "CHEMICAL", 75, 82], ["lactose", "CHEMICAL", 129, 136], ["lactose", "CHEMICAL", 177, 184], ["IPTG", "CHEMICAL", 227, 231], ["lactose", "CHEMICAL", 418, 425], ["DC4R", "GENE_OR_GENE_PRODUCT", 30, 34], ["lactose", "SIMPLE_CHEMICAL", 75, 82], ["1 lactose", "SIMPLE_CHEMICAL", 127, 136], ["IPTG", "SIMPLE_CHEMICAL", 227, 231], ["DC4R", "GENE_OR_GENE_PRODUCT", 234, 238], ["3-galactosidase", "GENE_OR_GENE_PRODUCT", 270, 285], ["DC4W", "SIMPLE_CHEMICAL", 308, 312], ["DC4R", "SIMPLE_CHEMICAL", 401, 405], ["DC4W", "SIMPLE_CHEMICAL", 410, 414], ["lactose", "SIMPLE_CHEMICAL", 418, 425], ["DC4R", "PROTEIN", 30, 34], ["DC4R", "PROTEIN", 401, 405], ["lactose", "TREATMENT", 75, 82], ["MacConkey lactose agar", "TREATMENT", 167, 189], ["DC4R", "TREATMENT", 234, 238], ["DC4W", "TREATMENT", 308, 312], ["strains DC4R", "TREATMENT", 393, 405]]], ["These recent results suggest that the tryptone-mediated induction of the lactose operon is only one manifestation of the genetic difference between DC4R and DC4W .", [["tryptone", "CHEMICAL", 38, 46], ["lactose", "CHEMICAL", 73, 80], ["tryptone", "CHEMICAL", 38, 46], ["lactose", "CHEMICAL", 73, 80], ["tryptone", "SIMPLE_CHEMICAL", 38, 46], ["lactose", "SIMPLE_CHEMICAL", 73, 80], ["lactose operon", "DNA", 73, 87], ["DC4R", "PROTEIN", 148, 152], ["DC4W", "DNA", 157, 161], ["the tryptone", "TREATMENT", 34, 46], ["the lactose operon", "TREATMENT", 69, 87], ["DC4R", "TREATMENT", 148, 152], ["DC4W", "TREATMENT", 157, 161]]], ["Yet, all the phenotypic differences between DC4R and DC4W are consistent with the idea that DC4R has an increased ability for lactose fermentation in the gut .Partially induced synthesis of lactose enzymes and pathogenicityOur working hypothesis is that a strain such as DC4R can begin fermentation of lactose as soon as infant formula from an intermittent feeding reaches the intestine, whereas fermentation by normal inducible strains will be delayed, until the lactose operon is fully induced .\"", [["gut", "ANATOMY", 154, 157], ["intestine", "ANATOMY", 377, 386], ["DC4R", "CHEMICAL", 92, 96], ["lactose", "CHEMICAL", 126, 133], ["lactose", "CHEMICAL", 190, 197], ["DC4R", "CHEMICAL", 271, 275], ["lactose", "CHEMICAL", 302, 309], ["lactose", "CHEMICAL", 464, 471], ["lactose", "CHEMICAL", 126, 133], ["lactose", "CHEMICAL", 190, 197], ["lactose", "CHEMICAL", 302, 309], ["lactose", "CHEMICAL", 464, 471], ["DC4R", "GENE_OR_GENE_PRODUCT", 44, 48], ["DC4W", "GENE_OR_GENE_PRODUCT", 53, 57], ["DC4R", "GENE_OR_GENE_PRODUCT", 92, 96], ["lactose", "SIMPLE_CHEMICAL", 126, 133], ["gut", "ORGANISM_SUBDIVISION", 154, 157], ["lactose enzymes", "GENE_OR_GENE_PRODUCT", 190, 205], ["DC4R", "GENE_OR_GENE_PRODUCT", 271, 275], ["lactose", "SIMPLE_CHEMICAL", 302, 309], ["intestine", "ORGAN", 377, 386], ["lactose", "SIMPLE_CHEMICAL", 464, 471], ["DC4R", "PROTEIN", 44, 48], ["DC4W", "DNA", 53, 57], ["DC4R", "PROTEIN", 92, 96], ["lactose enzymes", "PROTEIN", 190, 205], ["lactose operon", "DNA", 464, 478], ["DC4R", "TREATMENT", 44, 48], ["DC4W", "TREATMENT", 53, 57], ["lactose fermentation", "TREATMENT", 126, 146], ["Partially induced synthesis of lactose enzymes", "PROBLEM", 159, 205], ["pathogenicity", "PROBLEM", 210, 223], ["a strain", "PROBLEM", 254, 262], ["DC4R", "TREATMENT", 271, 275], ["lactose", "TREATMENT", 302, 309], ["normal inducible strains", "PROBLEM", 412, 436], ["the lactose operon", "TREATMENT", 460, 478], ["consistent with", "UNCERTAINTY", 62, 77], ["increased", "OBSERVATION_MODIFIER", 104, 113], ["gut", "ANATOMY", 154, 157], ["intestine", "ANATOMY", 377, 386]]], ["We believe that this rapid onset of lactose fermentation and the ensuing immediate production of organic acids may be responsible for the onset of NEC under certain circumstances .Partially induced synthesis of lactose enzymes and pathogenicityIt is interesting to note that strain MR1 containing plasmid pCC1 elicits a slightly more severe pathogenic response than strain DC1 7, which synthesizes lactose enzymes constitutively, even though /3-galactosidase specific activity is higher in strain DC17 .", [["plasmid", "ANATOMY", 297, 304], ["lactose", "CHEMICAL", 36, 43], ["organic acids", "CHEMICAL", 97, 110], ["NEC", "DISEASE", 147, 150], ["lactose", "CHEMICAL", 211, 218], ["lactose", "CHEMICAL", 398, 405], ["lactose", "CHEMICAL", 36, 43], ["lactose", "CHEMICAL", 211, 218], ["lactose", "CHEMICAL", 398, 405], ["lactose", "SIMPLE_CHEMICAL", 36, 43], ["organic acids", "SIMPLE_CHEMICAL", 97, 110], ["NEC", "PATHOLOGICAL_FORMATION", 147, 150], ["lactose enzymes", "GENE_OR_GENE_PRODUCT", 211, 226], ["MR1", "GENE_OR_GENE_PRODUCT", 282, 285], ["plasmid pCC1", "ORGANISM", 297, 309], ["DC1 7", "ORGANISM", 373, 378], ["lactose enzymes", "GENE_OR_GENE_PRODUCT", 398, 413], ["3-galactosidase", "GENE_OR_GENE_PRODUCT", 443, 458], ["lactose enzymes", "PROTEIN", 211, 226], ["strain MR1 containing plasmid pCC1", "DNA", 275, 309], ["lactose enzymes", "PROTEIN", 398, 413], ["lactose fermentation", "TREATMENT", 36, 56], ["organic acids", "TREATMENT", 97, 110], ["NEC", "PROBLEM", 147, 150], ["Partially induced synthesis of lactose enzymes", "PROBLEM", 180, 226], ["pathogenicity", "PROBLEM", 231, 244], ["a slightly more severe pathogenic response", "PROBLEM", 318, 360], ["lactose enzymes", "TEST", 398, 413], ["lactose fermentation", "OBSERVATION", 36, 56], ["NEC", "OBSERVATION", 147, 150], ["slightly", "OBSERVATION_MODIFIER", 320, 328], ["more severe", "OBSERVATION_MODIFIER", 329, 340], ["higher", "OBSERVATION_MODIFIER", 480, 486]]], ["The possibility that the genetic change occurring in the segregation from DC4R to DC4W involves a regulatory gene, which affects lactose enzyme expression as well as expression of other gene products important in pathogenicity has not been ruled out by our results .Partially induced synthesis of lactose enzymes and pathogenicityIn further studies we hope to elucidate the nature of the gene product(s) encoded by plasmid pCC1 .", [["plasmid", "ANATOMY", 415, 422], ["lactose", "CHEMICAL", 129, 136], ["lactose", "CHEMICAL", 297, 304], ["lactose", "CHEMICAL", 129, 136], ["lactose", "CHEMICAL", 297, 304], ["DC4R", "GENE_OR_GENE_PRODUCT", 74, 78], ["DC4W", "GENE_OR_GENE_PRODUCT", 82, 86], ["lactose enzyme", "GENE_OR_GENE_PRODUCT", 129, 143], ["lactose enzymes", "GENE_OR_GENE_PRODUCT", 297, 312], ["pCC1", "GENE_OR_GENE_PRODUCT", 423, 427], ["DC4R", "DNA", 74, 78], ["DC4W", "DNA", 82, 86], ["regulatory gene", "DNA", 98, 113], ["lactose enzyme", "PROTEIN", 129, 143], ["lactose enzymes", "PROTEIN", 297, 312], ["plasmid pCC1", "DNA", 415, 427], ["the genetic change", "PROBLEM", 21, 39], ["lactose enzyme expression", "TREATMENT", 129, 154], ["other gene products", "PROBLEM", 180, 199], ["Partially induced synthesis of lactose enzymes", "PROBLEM", 266, 312], ["pathogenicity", "PROBLEM", 317, 330], ["further studies", "TEST", 333, 348]]], ["We are also fractionating the tryptone broth in order to identify more precisely the chemical nature of the component responsible for the induction phenomenon .", [["tryptone", "CHEMICAL", 30, 38], ["tryptone", "CHEMICAL", 30, 38], ["the tryptone broth", "TREATMENT", 26, 44], ["the induction phenomenon", "PROBLEM", 134, 158]]], ["In addition we are looking at more predominant Enterobacteriaceae in stools of infants diagnosed with NEC, and hope to identify and characterize more isolates of the type described here .Materials and methodsMedia .", [["NEC", "DISEASE", 102, 105], ["Enterobacteriaceae", "CANCER", 47, 65], ["stools", "ORGANISM_SUBDIVISION", 69, 75], ["infants", "ORGANISM", 79, 86], ["infants", "SPECIES", 79, 86], ["Enterobacteriaceae in stools", "PROBLEM", 47, 75], ["NEC", "PROBLEM", 102, 105], ["predominant", "OBSERVATION_MODIFIER", 35, 46], ["Enterobacteriaceae", "OBSERVATION", 47, 65], ["stools", "OBSERVATION", 69, 75]]], ["Tryptone broth contains per I : 10 g Bacto-tryptone (Difco), 5 g NaCl .", [["Tryptone", "CHEMICAL", 0, 8], ["Bacto-tryptone", "CHEMICAL", 37, 51], ["NaCl", "CHEMICAL", 65, 69], ["Tryptone", "CHEMICAL", 0, 8], ["NaCl", "CHEMICAL", 65, 69], ["Tryptone", "SIMPLE_CHEMICAL", 0, 8], ["Bacto-tryptone", "SIMPLE_CHEMICAL", 37, 51], ["Difco", "SIMPLE_CHEMICAL", 53, 58], ["Tryptone broth", "TREATMENT", 0, 14], ["Bacto-tryptone (Difco)", "TREATMENT", 37, 59], ["NaCl", "TREATMENT", 65, 69]]], ["Minimal growth medium contains Vogel-Bonner minimal salts 33 supplemented with 2 mg ml -' glycerol .Materials and methodsBacterial strains .", [["glycerol", "CHEMICAL", 90, 98], ["glycerol", "CHEMICAL", 90, 98], ["ml -' glycerol", "SIMPLE_CHEMICAL", 84, 98], ["glycerol", "TREATMENT", 90, 98], ["Bacterial strains", "PROBLEM", 121, 138], ["growth", "OBSERVATION_MODIFIER", 8, 14], ["medium", "OBSERVATION_MODIFIER", 15, 21], ["Bacterial strains", "OBSERVATION", 121, 138]]], ["Stools were collected from neonates in the Syracuse area at the onset of NEC symptoms .", [["NEC", "DISEASE", 73, 76], ["neonates", "ORGANISM", 27, 35], ["Stools", "PROBLEM", 0, 6], ["NEC symptoms", "PROBLEM", 73, 85], ["NEC", "OBSERVATION", 73, 76]]], ["For each patient, the species of Enterobacteriaceae isolated on MacConkey lactose agar was either unique or by far the most predominant in the stool .", [["stool", "ANATOMY", 143, 148], ["lactose", "CHEMICAL", 74, 81], ["lactose", "CHEMICAL", 74, 81], ["patient", "ORGANISM", 9, 16], ["Enterobacteriaceae", "ORGANISM", 33, 51], ["stool", "ORGANISM_SUBSTANCE", 143, 148], ["patient", "SPECIES", 9, 16], ["Enterobacteriaceae", "PROBLEM", 33, 51], ["MacConkey lactose agar", "TREATMENT", 64, 86], ["most predominant", "OBSERVATION_MODIFIER", 119, 135], ["stool", "OBSERVATION", 143, 148]]], ["These organisms were purified and designated DC1 to DC6 .", [["DC1", "CELL", 45, 48], ["DC6", "CELL", 52, 55], ["DC1", "PROTEIN", 45, 48], ["DC6", "DNA", 52, 55]]], ["Purified normal flora Enterobacteriaceae controls (DC7-DC12) were obtained from stools of healthy infants at the Westchester County Medical Center nursery, Valhalla, New York .", [["DC7-DC12", "ANATOMY", 51, 59], ["DC7-DC12", "CELL", 51, 59], ["stools", "ORGANISM_SUBDIVISION", 80, 86], ["infants", "ORGANISM", 98, 105], ["infants", "SPECIES", 98, 105], ["DC7-DC12)", "TREATMENT", 51, 60], ["normal", "OBSERVATION_MODIFIER", 9, 15], ["flora Enterobacteriaceae", "OBSERVATION", 16, 40]]], ["All isolates were identified according to standard procedure using the Microscan system .", [["All isolates", "TREATMENT", 0, 12], ["standard procedure", "TREATMENT", 42, 60], ["the Microscan system", "TEST", 67, 87]]], ["DC4R is the original DC4 isolate .", [["DC4R", "GENE_OR_GENE_PRODUCT", 0, 4], ["DC4", "GENE_OR_GENE_PRODUCT", 21, 24], ["DC4R", "DNA", 0, 4], ["the original DC4 isolate", "TREATMENT", 8, 32]]], ["DC4W is a white segregant isolated upon subculturing of DC4R on MacConkey lactose agar .", [["lactose", "CHEMICAL", 74, 81], ["DC4W", "GENE_OR_GENE_PRODUCT", 0, 4], ["DC4R", "SIMPLE_CHEMICAL", 56, 60], ["DC4W", "DNA", 0, 4], ["DC4R", "PROTEIN", 56, 60], ["a white segregant", "PROBLEM", 8, 25], ["MacConkey lactose agar", "TREATMENT", 64, 86]]], ["DC4R* is a red back segregant of DC4W obtained upon subculturing of DC4W on MacConkey lactose agar .", [["lactose", "CHEMICAL", 86, 93], ["DC4R", "GENE_OR_GENE_PRODUCT", 0, 4], ["DC4W", "GENE_OR_GENE_PRODUCT", 33, 37], ["DC4W", "SIMPLE_CHEMICAL", 68, 72], ["DC4R*", "DNA", 0, 5], ["DC4W", "DNA", 33, 37], ["DC4W", "PROTEIN", 68, 72], ["a red back segregant", "TREATMENT", 9, 29], ["MacConkey lactose agar", "TREATMENT", 76, 98]]], ["Purity of strains DC4R, DC4W, and DC4R* was maintained by repeated subculture on MacConkey lactose agar .", [["lactose", "CHEMICAL", 91, 98], ["lactose", "CHEMICAL", 91, 98], ["DC4R", "GENE_OR_GENE_PRODUCT", 18, 22], ["DC4W", "GENE_OR_GENE_PRODUCT", 24, 28], ["DC4R", "GENE_OR_GENE_PRODUCT", 34, 38], ["strains DC4R, DC4W, and DC4R*", "DNA", 10, 39], ["strains DC4R", "TREATMENT", 10, 22], ["DC4W", "TREATMENT", 24, 28], ["DC4R", "TREATMENT", 34, 38], ["MacConkey lactose agar", "TREATMENT", 81, 103]]], ["MR1, a wild-type K. pneumoniae laboratory strain and plasmid pCR100, 34 a pBR322 derivative containing the entire K. pneumoniae lactose operon, were obtained from Dr Monica Riley .", [["pBR322", "CHEMICAL", 74, 80], ["lactose", "CHEMICAL", 128, 135], ["MR1", "GENE_OR_GENE_PRODUCT", 0, 3], ["K. pneumoniae", "ORGANISM", 17, 30], ["K. pneumoniae", "ORGANISM", 114, 127], ["lactose", "SIMPLE_CHEMICAL", 128, 135], ["MR1", "PROTEIN", 0, 3], ["plasmid pCR100", "DNA", 53, 67], ["K. pneumoniae lactose operon", "DNA", 114, 142], ["K. pneumoniae", "SPECIES", 17, 30], ["K. pneumoniae", "SPECIES", 114, 127], ["K. pneumoniae", "SPECIES", 17, 30], ["K. pneumoniae", "SPECIES", 114, 127], ["MR1", "TEST", 0, 3], ["plasmid pCR100", "TREATMENT", 53, 67], ["a pBR322 derivative", "TREATMENT", 72, 91], ["pneumoniae lactose operon", "TREATMENT", 117, 142]]], ["Strain DC17 was isolated following ethyl methanesulfonate mutagenesis 35 of the wild type strain MR1, as follows .", [["DC17", "CHEMICAL", 7, 11], ["ethyl methanesulfonate", "CHEMICAL", 35, 57], ["ethyl methanesulfonate", "CHEMICAL", 35, 57], ["ethyl methanesulfonate", "SIMPLE_CHEMICAL", 35, 57], ["MR1", "GENE_OR_GENE_PRODUCT", 97, 100], ["Strain DC17", "TREATMENT", 0, 11], ["ethyl methanesulfonate mutagenesis", "TREATMENT", 35, 69]]], ["Mutagenized cells were grown overnight in phenyl-fl-galactoside to enrich for mutants constitutive in /3-galactosidase synthesis, 36 and individual clones with this phenotype were identified by plating on tryptone plates containing XGal (5-bromo-4-chloro-3-indolyl-fl-D-galactoside) .", [["cells", "ANATOMY", 12, 17], ["clones", "ANATOMY", 148, 154], ["phenyl-fl-galactoside", "CHEMICAL", 42, 63], ["tryptone", "CHEMICAL", 205, 213], ["XGal", "CHEMICAL", 232, 236], ["5-bromo-4-chloro-3-indolyl-fl-D-galactoside", "CHEMICAL", 238, 281], ["phenyl-fl-galactoside", "CHEMICAL", 42, 63], ["XGal", "CHEMICAL", 232, 236], ["5-bromo-4-chloro-3-indolyl-fl-D-galactoside", "CHEMICAL", 238, 281], ["cells", "CELL", 12, 17], ["phenyl-fl-galactoside", "SIMPLE_CHEMICAL", 42, 63], ["3-galactosidase", "SIMPLE_CHEMICAL", 103, 118], ["clones", "CELL", 148, 154], ["XGal", "SIMPLE_CHEMICAL", 232, 236], ["5-bromo-4-chloro-3-indolyl-fl-D-galactoside", "SIMPLE_CHEMICAL", 238, 281], ["Mutagenized cells", "CELL_LINE", 0, 17], ["Mutagenized cells", "PROBLEM", 0, 17], ["phenyl", "TEST", 42, 48], ["galactoside", "TREATMENT", 52, 63], ["mutants constitutive", "PROBLEM", 78, 98], ["galactosidase synthesis", "TEST", 105, 128], ["this phenotype", "PROBLEM", 160, 174], ["tryptone plates", "TEST", 205, 220], ["XGal", "TEST", 232, 236], ["bromo", "TEST", 240, 245], ["chloro", "TEST", 248, 254], ["D-galactoside", "TREATMENT", 268, 281]]], ["36 One clone with high /3-galactosidase activity in the presence and absence of inducer, in both tryptone and minimal medium, was designated DC1 7 .", [["clone", "ANATOMY", 7, 12], ["tryptone", "CHEMICAL", 97, 105], ["clone", "CELL", 7, 12], ["3-galactosidase", "GENE_OR_GENE_PRODUCT", 24, 39]]], ["Introduction of a wild type lactose operon in trans (by transformation of DC17 with plasmid pCR100) restores the normal inducible phenotype, suggesting that DC17 is most likely deficient in repressor synthesis .", [["lactose", "CHEMICAL", 28, 35], ["lactose", "CHEMICAL", 28, 35], ["lactose", "SIMPLE_CHEMICAL", 28, 35], ["pCR100", "GENE_OR_GENE_PRODUCT", 92, 98], ["DC17", "GENE_OR_GENE_PRODUCT", 157, 161], ["wild type lactose operon", "DNA", 18, 42], ["DC17", "PROTEIN", 74, 78], ["plasmid pCR100", "DNA", 84, 98], ["DC17", "PROTEIN", 157, 161], ["a wild type lactose operon", "TREATMENT", 16, 42], ["plasmid pCR100", "TREATMENT", 84, 98], ["deficient in repressor synthesis", "PROBLEM", 177, 209], ["inducible phenotype", "OBSERVATION", 120, 139], ["most likely", "UNCERTAINTY", 165, 176], ["repressor synthesis", "OBSERVATION", 190, 209]]], ["All strains were maintained in 60% glycerol at -20\u00b0C .", [["glycerol", "CHEMICAL", 35, 43], ["glycerol", "CHEMICAL", 35, 43], ["glycerol", "SIMPLE_CHEMICAL", 35, 43], ["All strains", "PROBLEM", 0, 11], ["60% glycerol", "TREATMENT", 31, 43]]], ["39 Prior to their use in the experiments described, freezer stocks were subcultured onto nutrient agar and the phenotype of individual colonies was verified .Materials and methodsEnzyme assays . /3-galactosidase assays were performed on toluenized cells harvested during exponential growth at 37\u00b0C, as described by Miller .\"", [["colonies", "ANATOMY", 135, 143], ["cells", "ANATOMY", 248, 253], ["3-galactosidase", "GENE_OR_GENE_PRODUCT", 196, 211], ["cells", "CELL", 248, 253], ["toluenized cells", "CELL_LINE", 237, 253], ["freezer stocks", "TREATMENT", 52, 66], ["nutrient agar", "TEST", 89, 102], ["Enzyme assays", "TEST", 179, 192], ["galactosidase assays", "TEST", 198, 218]]], ["Lactose permease specific activities were determined as described by Carter et al. 37 In this assay the rate of hydrolysis of o-nitrophenyl-/3-D-galactopyranoside (ONPG) is measured in intact cells poisoned with azide .", [["cells", "ANATOMY", 192, 197], ["Lactose", "CHEMICAL", 0, 7], ["o-nitrophenyl-/3-D-galactopyranoside", "CHEMICAL", 126, 162], ["ONPG", "CHEMICAL", 164, 168], ["azide", "CHEMICAL", 212, 217], ["Lactose", "CHEMICAL", 0, 7], ["o-nitrophenyl-/3-D-galactopyranoside", "CHEMICAL", 126, 162], ["ONPG", "CHEMICAL", 164, 168], ["azide", "CHEMICAL", 212, 217], ["Lactose", "SIMPLE_CHEMICAL", 0, 7], ["o-nitrophenyl-/3-D-galactopyranoside", "SIMPLE_CHEMICAL", 126, 162], ["ONPG", "SIMPLE_CHEMICAL", 164, 168], ["cells", "CELL", 192, 197], ["azide", "SIMPLE_CHEMICAL", 212, 217], ["Lactose permease", "TREATMENT", 0, 16], ["hydrolysis", "TREATMENT", 112, 122], ["o-nitrophenyl", "TREATMENT", 126, 139], ["galactopyranoside (ONPG)", "TREATMENT", 145, 169], ["azide", "TREATMENT", 212, 217]]], ["Under these conditions the rate-limiting step is lactose permease mediated transport of ONPG into the cell .", [["cell", "ANATOMY", 102, 106], ["lactose", "CHEMICAL", 49, 56], ["lactose", "CHEMICAL", 49, 56], ["lactose", "SIMPLE_CHEMICAL", 49, 56], ["ONPG", "SIMPLE_CHEMICAL", 88, 92], ["cell", "CELL", 102, 106], ["lactose permease", "PROTEIN", 49, 65], ["ONPG", "PROTEIN", 88, 92], ["lactose permease", "TREATMENT", 49, 65], ["cell", "ANATOMY", 102, 106]]], ["Unless otherwise noted, induction of the lactose operon was achieved by growth in the presence of 1 mm IPTG .", [["lactose", "CHEMICAL", 41, 48], ["IPTG", "CHEMICAL", 103, 107], ["lactose", "CHEMICAL", 41, 48], ["IPTG", "CHEMICAL", 103, 107], ["lactose", "SIMPLE_CHEMICAL", 41, 48], ["lactose operon", "DNA", 41, 55], ["the lactose operon", "TREATMENT", 37, 55], ["1 mm IPTG", "PROBLEM", 98, 107]]], ["35 Pathogenicity assays .", [["Pathogenicity assays", "TEST", 3, 23]]], ["The pathogenicity of bacterial strains was assayed according to Clark et al .\"", [["bacterial strains", "PROBLEM", 21, 38], ["bacterial strains", "OBSERVATION", 21, 38]]], ["Weanling New Zealand white male rabbits were fasted for 8 h .", [["rabbits", "ORGANISM", 32, 39], ["rabbits", "SPECIES", 32, 39], ["New", "OBSERVATION_MODIFIER", 9, 12], ["Zealand", "OBSERVATION_MODIFIER", 13, 20]]], ["Each rabbit was anesthetized with Ketamine (35 mg kg -1 ) and Xylazine (5 mg kg -') intramuscularly.", [["Ketamine", "CHEMICAL", 34, 42], ["Xylazine", "CHEMICAL", 62, 70], ["Ketamine", "CHEMICAL", 34, 42], ["Xylazine", "CHEMICAL", 62, 70], ["rabbit", "ORGANISM", 5, 11], ["Ketamine", "SIMPLE_CHEMICAL", 34, 42], ["Xylazine", "SIMPLE_CHEMICAL", 62, 70], ["rabbit", "SPECIES", 5, 11], ["rabbit", "SPECIES", 5, 11], ["Ketamine", "TREATMENT", 34, 42], ["Xylazine", "TREATMENT", 62, 70]]], ["The abdomen was shaved and cleansed for surgery .", [["abdomen", "ANATOMY", 4, 11], ["abdomen", "ORGAN", 4, 11], ["surgery", "TREATMENT", 40, 47], ["abdomen", "ANATOMY", 4, 11]]], ["The peritoneum was opened and ligature was placed just distal to the ligament of Treitz .", [["peritoneum", "ANATOMY", 4, 14], ["ligament", "ANATOMY", 69, 77], ["peritoneum", "MULTI-TISSUE_STRUCTURE", 4, 14], ["ligament", "TISSUE", 69, 77], ["ligature", "TREATMENT", 30, 38], ["peritoneum", "ANATOMY", 4, 14], ["ligature", "OBSERVATION", 30, 38], ["ligament", "ANATOMY", 69, 77], ["Treitz", "ANATOMY", 81, 87]]], ["The intestine was then flushed with sterile saline and ligated into approximately 5 cm intestinal loops, with care being taken to preserve blood supply .", [["intestine", "ANATOMY", 4, 13], ["intestinal", "ANATOMY", 87, 97], ["blood", "ANATOMY", 139, 144], ["intestine", "ORGAN", 4, 13], ["saline", "SIMPLE_CHEMICAL", 44, 50], ["intestinal", "ORGAN", 87, 97], ["blood", "ORGANISM_SUBSTANCE", 139, 144], ["sterile saline", "TREATMENT", 36, 50], ["care", "TREATMENT", 110, 114], ["intestine", "ANATOMY", 4, 13], ["flushed", "OBSERVATION", 23, 30], ["5 cm", "OBSERVATION_MODIFIER", 82, 86], ["intestinal loops", "ANATOMY", 87, 103]]], ["These loops were then injected randomly using a 26 gauge needle with 1 ml per 2 cm of intestine of bacteria freshly grown in tryptone broth, diluted to 10 6 organisms per ml in proprietary infant formula .", [["intestine", "ANATOMY", 86, 95], ["tryptone", "CHEMICAL", 125, 133], ["intestine", "ORGAN", 86, 95], ["a 26 gauge needle", "TREATMENT", 46, 63], ["bacteria", "PROBLEM", 99, 107], ["tryptone broth", "TREATMENT", 125, 139], ["loops", "ANATOMY", 6, 11], ["intestine", "ANATOMY", 86, 95], ["bacteria", "OBSERVATION_MODIFIER", 99, 107], ["grown", "OBSERVATION_MODIFIER", 116, 121], ["tryptone broth", "OBSERVATION", 125, 139]]], ["Control loops were injected with infant formula or saline alone .", [["saline", "SIMPLE_CHEMICAL", 51, 57], ["infant formula", "TREATMENT", 33, 47], ["saline", "TREATMENT", 51, 57], ["loops", "ANATOMY_MODIFIER", 8, 13]]], ["The peritoneum was closed and the animal was allowed to recover from anesthesia .", [["peritoneum", "ANATOMY", 4, 14], ["peritoneum", "MULTI-TISSUE_STRUCTURE", 4, 14], ["anesthesia", "TREATMENT", 69, 79], ["peritoneum", "ANATOMY", 4, 14], ["closed", "OBSERVATION", 19, 25]]], ["18 h later the animal was sacrificed by Ketamine anesthesia with blood letting, and the intestine was removed .", [["blood", "ANATOMY", 65, 70], ["intestine", "ANATOMY", 88, 97], ["Ketamine", "CHEMICAL", 40, 48], ["Ketamine", "CHEMICAL", 40, 48], ["animal", "ORGANISM", 15, 21], ["Ketamine", "SIMPLE_CHEMICAL", 40, 48], ["blood", "ORGANISM_SUBSTANCE", 65, 70], ["intestine", "ORGAN", 88, 97], ["Ketamine anesthesia", "TREATMENT", 40, 59], ["intestine", "ANATOMY", 88, 97]]], ["The contents of each loop was drained into a syringe .", [["a syringe", "TREATMENT", 43, 52], ["contents", "OBSERVATION_MODIFIER", 4, 12], ["each", "OBSERVATION_MODIFIER", 16, 20], ["loop", "OBSERVATION_MODIFIER", 21, 25], ["drained", "OBSERVATION", 30, 37]]], ["Tissue and fluid were then studied histologically .", [["Tissue", "ANATOMY", 0, 6], ["fluid", "ANATOMY", 11, 16], ["Tissue", "TISSUE", 0, 6], ["fluid", "ORGANISM_SUBSTANCE", 11, 16], ["Tissue and fluid", "TEST", 0, 16], ["fluid", "OBSERVATION", 11, 16]]], ["Distention, mucosal thinning and hemorrhage were typical of a pathogenic response, and microscopy revealed mucosal disruption with villus destruction and a fibrinopurulent exudate .", [["mucosal", "ANATOMY", 12, 19], ["mucosal", "ANATOMY", 107, 114], ["villus", "ANATOMY", 131, 137], ["fibrinopurulent exudate", "ANATOMY", 156, 179], ["Distention", "DISEASE", 0, 10], ["hemorrhage", "DISEASE", 33, 43], ["mucosal", "MULTI-TISSUE_STRUCTURE", 12, 19], ["mucosal", "PATHOLOGICAL_FORMATION", 107, 114], ["villus", "TISSUE", 131, 137], ["Distention", "PROBLEM", 0, 10], ["mucosal thinning", "PROBLEM", 12, 28], ["hemorrhage", "PROBLEM", 33, 43], ["a pathogenic response", "PROBLEM", 60, 81], ["microscopy", "TEST", 87, 97], ["mucosal disruption", "PROBLEM", 107, 125], ["villus destruction", "PROBLEM", 131, 149], ["a fibrinopurulent exudate", "PROBLEM", 154, 179], ["mucosal", "ANATOMY", 12, 19], ["thinning", "OBSERVATION", 20, 28], ["hemorrhage", "OBSERVATION", 33, 43], ["pathogenic response", "OBSERVATION", 62, 81], ["mucosal disruption", "OBSERVATION", 107, 125], ["villus destruction", "OBSERVATION", 131, 149], ["fibrinopurulent", "OBSERVATION_MODIFIER", 156, 171], ["exudate", "OBSERVATION", 172, 179]]], ["Non-pathogenic strains did not cause these symptoms .", [["Non-pathogenic strains", "PROBLEM", 0, 22], ["these symptoms", "PROBLEM", 37, 51]]], ["A typical strong pathogenic response (Grade 3) and a non-pathogenic response (Grade 0) are shown in Fig .", [["A typical strong pathogenic response (Grade 3)", "PROBLEM", 0, 46], ["a non-pathogenic response (Grade 0)", "PROBLEM", 51, 86], ["strong", "OBSERVATION_MODIFIER", 10, 16], ["pathogenic", "OBSERVATION_MODIFIER", 17, 27]]], ["Intermediate responses were scored using the following grading system : Grade 0 : villi completely intact (non-pathogenic response) ; Grade 1 : villous tip necrosis with preservation of villous crypts ; Grade 2 : necrosis of villous tip and crypts with loss of mucosal and submucosal architecture ; Grade 3 : necrosis extending into muscularis ; Grade 4 : transmural necrosis .", [["villi", "ANATOMY", 82, 87], ["villous", "ANATOMY", 144, 151], ["villous crypts", "ANATOMY", 186, 200], ["villous tip", "ANATOMY", 225, 236], ["crypts", "ANATOMY", 241, 247], ["mucosal", "ANATOMY", 261, 268], ["submucosal", "ANATOMY", 273, 283], ["muscularis", "ANATOMY", 333, 343], ["necrosis", "DISEASE", 156, 164], ["necrosis", "DISEASE", 213, 221], ["necrosis", "DISEASE", 309, 317], ["necrosis", "DISEASE", 367, 375], ["villi", "MULTI-TISSUE_STRUCTURE", 82, 87], ["villous crypts", "TISSUE", 186, 200], ["villous tip", "TISSUE", 225, 236], ["crypts", "MULTI-TISSUE_STRUCTURE", 241, 247], ["mucosal", "TISSUE", 261, 268], ["muscularis", "MULTI-TISSUE_STRUCTURE", 333, 343], ["villous tip necrosis", "PROBLEM", 144, 164], ["villous crypts", "PROBLEM", 186, 200], ["necrosis of villous tip", "PROBLEM", 213, 236], ["loss of mucosal and submucosal architecture", "PROBLEM", 253, 296], ["necrosis", "PROBLEM", 309, 317], ["transmural necrosis", "PROBLEM", 356, 375], ["villi", "ANATOMY", 82, 87], ["villous tip", "OBSERVATION_MODIFIER", 144, 155], ["necrosis", "OBSERVATION", 156, 164], ["villous crypts", "OBSERVATION", 186, 200], ["Grade 2", "OBSERVATION_MODIFIER", 203, 210], ["necrosis", "OBSERVATION", 213, 221], ["villous", "ANATOMY_MODIFIER", 225, 232], ["tip", "OBSERVATION_MODIFIER", 233, 236], ["crypts", "ANATOMY_MODIFIER", 241, 247], ["loss", "OBSERVATION_MODIFIER", 253, 257], ["mucosal", "ANATOMY", 261, 268], ["submucosal architecture", "ANATOMY", 273, 296], ["Grade 3", "OBSERVATION_MODIFIER", 299, 306], ["necrosis", "OBSERVATION", 309, 317], ["muscularis", "ANATOMY", 333, 343], ["Grade 4", "OBSERVATION_MODIFIER", 346, 353], ["transmural", "ANATOMY_MODIFIER", 356, 366], ["necrosis", "OBSERVATION", 367, 375]]], ["The presence and extent of edema, lymphatic dilation, cell infiltration, hemorrhage and inflammation was also noted .", [["edema", "ANATOMY", 27, 32], ["lymphatic", "ANATOMY", 34, 43], ["cell", "ANATOMY", 54, 58], ["edema", "DISEASE", 27, 32], ["hemorrhage", "DISEASE", 73, 83], ["inflammation", "DISEASE", 88, 100], ["edema", "PATHOLOGICAL_FORMATION", 27, 32], ["lymphatic", "MULTI-TISSUE_STRUCTURE", 34, 43], ["cell", "CELL", 54, 58], ["edema", "PROBLEM", 27, 32], ["lymphatic dilation", "PROBLEM", 34, 52], ["cell infiltration", "PROBLEM", 54, 71], ["hemorrhage", "PROBLEM", 73, 83], ["inflammation", "PROBLEM", 88, 100], ["extent", "OBSERVATION_MODIFIER", 17, 23], ["edema", "OBSERVATION", 27, 32], ["lymphatic", "ANATOMY", 34, 43], ["dilation", "OBSERVATION", 44, 52], ["cell infiltration", "OBSERVATION", 54, 71], ["hemorrhage", "OBSERVATION", 73, 83], ["inflammation", "OBSERVATION", 88, 100]]], ["Animal care was in accordance with institutional guidelines .Materials and methodsFractionation of tryptone .", [["tryptone", "CHEMICAL", 99, 107], ["tryptone", "CHEMICAL", 99, 107], ["tryptone", "SIMPLE_CHEMICAL", 99, 107]]], ["A measured volume of 20x sterile tryptone was dialyzed to equilibrium versus sterile distilled water to retain the >3000 molecular weight fraction .", [["tryptone", "CHEMICAL", 33, 41], ["A measured volume of 20x sterile tryptone", "TREATMENT", 0, 41], ["sterile distilled water", "TREATMENT", 77, 100], ["volume", "OBSERVATION_MODIFIER", 11, 17]]], ["In a complementary experiment a measured volume of sterile water was dialyzed to equilibrium versus an excess of 20x sterile tryptone to collect the <3000 molecular weight fraction in the dialysis bag .", [["a measured volume of sterile water", "TREATMENT", 30, 64], ["20x sterile tryptone", "TREATMENT", 113, 133], ["the dialysis bag", "TREATMENT", 184, 200], ["dialysis bag", "OBSERVATION", 188, 200]]], ["Volume changes resulting from dialysis were taken in account in expressing the resulting fractions in tryptone concentration equivalents .Materials and methodsCloning methods .", [["tryptone", "CHEMICAL", 102, 110], ["tryptone", "SIMPLE_CHEMICAL", 102, 110], ["Volume changes", "PROBLEM", 0, 14], ["dialysis", "TREATMENT", 30, 38], ["Cloning methods", "TREATMENT", 159, 174], ["dialysis", "OBSERVATION", 30, 38], ["tryptone concentration", "OBSERVATION", 102, 124]]], ["Plasmid DNA was prepared by the rapid alkaline lysis method of Birnboim and Doly .", [["Plasmid", "ANATOMY", 0, 7], ["Plasmid", "CELLULAR_COMPONENT", 0, 7], ["DNA", "CELLULAR_COMPONENT", 8, 11], ["Plasmid DNA", "PROBLEM", 0, 11], ["the rapid alkaline lysis method", "TREATMENT", 28, 59], ["rapid", "OBSERVATION_MODIFIER", 32, 37], ["alkaline lysis", "OBSERVATION", 38, 52]]], ["38 Transformation was performed using the CaCl z method .\"", [["the CaCl z method", "TREATMENT", 38, 55]]], ["Lambda DNA was purchased from BRL .", [["Lambda", "GENE_OR_GENE_PRODUCT", 0, 6], ["DNA", "CELLULAR_COMPONENT", 7, 10], ["BRL", "CELL", 30, 33], ["Lambda DNA", "DNA", 0, 10], ["Lambda DNA", "PROBLEM", 0, 10], ["BRL", "ANATOMY", 30, 33]]], ["Restriction enzymes were obtained from IBI and restriction reactions were incubated overnight at 37\u00b0C in the buffers supplied by the manufacturer .", [["Restriction enzymes", "TEST", 0, 19], ["IBI", "TEST", 39, 42], ["restriction reactions", "PROBLEM", 47, 68]]], ["DNA fragments were separated on 0 .7% agarose using the standard Tris-borate buffer system .", [["fragments", "ANATOMY", 4, 13], ["Tris-borate", "CHEMICAL", 65, 76], ["Tris-borate", "CHEMICAL", 65, 76], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["agarose", "SIMPLE_CHEMICAL", 38, 45], ["Tris-borate", "SIMPLE_CHEMICAL", 65, 76], ["DNA fragments", "DNA", 0, 13], ["DNA fragments", "PROBLEM", 0, 13], ["the standard Tris-borate buffer system", "TREATMENT", 52, 90], ["fragments", "OBSERVATION", 4, 13]]], ["39 Gels were run at 50 V for 3 h and stained with ethidium bromide .", [["ethidium bromide", "CHEMICAL", 50, 66], ["ethidium bromide", "CHEMICAL", 50, 66], ["Gels", "SIMPLE_CHEMICAL", 3, 7], ["ethidium bromide", "SIMPLE_CHEMICAL", 50, 66], ["ethidium bromide", "TREATMENT", 50, 66]]]], "4780ad1e1310e82d7f7caf4b2124fa8fc7a62163": [["Interventions for the prevention or treatment of COVID-19 are crucial for the ongoing outbreak.", [["Interventions", "TREATMENT", 0, 13], ["COVID", "TEST", 49, 54], ["the ongoing outbreak", "PROBLEM", 74, 94]]], ["39 Pre-or post-exposure immunotherapies with neutralizing antibodies, would be of great use by 40 providing immediate mucosal immunity against SARS-CoV-2.", [["mucosal", "ANATOMY", 118, 125], ["SARS", "DISEASE", 143, 147], ["mucosal", "MULTI-TISSUE_STRUCTURE", 118, 125], ["SARS-CoV-2", "ORGANISM", 143, 153], ["neutralizing antibodies", "PROTEIN", 45, 68], ["SARS-CoV", "SPECIES", 143, 151], ["post-exposure immunotherapies", "TREATMENT", 10, 39], ["neutralizing antibodies", "TREATMENT", 45, 68]]], ["Although concerns, as occurred 41 with SARS-CoV 5,6 , that vaccines may cause disease enhancement will need to be addressed.", [["SARS", "DISEASE", 39, 43], ["SARS-CoV", "SPECIES", 39, 47], ["SARS", "PROBLEM", 39, 43], ["vaccines", "TREATMENT", 59, 67], ["disease enhancement", "PROBLEM", 78, 97]]], ["42 The feasibility of human monoclonal antibodies (MAbs) as immunoprophylaxis or therapy 43 against coronaviruses including SARS-CoV 7-10 and MERS-CoV 11 has been demonstrated.", [["SARS", "DISEASE", 124, 128], ["human", "ORGANISM", 22, 27], ["coronaviruses", "ORGANISM", 100, 113], ["SARS-CoV 7-10", "ORGANISM", 124, 137], ["MERS-CoV 11", "ORGANISM", 142, 153], ["human monoclonal antibodies", "PROTEIN", 22, 49], ["MAbs", "PROTEIN", 51, 55], ["human", "SPECIES", 22, 27], ["human", "SPECIES", 22, 27], ["SARS-CoV", "SPECIES", 124, 132], ["MERS-CoV", "SPECIES", 142, 150], ["human monoclonal antibodies (MAbs", "TREATMENT", 22, 55], ["immunoprophylaxis", "TREATMENT", 60, 77], ["therapy", "TREATMENT", 81, 88], ["coronaviruses", "PROBLEM", 100, 113], ["SARS", "TEST", 124, 128], ["CoV", "TEST", 129, 132]]], ["These In the current study we describe the discovery of a cross-neutralizing human IgA monoclonal 68 antibody, MAb362 IgA.", [["human", "ORGANISM", 77, 82], ["IgA", "GENE_OR_GENE_PRODUCT", 83, 86], ["cross-neutralizing human IgA monoclonal 68 antibody", "PROTEIN", 58, 109], ["MAb362 IgA.", "PROTEIN", 111, 122], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 77, 82], ["a cross-neutralizing human IgA monoclonal", "TEST", 56, 97], ["MAb", "TEST", 111, 114]]], ["This IgA antibody binds to SARS-CoV-2 RBD with high affinity 69 directly competing at the hACE2 binding interface by blocking interactions with the receptor.", [["IgA", "GENE_OR_GENE_PRODUCT", 5, 8], ["IgA antibody", "PROTEIN", 5, 17], ["SARS-CoV-2 RBD", "PROTEIN", 27, 41], ["hACE2", "PROTEIN", 90, 95], ["This IgA antibody binds", "TEST", 0, 23], ["SARS", "TEST", 27, 31], ["CoV", "TEST", 32, 35], ["high affinity", "PROBLEM", 47, 60], ["the receptor", "TREATMENT", 144, 156]]], ["75 We have previously developed and characterized a panel of human MAbs that targets the RBD 76 of the SARS-CoV S glycoprotein, isolated from transgenic mice expressing human 77 immunoglobulin genes 9,10 .", [["human", "ORGANISM", 61, 66], ["MAbs", "GENE_OR_GENE_PRODUCT", 67, 71], ["SARS-CoV S glycoprotein", "GENE_OR_GENE_PRODUCT", 103, 126], ["mice", "ORGANISM", 153, 157], ["human", "ORGANISM", 169, 174], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 178, 192], ["human MAbs", "PROTEIN", 61, 71], ["RBD 76", "PROTEIN", 89, 95], ["SARS-CoV S glycoprotein", "PROTEIN", 103, 126], ["human 77 immunoglobulin genes 9,10", "DNA", 169, 203], ["human", "SPECIES", 61, 66], ["mice", "SPECIES", 153, 157], ["human", "SPECIES", 169, 174], ["human", "SPECIES", 61, 66], ["SARS-CoV", "SPECIES", 103, 111], ["mice", "SPECIES", 153, 157], ["human", "SPECIES", 169, 174], ["human MAbs", "TEST", 61, 71], ["the RBD", "TEST", 85, 92], ["the SARS", "TEST", 99, 107], ["CoV S glycoprotein", "TEST", 108, 126], ["immunoglobulin genes", "TEST", 178, 198]]], ["These 36 hybridomas were recently screened against the SARS-CoV-78 2 Spike protein for potential cross-bind activity.", [["hybridomas", "ANATOMY", 9, 19], ["hybridomas", "CELL", 9, 19], ["SARS-CoV-78 2 Spike protein", "PROTEIN", 55, 82], ["SARS-CoV-78", "SPECIES", 55, 66], ["the SARS", "TEST", 51, 59], ["CoV", "TEST", 60, 63], ["Spike protein", "TEST", 69, 82]]], ["MAb362 was identified with cross-binding 79 activity against both the S1 subunit of the SARS-CoV S1-590 and SAR-CoV-2 S1-604 proteins 80 (Extended Data MAb362 IgG and IgA were assessed in ELISA binding assays against the receptor-binding 87 domain (RBD) of the S1 subunit for SARS-CoV S270-510 and SARS-CoV-2 S319-541 (Figure 1a ).88MAb362 IgA showed better binding activities, compared to its IgG counterpart against with 89 SARS-CoV-2 S319-541 (Figure 1b) .", [["MAb362", "CHEMICAL", 0, 6], ["MAb362", "GENE_OR_GENE_PRODUCT", 0, 6], ["SARS-CoV S1-590", "ORGANISM", 88, 103], ["IgA", "GENE_OR_GENE_PRODUCT", 167, 170], ["SARS-CoV", "ORGANISM", 276, 284], ["SARS-CoV-2 S319-541", "ORGANISM", 298, 317], ["IgA", "GENE_OR_GENE_PRODUCT", 340, 343], ["MAb362", "PROTEIN", 0, 6], ["S1 subunit", "PROTEIN", 70, 80], ["SARS-CoV S1-590 and SAR-CoV-2 S1-604 proteins 80", "PROTEIN", 88, 136], ["Extended Data MAb362 IgG", "PROTEIN", 138, 162], ["IgA", "PROTEIN", 167, 170], ["receptor-binding 87 domain", "PROTEIN", 221, 247], ["RBD", "PROTEIN", 249, 252], ["S1 subunit", "PROTEIN", 261, 271], ["IgA", "PROTEIN", 340, 343], ["IgG counterpart", "PROTEIN", 394, 409], ["SARS-CoV", "SPECIES", 88, 96], ["SARS-CoV S270-510", "SPECIES", 276, 293], ["SARS-CoV", "SPECIES", 298, 306], ["cross-binding", "TEST", 27, 40], ["the SARS", "TEST", 84, 92], ["CoV S1", "TEST", 93, 99], ["SAR", "TEST", 108, 111], ["CoV", "TEST", 112, 115], ["S1", "TEST", 118, 120], ["proteins", "TEST", 125, 133], ["Extended Data MAb", "TEST", 138, 155], ["IgG", "TEST", 159, 162], ["IgA", "TEST", 167, 170], ["ELISA binding assays", "TEST", 188, 208], ["the receptor", "TEST", 217, 229], ["SARS", "TEST", 276, 280], ["CoV S270", "TEST", 281, 289], ["SARS", "TEST", 298, 302], ["CoV", "TEST", 303, 306], ["Figure", "TEST", 319, 325], ["MA", "TEST", 333, 335], ["IgA", "TEST", 340, 343], ["better binding activities", "PROBLEM", 351, 376], ["SARS", "TEST", 426, 430], ["CoV", "TEST", 431, 434], ["S1", "ANATOMY", 261, 263]]], ["Assessment of the binding kinetics was consistent with the 90 ELISA binding trends, the binding affinity of IgA with RBD of SARS-CoV-2 is significantly 91 higher (0.3 nM) than that of IgG (13 nM) due to a much slower dissociation rate as an IgA (Koff 92 = 1.13x10 -3 \u00b1 1.06x10 -4 ) compared to an IgG (Koff = 7.75x10 -5 \u00b1 5.46x10 -5 ) (Figure 1c- To define the antibody-binding epitope, known co-crystal and cryo-EM complexes from SARS-98CoV and MERS spike protein in complex with neutralizing antibodies were evaluated for their 99 potential to competitively block hACE2 binding, based on the structural interface of hACE2- Complementing the mutational analysis, to correlate the epitope binding with functionality,135MAb362 IgG and IgA were tested in a receptor-blocking assay with hACE2 expressing Vero E6154To evaluate the neutralization potency of cross-reactive MAb362, we performed a pseudovirus IgG weakly neutralized SARS-CoV-2 pseudovirus despite its activities to block receptor binding.158Interestingly, isotype switch to MAb362 IgA1 resulted in significantly enhanced neutralization 159 potency, compared to its IgG subclass variant (Figure 4b) .", [["SARS", "DISEASE", 124, 128], ["MAb362", "CHEMICAL", 868, 874], ["IgA", "GENE_OR_GENE_PRODUCT", 108, 111], ["IgG", "GENE_OR_GENE_PRODUCT", 184, 187], ["IgA", "GENE_OR_GENE_PRODUCT", 241, 244], ["IgG", "GENE_OR_GENE_PRODUCT", 297, 300], ["SARS-98CoV", "GENE_OR_GENE_PRODUCT", 431, 441], ["MERS spike protein", "GENE_OR_GENE_PRODUCT", 446, 464], ["hACE2", "GENE_OR_GENE_PRODUCT", 566, 571], ["hACE2", "GENE_OR_GENE_PRODUCT", 618, 623], ["IgG", "GENE_OR_GENE_PRODUCT", 726, 729], ["IgA", "GENE_OR_GENE_PRODUCT", 734, 737], ["pseudovirus", "ORGANISM", 891, 902], ["IgG", "GENE_OR_GENE_PRODUCT", 903, 906], ["SARS-CoV-2", "ORGANISM", 926, 936], ["pseudovirus", "ORGANISM", 937, 948], ["MAb362 IgA1", "GENE_OR_GENE_PRODUCT", 1034, 1045], ["IgA", "PROTEIN", 108, 111], ["RBD", "PROTEIN", 117, 120], ["IgG", "PROTEIN", 184, 187], ["IgA", "PROTEIN", 241, 244], ["IgG", "PROTEIN", 297, 300], ["antibody-binding epitope", "PROTEIN", 361, 385], ["co-crystal and cryo-EM complexes", "PROTEIN", 393, 425], ["SARS-98CoV and MERS spike protein", "PROTEIN", 431, 464], ["neutralizing antibodies", "PROTEIN", 481, 504], ["hACE2", "PROTEIN", 566, 571], ["hACE2", "PROTEIN", 618, 623], ["135MAb362 IgG", "PROTEIN", 716, 729], ["IgA", "PROTEIN", 734, 737], ["hACE2", "PROTEIN", 784, 789], ["cross-reactive MAb362", "PROTEIN", 853, 874], ["pseudovirus IgG", "PROTEIN", 891, 906], ["MAb362 IgA1", "PROTEIN", 1034, 1045], ["IgG subclass variant", "PROTEIN", 1125, 1145], ["CoV-2 pseudovirus", "SPECIES", 931, 948], ["SARS-98CoV", "SPECIES", 431, 441], ["Vero E6154", "SPECIES", 801, 811], ["pseudovirus", "SPECIES", 891, 902], ["SARS-CoV-2 pseudovirus", "SPECIES", 926, 948], ["the binding kinetics", "TEST", 14, 34], ["RBD of SARS", "PROBLEM", 117, 128], ["CoV", "TEST", 129, 132], ["IgG", "TEST", 184, 187], ["a much slower dissociation rate", "PROBLEM", 203, 234], ["an IgA", "TEST", 238, 244], ["Koff", "TEST", 246, 250], ["an IgG", "TEST", 294, 300], ["Koff", "TEST", 302, 306], ["Figure 1c", "TEST", 336, 345], ["the antibody", "TEST", 357, 369], ["binding epitope", "PROBLEM", 370, 385], ["known co-crystal and cryo-EM complexes", "PROBLEM", 387, 425], ["SARS", "TEST", 431, 435], ["MERS spike protein", "PROBLEM", 446, 464], ["neutralizing antibodies", "TEST", 481, 504], ["competitively block hACE2 binding", "PROBLEM", 546, 579], ["the mutational analysis", "TEST", 639, 662], ["the epitope binding", "PROBLEM", 677, 696], ["IgG", "TEST", 726, 729], ["IgA", "TEST", 734, 737], ["a receptor", "TEST", 753, 763], ["cross-reactive MAb", "TEST", 853, 871], ["a pseudovirus IgG", "TEST", 889, 906], ["CoV", "TEST", 931, 934], ["block receptor binding", "PROBLEM", 975, 997], ["IgA1", "TEST", 1041, 1045], ["significantly enhanced neutralization 159 potency", "PROBLEM", 1058, 1107], ["neutralization", "OBSERVATION_MODIFIER", 1081, 1095], ["159 potency", "OBSERVATION_MODIFIER", 1096, 1107]]], ["Monomeric MAb362 IgA1 was also 160 co-expressed with J chain to produce dimeric IgA, which further improved neutralization 161 (Figure 4b) .", [["MAb362 IgA1", "GENE_OR_GENE_PRODUCT", 10, 21], ["IgA", "GENE_OR_GENE_PRODUCT", 80, 83], ["Monomeric MAb362 IgA1", "PROTEIN", 0, 21], ["J chain", "PROTEIN", 53, 60], ["dimeric IgA", "PROTEIN", 72, 83], ["Monomeric MAb362 IgA1", "TEST", 0, 21], ["J chain", "TEST", 53, 60], ["dimeric IgA", "PROBLEM", 72, 83], ["IgA", "OBSERVATION", 80, 83]]], ["This is consistent with our prior study showing isotype switch to IgA1 lead to 162 improved antibody neutralization of HIV infection 25 Our data extends this observation to 163 coronavirus, suggesting that IgA may play an important role in SARS-CoV-2 neutralization.", [["HIV infection", "DISEASE", 119, 132], ["IgA1", "GENE_OR_GENE_PRODUCT", 66, 70], ["HIV", "ORGANISM", 119, 122], ["coronavirus", "ORGANISM", 177, 188], ["IgA", "GENE_OR_GENE_PRODUCT", 206, 209], ["SARS-CoV-2", "ORGANISM", 240, 250], ["IgA1", "PROTEIN", 66, 70], ["IgA", "PROTEIN", 206, 209], ["HIV", "SPECIES", 119, 122], ["SARS-CoV", "SPECIES", 240, 248], ["our prior study", "TEST", 24, 39], ["isotype switch to IgA1 lead", "TREATMENT", 48, 75], ["HIV infection", "PROBLEM", 119, 132], ["coronavirus", "PROBLEM", 177, 188], ["consistent with", "UNCERTAINTY", 8, 23]]], ["CoV-2 (S319-541) were conducted using bio-layer interferometry and demonstrate nano and sub-303 nanomolar affinities.", [["S319-541", "CHEMICAL", 7, 15], ["CoV-2", "GENE_OR_GENE_PRODUCT", 0, 5], ["CoV", "TEST", 0, 3], ["bio-layer interferometry", "TEST", 38, 62], ["nano", "TEST", 79, 83], ["nanomolar affinities", "OBSERVATION", 96, 116]]], ["Dilutions of purified MAbs were tested in ELISA for reactivity against recombinant S protein.380Briefly, 96-well plates were coated with S proteins followed by incubation overnight at 4\u00b0C.", [["MAbs", "GENE_OR_GENE_PRODUCT", 22, 26], ["recombinant S protein", "GENE_OR_GENE_PRODUCT", 71, 92], ["purified MAbs", "PROTEIN", 13, 26], ["recombinant S protein", "PROTEIN", 71, 92], ["S proteins", "PROTEIN", 137, 147], ["purified MAbs", "TREATMENT", 13, 26], ["ELISA", "TEST", 42, 47]]]], "6083b39acbc4d587ef7933c6ed82bb32fe8cf12c": [["IntroductionRisk communication is an essential aspect of risk management and governance.", [["risk management", "TREATMENT", 57, 72]]], ["In the ISO 31000 standard for organizational risk management by the International Organization for Standardization [1], risk communication is part of the 'communication and consultation' activity of the risk management process, with the primary aims to promote awareness and understanding of risks.", [["ISO", "CHEMICAL", 7, 10], ["organizational risk management", "TREATMENT", 30, 60]]], ["Although not without its critics [2, 3] and notwithstanding ongoing work to define its conceptual basis [4] , this standard is very influential across industrial domains as a platform for sharing best practices and as a catalyst for professionalization of risk management [5, 6] .", [["a catalyst", "TREATMENT", 218, 228], ["risk management", "TREATMENT", 256, 271], ["not without", "UNCERTAINTY", 9, 20]]], ["Overview of scientometric techniques and tools used to answer the research questions.RQ1Publication output trends Regression analysis -Publication analysis (Bibliometrix) [42] RQ2 Geographic patterns Publication analysis (Bibliometrix) [42] Visualization of similarities (VOSviewer) [45] RQ3 Scientific categories Visualization of similarities (VOSviewer) [45] Global science map overlay [46] RQ4 Journal knowledge flow Journal distribution analysis (CiteSpace) [47] Journal-based dual-map overlay [48] RQ5 Narrative topics Automatic term identification method [49] Visualization of similarities (VOSviewer) [45]RQ6Research clusters and fronts Co-citation analysis (CiteSpace) [47] Trends in research outputs (RQ1) are basic scientometric indicators, providing insights into the development of research activity over time.", [["scientometric techniques", "TREATMENT", 12, 36], ["RQ1Publication output", "TEST", 85, 106], ["Regression analysis", "TEST", 114, 133], ["Publication analysis", "TEST", 135, 155], ["Bibliometrix", "TEST", 157, 169], ["Publication analysis", "TEST", 200, 220], ["Global science map overlay", "TEST", 361, 387], ["dual-map overlay", "TREATMENT", 481, 497]]], ["Apart from a simple count of publications per year, a regression analysis was performed to estimate the rate of change.", [["a regression analysis", "TEST", 52, 73], ["simple count", "OBSERVATION_MODIFIER", 13, 25]]], ["For each country-related subset of the data, additional metrics were calculated to provide insight in the temporal activity of different geographical areas and to assess the average impact of publications from the areas.", [["publications", "OBSERVATION", 192, 204]]], ["Bibliometrix software was used for these basic calculations [42] .", [["these basic calculations", "TEST", 35, 59]]], ["To identify collaboration networks between countries/regions in risk communication research, the visualization of similarities mapping technique was applied [45] .", [["similarities mapping technique", "TREATMENT", 114, 144]]], ["This technique quantitatively analyzes similarities between documents according to a chosen data object, in this case country/region of origin.", [["origin", "ANATOMY_MODIFIER", 136, 142]]], ["The VOSviewer software determines citation networks in which the distance between nodes shows the level of closeness to each other and the node size represents the number of documents [50] .RQ6Insights into the scientific categories represented in risk communication research (RQ3) were obtained by mapping the journal categories on the global science map [46] .", [["node", "ANATOMY", 139, 143], ["nodes", "OBSERVATION", 82, 87], ["node", "OBSERVATION", 139, 143], ["size", "OBSERVATION_MODIFIER", 144, 148]]], ["This map shows clusters of different scientific disciplines, providing a high-level visual overview of the complete scientific body of knowledge.", [["This map", "TEST", 0, 8], ["clusters", "OBSERVATION_MODIFIER", 15, 23]]], ["The analysis and visualization were done with VOSviewer [45] .RQ6The information flow to and between journals as knowledge carriers in risk communication research (RQ4) was analyzed using the dual-map overlay [48] .", [["The analysis", "TEST", 0, 12], ["visualization", "TEST", 17, 30]]], ["This map shows the interconnections between over 10,000 journals, where these journals are grouped in regions representing publication and citation activities at the domain level [51] .", [["This map", "TEST", 0, 8], ["publication", "OBSERVATION", 123, 134]]], ["The dual-map overlay enables insights into how specific domains of knowledge (citing articles) are influenced by other domains (cited literature), where the latter can be regarded as the intellectual base of the knowledge domain in focus [48] .RQ6The dominant narrative patterns in the risk communication domain (RQ5) were identified using the automatic term identification method [49] to extract terms or noun phrases from the bibliographic data about the documents in the dataset.", [["RQ5", "DNA", 313, 316]]], ["A data cleaning process was applied to combine similar terms in the resulting term list.", [["A data cleaning process", "TREATMENT", 0, 23]]], ["VOSviewer [45] was applied to cluster the terms, to determine associated heat maps, and to obtain additional bibliometric indicators such as the average publication year and average impact of terms.", [["heat maps", "TEST", 73, 82]]], ["This information provides insights into trending topics over time and helps to determine topics that are scientifically fruitful.RQ6The evolution of research clusters, research fronts, and key documents (RQ6) was performed through a co-citation analysis using CiteSpace software [47] .", [["a co-citation analysis", "TEST", 231, 253]]], ["Co-citation analysis was first proposed by Small [52] as a method to measure the relationship between two documents.", [["Co-citation analysis", "TEST", 0, 20]]], ["Furthermore, the articles citing most references from a given co-citation cluster are known as research fronts.", [["a given co-citation cluster", "TREATMENT", 54, 81]]], ["In scientometrics research, these research fronts are considered to be the figureheads of a research cluster, providing insight in a subdomain of academic focus [54] .ResultsIn this section, the results of the various scientific analyses are shown and interpreted.", [["the various scientific analyses", "TEST", 206, 237]]], ["Each subsection presents the analysis results to answer research questions RQ1 to RQ6.Temporal DistributionThe annual trend of publication activity in the risk communication research domain is shown in Figure 1 .", [["RQ6", "DNA", 82, 85], ["the analysis", "TEST", 25, 37], ["Temporal Distribution", "PROBLEM", 86, 107], ["publication activity", "PROBLEM", 127, 147], ["Distribution", "OBSERVATION_MODIFIER", 95, 107], ["annual", "OBSERVATION_MODIFIER", 111, 117], ["trend", "OBSERVATION_MODIFIER", 118, 123], ["publication activity", "OBSERVATION", 127, 147]]], ["This indicates that risk communication research originates from a practical need to inform patients about health risks.", [["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99]]], ["The global trend of annual number of publications and the associated cumulative number shows an exponential increase.", [["global", "OBSERVATION_MODIFIER", 4, 10], ["trend", "OBSERVATION_MODIFIER", 11, 16], ["annual", "OBSERVATION_MODIFIER", 20, 26], ["number", "OBSERVATION_MODIFIER", 27, 33], ["exponential", "OBSERVATION_MODIFIER", 96, 107], ["increase", "OBSERVATION_MODIFIER", 108, 116]]], ["From then onwards, the number of publications escalated quickly, with an increase to over 70 articles published annually after 2015.", [["increase", "OBSERVATION_MODIFIER", 73, 81]]], ["The research volume before 1990 amounts to 2.9% of the total, with the relative share of the period of 1990-1999 rising to 12.0%, further increasing to 29.3% in the period of 2000-2009, and finally reaching 55.8% in the period after 2010.", [["The research volume", "TEST", 0, 19]]], ["This shows that risk communication research has experienced a rather dramatic increase in research productivity since its inception. terms.", [["dramatic", "OBSERVATION_MODIFIER", 69, 77], ["increase", "OBSERVATION_MODIFIER", 78, 86]]], ["The evolution of research clusters, research fronts, and key documents (RQ6) was performed through a co-citation analysis using CiteSpace software [47] .", [["a co-citation analysis", "TEST", 99, 121]]], ["Co-citation analysis was first proposed by Small [52] as a method to measure the relationship between two documents.", [["Co-citation analysis", "TEST", 0, 20]]], ["Furthermore, the articles citing most references from a given co-citation cluster are known as research fronts.", [["a given co-citation cluster", "TREATMENT", 54, 81]]], ["In scientometrics research, these research fronts are considered to be the figureheads of a research cluster, providing insight in a subdomain of academic focus [54] .ResultsIn this section, the results of the various scientific analyses are shown and interpreted.", [["the various scientific analyses", "TEST", 206, 237]]], ["Each subsection presents the analysis results to answer research questions RQ1 to RQ6.Temporal DistributionThe annual trend of publication activity in the risk communication research domain is shown in Figure 1 .", [["RQ6", "DNA", 82, 85], ["the analysis", "TEST", 25, 37], ["Temporal Distribution", "PROBLEM", 86, 107], ["publication activity", "PROBLEM", 127, 147], ["Distribution", "OBSERVATION_MODIFIER", 95, 107], ["annual", "OBSERVATION_MODIFIER", 111, 117], ["trend", "OBSERVATION_MODIFIER", 118, 123], ["publication activity", "OBSERVATION", 127, 147]]], ["This indicates that risk communication research originates from a practical need to inform patients about health risks.", [["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99]]], ["The global trend of annual number of publications and the associated cumulative number shows an exponential increase.", [["global", "OBSERVATION_MODIFIER", 4, 10], ["trend", "OBSERVATION_MODIFIER", 11, 16], ["annual", "OBSERVATION_MODIFIER", 20, 26], ["number", "OBSERVATION_MODIFIER", 27, 33], ["exponential", "OBSERVATION_MODIFIER", 96, 107], ["increase", "OBSERVATION_MODIFIER", 108, 116]]], ["From then onwards, the number of publications escalated quickly, with an increase to over 70 articles published annually after 2015.", [["increase", "OBSERVATION_MODIFIER", 73, 81]]], ["The research volume before 1990 amounts to 2.9% of the total, with the relative share of the period of 1990-1999 rising to 12.0%, further increasing to 29.3% in the period of 2000-2009, and finally reaching 55.8% in the period after 2010.", [["The research volume", "TEST", 0, 19]]], ["This shows that risk communication research has experienced a rather dramatic increase in research productivity since its inception.", [["dramatic", "OBSERVATION_MODIFIER", 69, 77], ["increase", "OBSERVATION_MODIFIER", 78, 86]]], ["Figure 2 shows the geographic distribution of risk communication research globally.", [["geographic", "OBSERVATION_MODIFIER", 19, 29], ["distribution", "OBSERVATION_MODIFIER", 30, 42]]], ["The most productive countries, defined here as those with more than five publications, are listed in Table 3 .", [["most", "OBSERVATION_MODIFIER", 4, 8], ["productive", "OBSERVATION_MODIFIER", 9, 19]]], ["Figure 2 shows the geographic distribution of risk communication research globally.", [["geographic", "OBSERVATION_MODIFIER", 19, 29], ["distribution", "OBSERVATION_MODIFIER", 30, 42]]], ["The most productive countries, defined here as those with more than five publications, are listed in Table 3 .", [["most", "OBSERVATION_MODIFIER", 4, 8], ["productive", "OBSERVATION_MODIFIER", 9, 19]]], ["It is seen that the vast majority of risk communication research originates from Western countries, with the United States of America (502 articles, 41.9%), the United Kingdom (177, 14.8%), Germany (93, 7 .8%), the Netherlands (68, 5.7%), and Canada (58, 4.8%) comprising the top five most productive countries.", [["Germany", "TEST", 190, 197], ["Canada", "TEST", 243, 249], ["vast", "OBSERVATION_MODIFIER", 20, 24], ["majority", "OBSERVATION_MODIFIER", 25, 33], ["productive", "OBSERVATION_MODIFIER", 290, 300]]], ["The dominance of North America and Western Europe in research productivity is striking, while the research activity in Oceania, Asia, Eastern Europe, South America, and Africa is much lower.", [["dominance", "OBSERVATION_MODIFIER", 4, 13], ["North", "OBSERVATION_MODIFIER", 17, 22], ["America", "OBSERVATION_MODIFIER", 23, 30]]], ["Within Europe, by far, most of the work originates from the United Kingdom, Germany, and the Netherlands, with Italy, Sweden, France, Norway, and Spain also contributing moderately.", [["moderately", "OBSERVATION_MODIFIER", 170, 180]]], ["In Asia, the research is most developed in the Far East, including Japan, the People's Republic of China, and South Korea.Geographical DistributionDespite the lower productivity in absolute terms, it is found that some countries in the list of Table 3 , such as the People's Republic of China and South Korea, have only relatively recently become active in this research domain.", [["People", "SPECIES", 266, 272], ["Distribution", "OBSERVATION_MODIFIER", 135, 147], ["lower", "OBSERVATION_MODIFIER", 159, 164], ["productivity", "OBSERVATION_MODIFIER", 165, 177], ["absolute terms", "OBSERVATION_MODIFIER", 181, 195], ["active", "OBSERVATION", 347, 353]]], ["The top five most productive countries have been active for a much longer time, as seen from their comparatively low average year of publication.", [["top", "OBSERVATION_MODIFIER", 4, 7], ["active", "OBSERVATION_MODIFIER", 49, 55]]], ["In terms of impact, the top highly productive countries also generally contribute the most impactful research.", [["impact", "OBSERVATION", 12, 18]]], ["As is seen from the average number of citations, research originating from the USA, UK, Canada, and the Netherlands has attracted most citations on average, while work from some less productive countries including Switzerland, Israel, and Belgium also ranks relatively highly.", [["average", "OBSERVATION_MODIFIER", 20, 27], ["number", "OBSERVATION_MODIFIER", 28, 34]]], ["This underscores the dominance of North America and Western Europe in the risk communication research domain.Geographical DistributionThe country collaboration network, shown in Figure 3 , shows that the most active countries in North American and Western Europe, the United States of America and the United Kingdom, are also the ones with most international collaborations.", [["dominance", "OBSERVATION_MODIFIER", 21, 30], ["North", "OBSERVATION_MODIFIER", 34, 39], ["America", "OBSERVATION_MODIFIER", 40, 47], ["most", "OBSERVATION_MODIFIER", 204, 208], ["active", "OBSERVATION_MODIFIER", 209, 215]]], ["While the USA has the strongest academic links with Canada, Australia, Japan, China, and South Korea, the UK has stronger links with other European countries. including Switzerland, Israel, and Belgium also ranks relatively highly.", [["UK", "GENE_OR_GENE_PRODUCT", 106, 108]]], ["This underscores the dominance of North America and Western Europe in the risk communication research domain.", [["dominance", "OBSERVATION_MODIFIER", 21, 30], ["North", "OBSERVATION_MODIFIER", 34, 39], ["America", "OBSERVATION_MODIFIER", 40, 47]]], ["While the USA has the strongest academic links with Canada, Australia, Japan, China, and South Korea, the UK has stronger links with other European countries.Scientific CategoriesEach journal in the Web of Science Core Collection is classified according to different scientific categories.", [["UK", "GENE_OR_GENE_PRODUCT", 106, 108]]], ["Within that cluster, the scientific categories 'Public, Environmental, and Occupational Health' (362 articles, 30 Apart from highlighting the main contributing scientific categories, the visualization of risk communication research on the global science map in Figure 4 also indicates that this research domain is highly interdisciplinary.", [["cluster", "OBSERVATION_MODIFIER", 12, 19]]], ["Furthermore, mathematical methods and their interdisciplinary application in social sciences also are an important aspect in the research domain.", [["mathematical methods", "TREATMENT", 13, 33]]], ["This shows that most work in the risk communication domain originates from practical needs in specific risk management and governance contexts, rather than as a subdiscipline from communications research.Scientific CategoriesTo further support the finding that risk communication is highly interdisciplinary, the Stirling-Rao diversity index is calculated.", [["Rao diversity index", "TEST", 322, 341]]], ["For the risk communication research domain, the global diversity index is 0.803, which is a very high score.", [["the global diversity index", "TEST", 44, 70], ["global", "OBSERVATION_MODIFIER", 48, 54], ["diversity", "OBSERVATION_MODIFIER", 55, 64], ["index", "OBSERVATION_MODIFIER", 65, 70], ["very", "OBSERVATION_MODIFIER", 92, 96], ["high", "OBSERVATION_MODIFIER", 97, 101]]], ["This indicates that there is a high diversity in scientific categories concerned with this domain, and that these collectively contribute to the knowledge production.Scientific CategoriesFocusing on Table 4 , the average year in which articles in a category are published shows that the oldest categories are 'Social Sciences, Mathematical Methods' and 'Mathematics, Interdisciplinary Applications', which are among the most active categories overall.", [["Interdisciplinary Applications'", "TREATMENT", 367, 398], ["high", "OBSERVATION_MODIFIER", 31, 35], ["diversity", "OBSERVATION_MODIFIER", 36, 45]]], ["Categories in which the contributions appear significantly earlier (average before 2008) are 'Engineering, Civil', 'Nuclear Science and Technology', 'Public, Environmental, and Occupational Health' and 'Environmental Sciences'.", [["significantly", "OBSERVATION_MODIFIER", 45, 58]]], ["Remarkably, highly productive application-focused categories in other scientific clusters are much less academically impactful, with even categories which became active comparatively early, such as 'Environmental Sciences' and 'Water Resources' (cluster #3), 'Engineering, Civil' (cluster #4), and 'Nuclear Science and Technology' (cluster #2) receiving few citations on average.", [["highly", "OBSERVATION_MODIFIER", 12, 18], ["productive", "OBSERVATION_MODIFIER", 19, 29]]], ["Nevertheless, the above-identified recently emerging categories 'Meteorology and Atmospheric Sciences' and 'Geosciences, Multidisciplinary' (cluster #3) also have a comparatively high average number of citations and hence academic impact, given their relatively short time to attract citations.Journals' Distribution and Intellectual BaseA dual-map overlay analysis is applied to identify highly productive and highly cited journals in the risk communication research domain and to trace their intellectual basis.", [["Intellectual BaseA dual-map overlay analysis", "TEST", 321, 365], ["productive", "OBSERVATION_MODIFIER", 396, 406]]], ["Remarkably, highly productive application-focused categories in other scientific clusters are much less academically impactful, with even categories which became active comparatively early, such as 'Environmental Sciences' and 'Water Resources' (cluster #3), 'Engineering, Civil' (cluster #4), and 'Nuclear Science and Technology' (cluster #2) receiving few citations on average.", [["highly", "OBSERVATION_MODIFIER", 12, 18], ["productive", "OBSERVATION_MODIFIER", 19, 29]]], ["Nevertheless, the aboveidentified recently emerging categories 'Meteorology and Atmospheric Sciences' and 'Geosciences, Multidisciplinary' (cluster #3) also have a comparatively high average number of citations and hence academic impact, given their relatively short time to attract citations.Journals' Distribution and Intellectual BaseA dual-map overlay analysis is applied to identify highly productive and highly cited journals in the risk communication research domain and to trace their intellectual basis.", [["Intellectual BaseA dual-map overlay analysis", "TEST", 320, 364], ["productive", "OBSERVATION_MODIFIER", 395, 405]]], ["Only terms which appeared at least five times are retained for further analysis, with similar terms are merged to increase clarity in and focus of the results, as is commonly recommended in scientometric analyses [28] .", [["further analysis", "TEST", 63, 79]]], ["In total, 458 terms are retained, which are clustered using VOSviewer and subsequently transformed in heat maps to identify concentrations of higher activity.", [["VOSviewer", "TREATMENT", 60, 69], ["heat maps", "TEST", 102, 111], ["higher activity", "OBSERVATION", 142, 157]]], ["Figure 6 shows the dominant narrative patterns of the entire dataset, indicating the existence of two large clusters.", [["dominant", "OBSERVATION_MODIFIER", 19, 27], ["narrative patterns", "OBSERVATION", 28, 46], ["two", "OBSERVATION_MODIFIER", 98, 101], ["large", "OBSERVATION_MODIFIER", 102, 107], ["clusters", "OBSERVATION", 108, 116]]], ["Additionally, Figures 7 and 8 show a term density map of the term clusters by average year of publication of the terms, which highlights the temporal evolution of the clusters.Terms Analysis: Narrative PatternsThe automatic term identification method in the VOSviewer software [45, 49] is applied to extract terms and noun phrases related to the risk communication dataset of Section 2.1.", [["Figures", "TEST", 14, 21], ["term clusters", "OBSERVATION_MODIFIER", 61, 74], ["temporal", "OBSERVATION_MODIFIER", 141, 149], ["clusters", "OBSERVATION_MODIFIER", 167, 175]]], ["Only terms which appeared at least five times are retained for further analysis, with similar terms are merged to increase clarity in and focus of the results, as is commonly recommended in scientometric analyses [28] .", [["further analysis", "TEST", 63, 79]]], ["In total, 458 terms are retained, which are clustered using VOSviewer and subsequently transformed in heat maps to identify concentrations of higher activity.", [["VOSviewer", "TREATMENT", 60, 69], ["heat maps", "TEST", 102, 111], ["higher activity", "OBSERVATION", 142, 157]]], ["Figure 6 shows the dominant narrative patterns of the entire dataset, indicating the existence of two large clusters.", [["dominant", "OBSERVATION_MODIFIER", 19, 27], ["narrative patterns", "OBSERVATION", 28, 46], ["two", "OBSERVATION_MODIFIER", 98, 101], ["large", "OBSERVATION_MODIFIER", 102, 107], ["clusters", "OBSERVATION", 108, 116]]], ["Additionally, Figures 7 and 8 show a term density map of the term clusters by average year of publication of the terms, which highlights the temporal evolution of the clusters.", [["Figures", "TEST", 14, 21], ["term clusters", "OBSERVATION_MODIFIER", 61, 74], ["temporal", "OBSERVATION_MODIFIER", 141, 149], ["clusters", "OBSERVATION_MODIFIER", 167, 175]]], ["In the left cluster in Figure 6 (Cluster A in Table 7 ), the main terms are 'agency', 'government', 'stakeholder', 'organization', and 'case study', whereas in the right cluster (Cluster B in Table 7) , the most frequently occurring terms are 'patient', 'intervention', 'decision making', 'probability', and 'woman'.", [["patient", "ORGANISM", 244, 251], ["woman", "ORGANISM", 309, 314], ["patient", "SPECIES", 244, 251], ["woman", "SPECIES", 309, 314], ["left", "ANATOMY_MODIFIER", 7, 11], ["right", "ANATOMY_MODIFIER", 164, 169]]], ["On a high level, this indicates that the risk communication domain contains two major domains of work.", [["the risk communication domain", "PROBLEM", 37, 66]]], ["On the other hand, there is an important role for risk communication on a more personal level in medical contexts, where medical practitioners interact with patients about treatments of specific medical conditions, as in the guidance by the Risk Communication Institute [58] .", [["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 157, 165]]], ["The most frequently occurring keywords here are 'patient', 'intervention', 'decision making', 'probability', and 'woman'.", [["patient", "ORGANISM", 49, 56], ["woman", "ORGANISM", 114, 119], ["patient", "SPECIES", 49, 56], ["woman", "SPECIES", 114, 119]]], ["In the left cluster in Figure 6 (Cluster A in Table 7 ), the main terms are 'agency', 'government', 'stakeholder', 'organization', and 'case study', whereas in the right cluster (Cluster B in Table 7) , the most frequently occurring terms are 'patient', 'intervention', 'decision making', 'probability', and 'woman'.", [["patient", "ORGANISM", 244, 251], ["woman", "ORGANISM", 309, 314], ["patient", "SPECIES", 244, 251], ["woman", "SPECIES", 309, 314], ["left", "ANATOMY_MODIFIER", 7, 11], ["right", "ANATOMY_MODIFIER", 164, 169]]], ["On a high level, this indicates that the risk communication domain contains two major domains of work.", [["the risk communication domain", "PROBLEM", 37, 66]]], ["On the other hand, there is an important role for risk communication on a more personal level in medical contexts, where medical practitioners interact with patients about treatments of specific medical conditions, as in the guidance by the Risk Communication Institute [58] .", [["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 157, 165]]], ["The most frequently occurring keywords here are 'patient', 'intervention', 'decision making', 'probability', and 'woman'.", [["patient", "ORGANISM", 49, 56], ["woman", "ORGANISM", 114, 119], ["patient", "SPECIES", 49, 56], ["woman", "SPECIES", 114, 119]]], ["Dominant narratives after 2010 became stakeholders and organizations, with more attention to emergencies, crises, disasters, preparedness, outbreaks and disease control, and consumer products.", [["crises", "DISEASE", 106, 112], ["crises", "PROBLEM", 106, 112], ["disasters", "PROBLEM", 114, 123], ["disease control", "TREATMENT", 153, 168]]], ["Impactful topic-focused narratives concern disaster, crisis, emergency, and flood.Terms Analysis: Narrative PatternsIn Cluster B (medical risk communication), important narratives revolve around risk issues such as 'treatment', 'age', 'family', 'cancer', 'diagnosis', 'medicine', and 'screening'.", [["cancer", "ANATOMY", 246, 252], ["cancer", "DISEASE", 246, 252], ["cancer", "CANCER", 246, 252], ["crisis", "PROBLEM", 53, 59]]], ["Methodological and conceptual aspects of medical risk communication include 'probability', 'scale', 'scenario', 'skill', 'decision making', 'test', and 'patient knowledge'.", [["patient", "ORGANISM", 153, 160], ["patient", "SPECIES", 153, 160], ["medical risk communication", "TREATMENT", 41, 67]]], ["Inspecting Figures 7 and 8 and Table 7 shows that narratives around decision making, probability, treatment, cancer, family, woman, and consultation were dominant before 2010.", [["cancer", "ANATOMY", 109, 115], ["cancer", "DISEASE", 109, 115], ["cancer", "CANCER", 109, 115], ["woman", "ORGANISM", 125, 130], ["woman", "SPECIES", 125, 130], ["cancer", "OBSERVATION", 109, 115]]], ["After 2010, narratives focused more on patients, intervention, risk factors, age, and intentions.", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["intervention", "TREATMENT", 49, 61]]], ["Academically impactful narratives in Cluster B involve skill, relative risk, scale, decision making, subject, systematic review, tests, and frequency.Terms Analysis: Narrative PatternsOverall, the results show that some narratives are rather robust in the risk communication research Figure 6 show that risk issues around 'public health', 'food', 'floods', 'disasters', (disease) 'outbreak', and 'emergency' are important topics in cluster A (societal risk governance).", [["tests", "TEST", 129, 134]]], ["Dominant narratives after 2010 became stakeholders and organizations, with more attention to emergencies, crises, disasters, preparedness, outbreaks and disease control, and consumer products.", [["crises", "DISEASE", 106, 112], ["crises", "PROBLEM", 106, 112], ["disasters", "PROBLEM", 114, 123], ["disease control", "TREATMENT", 153, 168]]], ["Impactful topic-focused narratives concern disaster, crisis, emergency, and flood.Terms Analysis: Narrative PatternsIn Cluster B (medical risk communication), important narratives revolve around risk issues such as 'treatment', 'age', 'family', 'cancer', 'diagnosis', 'medicine', and 'screening'.", [["cancer", "ANATOMY", 246, 252], ["cancer", "DISEASE", 246, 252], ["cancer", "CANCER", 246, 252], ["crisis", "PROBLEM", 53, 59]]], ["Methodological and conceptual aspects of medical risk communication include 'probability', 'scale', 'scenario', 'skill', 'decision making', 'test', and 'patient knowledge'.", [["patient", "ORGANISM", 153, 160], ["patient", "SPECIES", 153, 160], ["medical risk communication", "TREATMENT", 41, 67]]], ["Inspecting Figures 7 and 8 and Table 7 shows that narratives around decision making, probability, treatment, cancer, family, woman, and consultation were dominant before 2010.", [["cancer", "ANATOMY", 109, 115], ["cancer", "DISEASE", 109, 115], ["cancer", "CANCER", 109, 115], ["woman", "ORGANISM", 125, 130], ["woman", "SPECIES", 125, 130], ["cancer", "OBSERVATION", 109, 115]]], ["After 2010, narratives focused more on patients, intervention, risk factors, age, and intentions.", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["intervention", "TREATMENT", 49, 61]]], ["Academically impactful narratives in Cluster B involve skill, relative risk, scale, decision making, subject, systematic review, tests, and frequency.Terms Analysis: Narrative PatternsOverall, the results show that some narratives are rather robust in the risk communication research domain, with a continued focus on patient-, treatment-, and risk-related information in Cluster B and a continued attention to societal health risks.", [["patient", "ORGANISM", 318, 325], ["patient", "SPECIES", 318, 325], ["tests", "TEST", 129, 134], ["treatment", "TREATMENT", 328, 337]]], ["The results also indicate that risk communication in emergency and disaster contexts has become a topic of academic interest more recently.Cited References-Research FrontsCiteSpace [47] is applied in this section to perform a co-citation analysis of the risk communication dataset of Section 2.1 in order to determine research clusters based on co-citation information.", [["a co-citation analysis", "TEST", 224, 246]]], ["Articles citing the largest number of references from a cluster are known as 'research fronts'.", [["largest", "OBSERVATION_MODIFIER", 20, 27], ["number", "OBSERVATION_MODIFIER", 28, 34]]], ["These can be seen as spearheading contributions leading the development of the research domain, and together they provide insight in the overall evolution of the research domain in terms of focus topics [38, 51] .Cited References-Research FrontsIn order to obtain a clear structure of the results, the co-citation analysis is here performed for the entire timespan of the dataset (1985-2019), using a time slice length of one year, an eight year look-back period of considering cited references, and a minimum of two citations per period.", [["the co-citation analysis", "TEST", 298, 322]]], ["The resulting co-citation network has 1157 nodes and 3924 co-citation links.", [["nodes", "ANATOMY", 43, 48], ["co-citation network", "MULTI-TISSUE_STRUCTURE", 14, 33], ["nodes", "OBSERVATION", 43, 48]]], ["The largest connected component of this co-citation network is shown in Figure 9 to show the most important parts of the structure and the intellectual basis of the research clusters.", [["this co-citation network", "TEST", 35, 59], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["component", "OBSERVATION_MODIFIER", 22, 31]]], ["In the figure, the node sizes are proportional to the number of citations of a publication, while the colors of the links between articles indicates the year when two documents were first cited together.", [["node", "ANATOMY", 19, 23], ["node", "MULTI-TISSUE_STRUCTURE", 19, 23], ["node", "OBSERVATION", 19, 23], ["sizes", "OBSERVATION_MODIFIER", 24, 29], ["proportional", "OBSERVATION_MODIFIER", 34, 46], ["number", "OBSERVATION_MODIFIER", 54, 60], ["publication", "OBSERVATION", 79, 90]]], ["The color shade of the clusters indicates the average publication year of the references.", [["color", "OBSERVATION_MODIFIER", 4, 9], ["shade", "OBSERVATION_MODIFIER", 10, 15], ["clusters", "OBSERVATION_MODIFIER", 23, 31]]], ["The main analysis results of the co-citation analysis for the largest network of connected clusters is shown in Table 8 .", [["the co-citation analysis", "TEST", 29, 53], ["main", "OBSERVATION_MODIFIER", 4, 8], ["largest", "OBSERVATION_MODIFIER", 62, 69]]], ["This table shows the name of the research cluster, the number of references included in the cluster, the associated article representing the research front, the average year of publication of the cited references, and the silhouette value.", [["silhouette", "ANATOMY", 222, 232]]], ["The silhouette value of a cluster ranges from \u22121 to 1 and indicates the uncertainty which needs to be considered when interpreting the nature of the cluster.", [["The silhouette value", "TEST", 0, 20], ["silhouette", "ANATOMY", 4, 14], ["cluster", "OBSERVATION_MODIFIER", 26, 33], ["ranges", "OBSERVATION_MODIFIER", 34, 40]]], ["A value of 1 represents a perfect separation from other clusters [59] .Cited References-Research FrontsIn Figure 10 , the five most highly cited references in each research cluster are shown.", [["A value", "TEST", 0, 7]]], ["Top five highly cited references in each co-citation network cluster.", [["highly", "OBSERVATION_MODIFIER", 9, 15]]], ["Top five highly cited references in each co-citation network cluster.", [["highly", "OBSERVATION_MODIFIER", 9, 15]]], ["Top five highly cited references with at least five citations received in the largest co-citation clusters (NP > 50) of Figure 10 , see also Referring to Tables 8 and 9 , the largest cluster spans 84 articles with a silhouette value of 0.769, indicating a relatively large overlap with other clusters.", [["NP", "TEST", 108, 110], ["a silhouette value", "TEST", 214, 232], ["a relatively large overlap with other clusters", "PROBLEM", 254, 300], ["largest", "OBSERVATION_MODIFIER", 78, 85], ["largest", "OBSERVATION_MODIFIER", 175, 182], ["silhouette", "ANATOMY", 216, 226], ["relatively", "OBSERVATION_MODIFIER", 256, 266], ["large", "OBSERVATION_MODIFIER", 267, 272], ["overlap", "OBSERVATION", 273, 280]]], ["It is labeled '\u03b1 Pictographs' based on LLR analysis.", [["LLR analysis", "TEST", 39, 51]]], ["The research front is [60] , which focuses on the use of pictographs for communicating medical screening information to persons with higher and lower numeracy skills.", [["persons", "ORGANISM", 120, 127], ["persons", "SPECIES", 120, 127], ["pictographs", "TREATMENT", 57, 68], ["communicating medical screening", "TREATMENT", 73, 104]]], ["The most highly cited reference in this cluster is [68] , which focuses on best practices on conveying health risks using numeric, verbal, and visual formats.", [["numeric, verbal, and visual formats", "TEST", 122, 157], ["most highly", "OBSERVATION_MODIFIER", 4, 15]]], ["Other highly cited references include [58, [69] [70] [71] , which focus on patient understanding of risks, numeracy, and the relation to decision making.", [["patient", "ORGANISM", 75, 82], ["patient", "SPECIES", 75, 82]]], ["The cluster also contains a review on the use of probability information in risk communication [21, 71] .Cited References-Research FrontsThe second largest cluster is labeled '\u03b2 Learning through Conflict'.", [["largest", "OBSERVATION_MODIFIER", 148, 155]]], ["It includes 78 references with a silhouette value of 0.931, indicating that it is well separated from other clusters.", [["a silhouette value", "TEST", 31, 49]]], ["The reference with highest number of citations is [72] , a book on risk communication aimed at decision-makers in government and industry, highlighting both the importance of procedure and content of risk messages.", [["procedure", "TREATMENT", 175, 184]]], ["Other significant references are [73] , a manual for industrial managers outlining a number of key rules for communicating with the public; [74] , which outlines a mental model of how lay people respond to environmental hazards; and [75] , which studies differences in lay and expert judgments of toxicological risks.Cited References-Research FrontsThe third largest cluster is labeled '\u03b3 Food Risk Communication', which includes 75 references with an average publication year of 2003 and a silhouette value of 0.867, indicating a reasonable separation of other research clusters.", [["people", "ORGANISM", 188, 194], ["people", "SPECIES", 188, 194], ["a silhouette value", "TEST", 489, 507], ["third", "OBSERVATION_MODIFIER", 353, 358], ["largest", "OBSERVATION_MODIFIER", 359, 366], ["silhouette", "ANATOMY", 491, 501]]], ["It highlights media amplification, public trust, and communication of uncertainty as essential ingredients.", [["media amplification", "TREATMENT", 14, 33], ["media amplification", "OBSERVATION", 14, 33]]], ["Other impactful references include [77] , a book outlining the social amplification of risk framework, and [78] , a book describing theory and applications of a mental models approach to risk communication.", [["a mental models approach", "TREATMENT", 159, 183]]], ["The last two highly impactful references in this cluster are [18] , a review article describing the evolution of some major developments in risk communication in the period 1996-2005, and [79] , a book outlining four risk management strategies (political regulatory process, public deliberation, the technocratic/scientific perspective, and strictly economics-based risk management) and risk management case studies in Germany, the USA, and Sweden.Cited References-Research FrontsThe fourth largest cluster is '\u03b4 Rational Public Discourse', which includes 69 references with an average publication year of 1988.", [["four risk management strategies", "TREATMENT", 212, 243], ["risk management", "TREATMENT", 366, 381], ["fourth", "OBSERVATION_MODIFIER", 484, 490], ["largest", "OBSERVATION_MODIFIER", 491, 498]]], ["Its silhouette value is 0.898, indicating a high degree of separation of other co-citation clusters.", [["Its silhouette value", "TEST", 0, 20], ["other co-citation clusters", "PROBLEM", 73, 99], ["silhouette", "ANATOMY", 4, 14], ["high degree", "OBSERVATION_MODIFIER", 44, 55], ["separation", "OBSERVATION_MODIFIER", 59, 69], ["co-citation clusters", "OBSERVATION", 79, 99]]], ["The research front of this cluster is [63] , which discusses a communication process between stakeholders with conflicting interests from the viewpoint of message recognition, inducing attitude and behavior changes, and conflict resolution.", [["behavior changes", "PROBLEM", 198, 214]]], ["The reference with the highest number of citations in this cluster is [80] , an influential book on risk communication, introducing it as a technical and cultural phenomenon.", [["a technical and cultural phenomenon", "PROBLEM", 138, 173]]], ["Another influential reference is [81] , a book outlining seven cardinal rules for effective risk communication in environmental risk management.", [["environmental risk management", "TREATMENT", 114, 143]]], ["The final two highly influential references in this cluster are [82] , which introduces the social amplification of risk framework, and [83] , which presents results of a study on risk communication in response to public concerns about geological radon health hazards.Cited References-Research FrontsThe fifth largest co-citation cluster, spanning 61 references with an average publication year of 2001, is labeled '\u03b5 General Practice Patient Involvement'.", [["a study", "TEST", 169, 176], ["fifth", "OBSERVATION_MODIFIER", 304, 309], ["largest", "OBSERVATION_MODIFIER", 310, 317], ["co-citation", "OBSERVATION_MODIFIER", 318, 329], ["cluster", "OBSERVATION_MODIFIER", 330, 337]]], ["It has a silhouette value of 0.835, indicating a relatively large overlap with other clusters.", [["a silhouette value", "TEST", 7, 25], ["a relatively large overlap with other clusters", "PROBLEM", 47, 93], ["silhouette", "OBSERVATION_MODIFIER", 9, 19], ["relatively", "OBSERVATION_MODIFIER", 49, 59], ["large", "OBSERVATION_MODIFIER", 60, 65], ["overlap", "OBSERVATION", 66, 73]]], ["The research front of this cluster is [64] , which presents results of a study on the use of risk communication for shared decision making in general practice.", [["a study", "TEST", 71, 78]]], ["Other highly impactful references include [20, [85] [86] [87] [88] , which concern various aspects of the visual communication of medical-related risks and the impacts on effectiveness of patient decision making.", [["patient", "ORGANISM", 188, 195], ["patient", "SPECIES", 188, 195]]], ["The references [89, 90] address case studies of representation of risk information related to violence and cancer, whereas [91, 92] address patient participation and teaching and learning in shared decision making.Cited References-Research FrontsThe sixth largest research cluster spans 56 references with an average publication year of 2009 and is labeled '\u03b6 Flood Risk Communication'.", [["cancer", "ANATOMY", 107, 113], ["violence", "DISEASE", 94, 102], ["cancer", "DISEASE", 107, 113], ["cancer", "CANCER", 107, 113], ["patient", "ORGANISM", 140, 147], ["patient", "SPECIES", 140, 147], ["cancer", "PROBLEM", 107, 113], ["cancer", "OBSERVATION", 107, 113], ["sixth", "OBSERVATION_MODIFIER", 250, 255], ["largest", "OBSERVATION_MODIFIER", 256, 263]]], ["With a silhouette value of 0.852, it has a relatively large overlap with other clusters.", [["a silhouette value", "TEST", 5, 23], ["silhouette", "ANATOMY", 7, 17], ["relatively", "OBSERVATION_MODIFIER", 43, 53], ["large", "OBSERVATION_MODIFIER", 54, 59], ["overlap", "OBSERVATION", 60, 67]]], ["The research front of this cluster is [65] , which describes a best practices model for risk communication and management in environmental hazards related to floods.", [["management", "TREATMENT", 111, 121]]], ["The highest cited reference in this cluster is [93] , which builds on an extensive body of risk communication literature to address four questions about risk communication, including how to communicate uncertainty, how declining trust can be handled, and what the lessons learned from earlier work can be used to define new principles for risk communication.", [["highest", "OBSERVATION_MODIFIER", 4, 11]]], ["It has a silhouette value of 0.934, indicating a good separation from other co-citation clusters.", [["a silhouette value", "TEST", 7, 25], ["silhouette", "OBSERVATION_MODIFIER", 9, 19], ["good", "OBSERVATION_MODIFIER", 49, 53], ["separation", "OBSERVATION", 54, 64], ["co-citation clusters", "OBSERVATION", 76, 96]]], ["Its research front is [66] , which is a highly impactful article describing risk perceptions and communication strategies for release of a biohazard pathogen in an urban setting.", [["communication strategies", "TREATMENT", 97, 121], ["a biohazard pathogen", "TREATMENT", 137, 157]]], ["The highest cited references in this cluster are [16] , which describes the evolution of 20 years of risk perception and risk communication research; [98] , which addresses the issue of various scales of risk as a challenge for risk communication; and [99] , which presents an analytical-deliberative process for risk communication.Interpretation of the ResultsThe analysis of research outputs in the risk communication research domain in Section 2.1 shows a fast accelerating growth, especially over the last two decades.", [["risk perception", "PROBLEM", 101, 116], ["research outputs", "TEST", 377, 393], ["a fast accelerating growth", "PROBLEM", 457, 483], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["fast", "OBSERVATION_MODIFIER", 459, 463], ["accelerating", "OBSERVATION_MODIFIER", 464, 476], ["growth", "OBSERVATION_MODIFIER", 477, 483]]], ["It has been shown that publication rates have increased sharply across the entire scientific enterprise [100] , and similar surges in publication rates have been observed in other risk-related scientometric analyses [33, 35, 41] .", [["publication rates", "TEST", 23, 40], ["scientometric analyses", "TEST", 193, 215], ["increased", "OBSERVATION_MODIFIER", 46, 55], ["sharply", "OBSERVATION_MODIFIER", 56, 63]]], ["Hence, it is not entirely clear whether the increased risk communication research outputs are indeed indicative of its relative increased academic significance, whether these are the result of the increased relevance in societal governance or medical contexts, or whether the trends are caused by internal dynamics of academia.Interpretation of the ResultsFocusing on the geographical distribution of the research outputs shown in Section 3.2, it is very clear that, for the time being, the domain is very strongly dominated by research originating from Western countries, with the United States of America being by far the largest contributor.", [["the increased risk communication research outputs", "PROBLEM", 40, 89], ["academia", "PROBLEM", 318, 326], ["the research outputs", "TEST", 401, 421], ["increased", "OBSERVATION_MODIFIER", 44, 53], ["increased", "OBSERVATION_MODIFIER", 128, 137], ["increased", "OBSERVATION_MODIFIER", 197, 206], ["very", "OBSERVATION_MODIFIER", 450, 454], ["clear", "OBSERVATION", 455, 460]]], ["Only some Western European countries also have significantly contributed to the domain, with other geographical regions displaying a much lower research output.", [["a much lower research output", "PROBLEM", 131, 159], ["much", "OBSERVATION_MODIFIER", 133, 137], ["lower", "OBSERVATION_MODIFIER", 138, 143], ["research output", "OBSERVATION", 144, 159]]], ["The research impact shows a similar picture.", [["similar picture", "OBSERVATION", 28, 43]]], ["This may indicate that the Western dominance may decrease in the future and that new perspectives may enter the research domain.Interpretation of the ResultsThe relative dearth of risk communication research in South American, Eastern European, African, Middle Eastern, Asian, and Oceanian countries/regions may be a reflection of the governance structures of those societies, because governance approaches and mechanisms are necessarily embedded in cultural, organizational, and political contexts [11] .", [["governance approaches", "TREATMENT", 385, 406], ["decrease", "OBSERVATION_MODIFIER", 49, 57], ["Middle", "ANATOMY_MODIFIER", 254, 260]]], ["Nevertheless, informing the public in disaster or crisis situations, e.g., related to public health or natural hazards, is likely important irrespective of the political governance style.Interpretation of the ResultsThe activity in the broad co-citation clusters of Section 3.6 and the research activity across scientific categories of Section 3.3 indicates that risk communication research follows general societal concerns: while health, medicine, and environmental issues are of continuous relevance, concerns about specific technologies such as nuclear power are more transitory.", [["nuclear", "CELLULAR_COMPONENT", 549, 556], ["crisis situations", "PROBLEM", 50, 67], ["Section", "TEST", 266, 273]]], ["The recent focus on meteorology and atmospheric sciences and geosciences furthermore indicate a broad trend in increased focus on effects of climate change and natural disasters.", [["a broad trend", "PROBLEM", 94, 107], ["broad", "OBSERVATION_MODIFIER", 96, 101], ["increased", "OBSERVATION_MODIFIER", 111, 120], ["focus", "OBSERVATION", 121, 126]]], ["These broad trends are also found in risk perception research [102] , which is closely linked with risk communication as these are commonly discussed together, especially in a societal risk governance context [11, 97] .Interpretation of the ResultsThe scientific category analysis of Section 3.3 and the journals' distribution and intellectual basis analysis of Section 3.4 show that the risk communication body of knowledge is interdisciplinary.", [["Section", "TEST", 284, 291], ["intellectual basis analysis", "TEST", 331, 358], ["Section", "TEST", 362, 369]]], ["The results of the co-citation analysis and research fronts described in Section 3.6 show that applied research in risk communication appears to follow large societal trends and topics of societal concern, including public health, nuclear power, epidemics, natural disasters, and food regulation.Interpretation of the ResultsThe analysis of narrative patterns in Section 3.5 shows that there are two major clusters in terms: one related to societal risk governance and one addressing medical risk communication.", [["the co-citation analysis", "TEST", 15, 39], ["epidemics", "PROBLEM", 246, 255], ["narrative patterns", "TEST", 341, 359], ["major", "OBSERVATION_MODIFIER", 400, 405], ["clusters", "OBSERVATION", 406, 414]]], ["These address largely different problems, in that the former focuses on communication between different societal stakeholders with possibly conflicting value systems and objectives, while the latter is concerned with interpersonal communication in a trust relationship between medical practitioner and patient (or family).", [["patient", "ORGANISM", 302, 309], ["patient", "SPECIES", 302, 309], ["largely different problems", "PROBLEM", 14, 40], ["different", "OBSERVATION_MODIFIER", 22, 31], ["problems", "OBSERVATION", 32, 40]]], ["Table 7 show that these clusters are mostly disjoint.", [["clusters", "OBSERVATION_MODIFIER", 24, 32], ["mostly", "OBSERVATION_MODIFIER", 37, 43], ["disjoint", "OBSERVATION_MODIFIER", 44, 52]]], ["The results of the co-citation cluster results of Section 3.6 also show that medicine-related risk communication knowledge remains mostly in that broad subdomain of the research field, while application-specific knowledge related to other societal risks also is rather contained, as can be judged from the mostly very high silhouette values.The term analysis of Figures 6-8 andFinally, in the analysis of journal distribution in Section 3.4, it is noteworthy that Risk Analysis and Journal of Risk Research, which have been identified as core journals in risk and safety research [103] , concentrate a large body of work on risk communication, while also having a significant scientific impact in this domain.", [["the mostly very high silhouette values", "PROBLEM", 302, 340], ["The term analysis", "TEST", 341, 358], ["Figures", "TEST", 362, 369]]], ["This can be seen to support arguments that risk research is not merely an interdisciplinary or transdisciplinary research activity, but that it has its own foundational basis of concepts, theories, models, and approaches, and that it hence could be seen as a research domain in its own right [67] .The term analysis of Figures 6-8 andAs noted by one of the reviewers of an earlier version of this manuscript, the answers found to the questions stated in the introduction are in line with what knowledgeable domain experts would expect.", [["The term analysis", "TEST", 298, 315], ["Figures", "TEST", 319, 326], ["right", "ANATOMY_MODIFIER", 286, 291]]], ["Through a data-driven approach, the results obtained in this work substantiate these intuitive expert insights, providing evidence for the stated research questions, while raising new questions and research directions, as outlined next.Future WorkBased on the results of Section 3 as discussed in Section 4.1, a number of avenues for future work can be identified, either to further develop the research domain of risk communication itself, or to better understand how it has developed as a domain of scientific activity.Future WorkConsidering that risks are mediated and socially conveyed differently across varying cultural traditions [104] , the lack of risk communication research in non-Western societies may result in a culturally biased approach.", [["a culturally biased approach", "TREATMENT", 724, 752]]], ["Judging from The Global Risks Report 2020 [105] and considering that perceptions of importance of societal risks are usually mostly driven by the severity of potential impacts [106] , such research could focus on climate action failure, weapons of mass destruction, biodiversity loss, extreme weather, water crises, information infrastructure breakdown, natural disasters, cyberattacks, human-made environmental disasters, and infectious diseases.", [["biodiversity loss", "DISEASE", 266, 283], ["cyberattacks", "DISEASE", 373, 385], ["infectious diseases", "DISEASE", 427, 446], ["human", "ORGANISM", 387, 392], ["human", "SPECIES", 387, 392], ["human", "SPECIES", 387, 392], ["societal risks", "TREATMENT", 98, 112], ["climate action failure", "PROBLEM", 213, 235], ["mass destruction", "PROBLEM", 248, 264], ["biodiversity loss", "PROBLEM", 266, 283], ["water crises", "PROBLEM", 302, 314], ["infectious diseases", "PROBLEM", 427, 446], ["mass", "OBSERVATION", 248, 252], ["biodiversity loss", "OBSERVATION", 266, 283], ["infectious", "OBSERVATION", 427, 437]]], ["Risk communication research may be especially relevant where such technologies lead to concerns about human health or safety, in particular in contexts where uncertainty and ambiguity are societally important dimensions of risk.", [["human", "ORGANISM", 102, 107], ["human", "SPECIES", 102, 107], ["human", "SPECIES", 102, 107]]], ["One example of this is the human health concerns related to the adoption of 5G wireless communication technology [107] , about which conspiracy theories circulate on social media platforms, linking 5G technology to the COVID-19 pandemic [108] .", [["human", "ORGANISM", 27, 32], ["human", "SPECIES", 27, 32], ["human", "SPECIES", 27, 32]]], ["Another example may be the industrial developments towards autonomous cars and maritime autonomous surface ships.", [["surface", "ANATOMY", 99, 106], ["may be", "UNCERTAINTY", 16, 22]]], ["Risk communication research can help to inform and interact with the public for such new developments.Future WorkBased on the finding that risk communication research related to societal risk governance issues and research in medical contexts are as yet largely separated areas of work, it may be fruitful for future research to identify links between certain themes within these subdomains.", [["societal risk governance issues", "PROBLEM", 178, 209]]], ["Such knowledge exchange can, for instance, lead to new conceptual, theoretical, or methodological approaches.Future WorkWhile scientometrics analyses are well suited to obtain high-level insights into a research domain in terms of its structure, patterns, and evolution, the existing scientometric techniques are ill-suited to detect research gaps, recent patterns, or research directions related to specific frameworks or approaches.", [["Future WorkWhile scientometrics analyses", "TEST", 109, 149]]], ["Narrative reviews and other research methods are better suited for such more in-depth questions about the risk communication research domain than the scientometric analyses presented here.", [["the scientometric analyses", "TEST", 146, 172]]], ["Nevertheless, the results of Section 3 may serve as a basis for directing such future research.LimitationsAs in any study, it is important to be aware of the limitations of the presented work.", [["any study", "TEST", 112, 121]]], ["First, the analysis is conditional to the search strategy described in Section 2.1.", [["the analysis", "TEST", 7, 19]]], ["Finally, the language restriction to English language publications may also induce some blind spots in the analysis.LimitationsIt is noted here that using other terms such as 'crisis communication', 'emergency communication', or 'disaster communication' will almost certainly lead to detecting other patterns and trends.", [["some blind spots", "PROBLEM", 83, 99], ["the analysis", "TEST", 103, 115]]], ["While these themes clearly have a close relationship to risk communication, as evidenced, e.g., by the results of the terms analysis (Section 3.5) or the co-citation clusters (Section 3.6), the choice has been made in this article to restrict the search to 'risk communication'.", [["the terms analysis", "TEST", 114, 132]]], ["While there is no scientific agreement about what exactly 'risk' means, it is broadly agreed that this carries the notion of possible or uncertain future events [110] .", [["no", "UNCERTAINTY", 15, 17]]], ["In contrast, crisis, emergency, or disaster communication is more focused on providing information about events which have already occurred or are ongoing [111] .", [["crisis", "PROBLEM", 13, 19]]], ["While this delineation is not exact due to linguistic ambiguities, risk communication for example relates more to stakeholder processes in preparedness planning for natural or technological disasters, while crisis communication would focus on what information to provide, when, and how, to affected people in an ongoing disaster.", [["people", "ORGANISM", 299, 305], ["people", "SPECIES", 299, 305], ["linguistic ambiguities", "PROBLEM", 43, 65]]], ["Follow-up research may explore the domains of research covered by the other mentioned search terms, from which more conclusive statements about their specific relationships can be made.LimitationsIn the analyses involving temporal evolutions of geographical research productivity (Section 3.2), active scientific categories (Section 3.3), narrative patterns (Section 3.5), and co-citation clusters (Section 3.6), the average publication year is used as a metric.", [["temporal", "OBSERVATION_MODIFIER", 222, 230], ["geographical", "OBSERVATION_MODIFIER", 245, 257]]], ["This may be because of the actual lower impact in the academic community, but the measures are also confounded by the shorter time of citations to accumulate to this research.", [["lower", "OBSERVATION_MODIFIER", 34, 39], ["impact", "OBSERVATION", 40, 46]]], ["Furthermore, using citations as a proxy for significance of research contributions is controversial [112, 113] , e.g., because of the potential for manipulation and lack of consideration of why an article was cited.", [["manipulation", "TREATMENT", 148, 160]]], ["Consequently, the presented scientometric analysis should not be seen as an endorsement of the correctness, value, or effectiveness of the highlighted risk communication research works.", [["the presented scientometric analysis", "TEST", 14, 50]]], ["Instead, the analyses should rather be understood as descriptive of the development of the field and the countries, scientific categories, journals, terms, and references which have jointly forged and shaped the research domain to what it currently is.ConclusionsIn this work, a scientometric analysis of the risk communication research literature has been presented, spanning the period from 1985 to 2019.", [["a scientometric analysis", "TEST", 277, 301]]], ["Various scientometric methods and visualization tools are applied to determine temporal trends and geographical patterns, contributing scientific categories and domains, the distribution of contributing journals and the intellectual basis of the domain, narrative patterns, and the evolution of the research domain using co-citation clusters.", [["Various scientometric methods", "TREATMENT", 0, 29], ["visualization tools", "TEST", 34, 53]]], ["The analyses provide unprecedented insights into the structure, patterns, and developments of the risk communication domain, leading to several avenues of future research.", [["The analyses", "TEST", 0, 12]]], ["The following main key conclusions are drawn:Conclusions(i) Risk communication research has grown exponentially, especially with a very significant increase since the early 2000s. (ii) The domain is dominated by Western science, primarily from the USA and Western European countries, with non-Western research however recently emerging. (iii) The research domain is highly interdisciplinary, where typically knowledge from 'Psychology and Social Sciences' is combined with application-specific knowledge, with the domains 'Biology and Medicine', and 'Ecology and Environmental Science and Technology' being the most prominent. (iv) The most important journals in the field are Risk Analysis and Journal of Risk Research, which may suggest that risk research can been seen as a scientific domain in its own right. (v) There are two main, largely disconnected, narrative clusters in risk communication research.ConclusionsThe first cluster is that of communication between medical practitioners and patients, and the other cluster concerns stakeholder communication for societal risk governance.", [["(iii)", "CHEMICAL", 337, 342], ["patients", "ORGANISM", 997, 1005], ["patients", "SPECIES", 997, 1005], ["very", "OBSERVATION_MODIFIER", 131, 135], ["significant", "OBSERVATION_MODIFIER", 136, 147], ["increase", "OBSERVATION", 148, 156], ["highly", "OBSERVATION_MODIFIER", 366, 372], ["interdisciplinary", "OBSERVATION_MODIFIER", 373, 390], ["most prominent", "OBSERVATION_MODIFIER", 611, 625], ["right", "ANATOMY_MODIFIER", 806, 811], ["two", "OBSERVATION_MODIFIER", 827, 830], ["main", "OBSERVATION_MODIFIER", 831, 835], ["largely", "OBSERVATION_MODIFIER", 837, 844], ["disconnected", "OBSERVATION", 845, 857]]], ["The dominant narratives in the former concern interventions, decision making, and various medical conditions, whereas the latter focuses on societal risks such as public health, food, floods, or disease outbreaks. (vi) Risk communication research originates from a practice-oriented need to communicate regarding industrial (environmental) contamination and public health.", [["disease outbreaks", "PROBLEM", 195, 212], ["dominant", "OBSERVATION_MODIFIER", 4, 12], ["narratives", "OBSERVATION", 13, 23]]], ["Most subsequent research clusters address particular medical issues or societal concerns, including nuclear power, epidemics, or natural disasters.", [["epidemics", "PROBLEM", 115, 124]]], ["Many clusters are quite disjoint.", [["clusters", "OBSERVATION_MODIFIER", 5, 13], ["disjoint", "OBSERVATION_MODIFIER", 24, 32]]], ["This indicates that knowledge exchange between application domains is not very significant, which may therefore be a fruitful direction for future scholarship.ConclusionsApart from providing insights into the structure and evolution of the research domain and leading to the formulation of several avenues for future research, the results are considered particularly useful for early career researchers who are relatively new to the very extensive domain of risk communication research.", [["not very", "UNCERTAINTY", 70, 78]]], ["They can also assist experienced academics in navigating the fast-increasing volume of research, either for teaching or research purposes.", [["research purposes", "TEST", 120, 137]]]], "PMC7273285": [["IntroductionThe Coronavirus disease 2019 (COVID-19) pandemic that emerged in the city of Wuhan in China in December 2019 has invaded nearly every nation of the world, becoming the most important public health emergency of the last century after the 1918\u20131920 influenza pandemic (WHO, 2020).", [["Coronavirus disease", "DISEASE", 16, 35], ["COVID-19", "CHEMICAL", 42, 50], ["influenza pandemic", "DISEASE", 259, 277], ["COVID-19", "ORGANISM", 42, 50], ["Coronavirus disease 2019 (COVID-19", "SPECIES", 16, 50], ["The Coronavirus disease", "PROBLEM", 12, 35], ["COVID", "TEST", 42, 47], ["pandemic", "PROBLEM", 52, 60], ["Coronavirus disease", "OBSERVATION", 16, 35]]], ["In particular, the novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has an ability to exert substantial severe disease and mortality burden especially affecting individuals older than 60 years and those with prior health conditions including hypertension, cardiovascular disease, obesity and diabetes (Adler, 2020; Team, 2020).", [["cardiovascular", "ANATOMY", 274, 288], ["Acute Respiratory Syndrome Coronavirus", "DISEASE", 32, 70], ["SARS-CoV-2", "CHEMICAL", 74, 84], ["hypertension", "DISEASE", 260, 272], ["cardiovascular disease", "DISEASE", 274, 296], ["obesity", "DISEASE", 298, 305], ["diabetes", "DISEASE", 310, 318], ["SARS-CoV-2", "ORGANISM", 74, 84], ["Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2", "SPECIES", 25, 84], ["the novel Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 15, 70], ["SARS-CoV", "TEST", 74, 82], ["substantial severe disease", "PROBLEM", 110, 136], ["mortality burden", "PROBLEM", 141, 157], ["prior health conditions", "PROBLEM", 226, 249], ["hypertension", "PROBLEM", 260, 272], ["cardiovascular disease", "PROBLEM", 274, 296], ["obesity", "PROBLEM", 298, 305], ["diabetes", "PROBLEM", 310, 318], ["Severe", "OBSERVATION_MODIFIER", 25, 31], ["Acute", "OBSERVATION_MODIFIER", 32, 37], ["Respiratory Syndrome", "OBSERVATION", 38, 58], ["substantial", "OBSERVATION_MODIFIER", 110, 121], ["severe", "OBSERVATION_MODIFIER", 122, 128], ["disease", "OBSERVATION", 129, 136], ["hypertension", "OBSERVATION", 260, 272], ["cardiovascular", "ANATOMY", 274, 288], ["disease", "OBSERVATION", 289, 296], ["obesity", "OBSERVATION", 298, 305], ["diabetes", "OBSERVATION", 310, 318]]], ["As of April 15th, 2020, the trajectory of the pandemic varies significantly around the world ranging from relatively well contained outbreaks in Thailand, Taiwan and Hong Kong to explosive epidemics characterized by initial exponential growth periods in a few hotspots located in various countries around the world including the United States, Italy, Spain, UK, France, and Iran (Ebbs, 2020; Griffiths, 2020; Minder, 2020).IntroductionBy April 15th, 2020, SARS-CoV-2 is generating local transmission in over 200 countries and over 2.2 million cases and 150 thousand deaths have been reported globally (WHO, 2020).", [["SARS", "DISEASE", 456, 460], ["deaths", "DISEASE", 566, 572], ["SARS-CoV", "SPECIES", 456, 464], ["the pandemic varies", "PROBLEM", 42, 61], ["explosive epidemics", "PROBLEM", 179, 198], ["initial exponential growth periods", "PROBLEM", 216, 250], ["pandemic", "OBSERVATION", 46, 54], ["exponential", "OBSERVATION_MODIFIER", 224, 235], ["growth", "OBSERVATION_MODIFIER", 236, 242]]], ["The COVID-19 pandemic was confirmed to have reached Latin America in February 2020 with a gradual expansion in the region until March 2020 when the COVID-19 incidence curve started to grow more rapidly.", [["The COVID", "TEST", 0, 9], ["a gradual expansion in the region", "TREATMENT", 88, 121], ["the COVID", "TEST", 144, 153], ["gradual", "OBSERVATION_MODIFIER", 90, 97], ["expansion", "OBSERVATION_MODIFIER", 98, 107]]], ["The US, the country with the highest number of reported COVID-19 cases in the world, has recorded 637,196 COVID-19 cases by April 15th, 2020.", [["The US", "TEST", 0, 6], ["COVID", "TEST", 56, 61], ["COVID", "TEST", 106, 111]]], ["In Latin America, Brazil has reported 28320 cases, the highest number of cases in the region followed by Peru with a total of 11475 cases (Worldometer, 2020).IntroductionPeru, a country located in western South America, reported its first imported case of COVID-19 in Lima, on March 6th, 2020, a Peruvian with recent travel history to France, Spain and Czech Republic (Aquino & Garrison, 2020).", [["Lima", "ANATOMY", 268, 272]]], ["By April 15th, 2020, a total of 11475 cases including 254 deaths have been reported by the Peruvian government.", [["deaths", "DISEASE", 58, 64]]], ["Lima, the capital of Peru has recorded 8412 cases, the highest number of cases within Peru (MOH, 2020).", [["capital", "ANATOMY_MODIFIER", 10, 17], ["highest", "OBSERVATION_MODIFIER", 55, 62]]], ["To respond to the growing number of COVID-19 cases in the country, the government shuttered schools on March 11th, 2020.", [["COVID", "TEST", 36, 41]]], ["The next day, the government banned gatherings of more than 300 people and suspended all international flights from Europe and Asia.", [["people", "SPECIES", 64, 70]]], ["Subsequently, on March 17th, 2020 the president of Peru announced the beginning of community transmission of SARS-CoV-2 in the country, and ordered a curfew in the region on March 18th, 2020 to avoid night time socializing to prevent disease transmission (Explorer, 2020; Writing, 2020).IntroductionIn order to combat the spread of the COVID-19 epidemic in Lima, the capital and largest city of Peru, estimates of the transmission potential of COVID-19 can guide the intensity of interventions including the reproduction number, R, during the early transmission phase (Nishiura & Chowell, 2009, 2014).", [["SARS", "DISEASE", 109, 113], ["COVID-19", "CHEMICAL", 444, 452], ["SARS-CoV", "SPECIES", 109, 117], ["the COVID", "TEST", 332, 341], ["COVID", "TEST", 444, 449], ["interventions", "TREATMENT", 480, 493], ["Lima", "ANATOMY", 357, 361], ["capital", "ANATOMY_MODIFIER", 367, 374], ["largest", "OBSERVATION_MODIFIER", 379, 386]]], ["Moreover, using the epidemiological data and mathematical modeling, it is possible to gauge the impact of control interventions including school closures and a national emergency declaration in Lima by assessing short-term forecasts grounded on the trajectory of the epidemic prior to the implementation of control interventions (Funk, Camacho, Kucharski, Eggo, & Edmunds, 2018; Shanafelt, Jones, Lima, Perrings, & Chowell, 2018).Data ::: MethodsWe analyzed the daily number of COVID-19 confirmed cases by date of symptoms onset in Lima, Peru by March 30th, 2020.", [["the epidemiological data", "TEST", 16, 40], ["mathematical modeling", "TEST", 45, 66], ["control interventions", "TREATMENT", 106, 127], ["school closures", "TREATMENT", 138, 153], ["control interventions", "TREATMENT", 307, 328], ["COVID", "TEST", 478, 483], ["symptoms", "PROBLEM", 514, 522], ["Lima", "ANATOMY", 397, 401]]], ["We also examined the daily testing rate and the positivity rate from the daily number of positive and negative PCR test results by the date of reporting until March 30th, 2020.Early growth model ::: MethodsWe generate short-term forecasts in real time using the generalized growth model (GGM) that relies on two parameters and characterizes the early ascending phase of the epidemic allowing to capture a range of epidemic growth profiles including sub-exponential (polynomial) and exponential growth.", [["the daily testing rate", "TEST", 17, 39], ["the positivity rate", "TEST", 44, 63], ["epidemic growth profiles", "PROBLEM", 414, 438], ["exponential growth", "PROBLEM", 482, 500], ["growth model", "OBSERVATION", 182, 194], ["early", "OBSERVATION_MODIFIER", 345, 350], ["ascending", "OBSERVATION_MODIFIER", 351, 360], ["phase", "OBSERVATION_MODIFIER", 361, 366], ["exponential", "OBSERVATION_MODIFIER", 482, 493], ["growth", "OBSERVATION_MODIFIER", 494, 500]]], ["GGM characterizes epidemic growth by estimating two parameters (i) the intrinsic growth rate, r and (ii) a dimensionless \u201cdeacceleration of growth\u201d or \u201cscaling of growth\u201d parameter, p.", [["epidemic growth", "PROBLEM", 18, 33], ["the intrinsic growth rate", "TEST", 67, 92], ["growth\u201d", "PROBLEM", 140, 147], ["epidemic", "OBSERVATION_MODIFIER", 18, 26], ["growth", "OBSERVATION_MODIFIER", 27, 33], ["growth", "OBSERVATION_MODIFIER", 140, 146]]], ["The latter parameter modulates the epidemic growth patterns including the sub-exponential growth (p<1) and exponential growth dynamics (p=1).", [["the epidemic growth patterns", "PROBLEM", 31, 59], ["exponential growth dynamics", "PROBLEM", 107, 134], ["epidemic", "OBSERVATION_MODIFIER", 35, 43], ["growth", "OBSERVATION_MODIFIER", 44, 50], ["sub", "OBSERVATION_MODIFIER", 74, 77], ["exponential", "OBSERVATION_MODIFIER", 78, 89], ["growth", "OBSERVATION_MODIFIER", 90, 96], ["exponential", "OBSERVATION_MODIFIER", 107, 118], ["growth", "OBSERVATION_MODIFIER", 119, 125]]], ["The GGM model is given by the following differential equation:dC(t)dt=C\u2032(t)=rC(t)pWhere C\u2032(t) describes case incidence over time t.", [["dt", "TEST", 67, 69]]], ["The cumulative number of cases at time t is given by C\u2032(t) while r is a positive parameter denoting the growth rate (1/time) and p\u2208[0,1] is a \u201cdeceleration of growth\u201d parameter (Chowell, 2017; Viboud, Simonsen, & Chowell, 2016).Short term forecast to assess interventions ::: MethodsWe calibrate the GGM model to the daily case incidence by the date of symptoms onset for Lima.", [["the growth rate", "TEST", 100, 115], ["MethodsWe", "TREATMENT", 276, 285], ["symptoms", "PROBLEM", 353, 361], ["positive", "OBSERVATION", 72, 80]]], ["Our model was calibrated using case series from February 29th-March 15th, 2020, prior to the implementation of national emergency in Lima.Short term forecast to assess interventions ::: MethodsThe best fit model solution is estimated by using a non-linear least square fitting approach (full details provided in (Chowell, 2017)).", [["Methods", "TREATMENT", 186, 193], ["Lima", "ANATOMY", 133, 137]]], ["This process searches for the set of model parameters that minimizes the sum of squared differences between the observed data yti = yt1, yt2, .ytn and the corresponding model solution given by f(ti, \u0398): where \u0398 = (r, p) correspond to estimated set of parameters of the GGM model.", [["yt2", "GENE_OR_GENE_PRODUCT", 137, 140], ["yt1", "PROTEIN", 132, 135], ["yt2", "PROTEIN", 137, 140], [".ytn", "PROTEIN", 142, 146]]], ["Thus, the objective function for the best fit solution of f(ti, \u0398) is given by\u0398^=argmin\u2211i=1n(f(ti,\u0398)\u2212yti)2The initial condition is fixed to the first observation in the data.", [["argmin\u2211i", "TEST", 81, 89]]], ["Next, we derive uncertainty around the best fit model solution as well as the confidence intervals of the parameters utilizing a parametric bootstrapping approach assuming a Poisson error structure as described in ref (Chowell, 2017).Reproduction number from case incidence using the generalized-growth model ::: MethodsGenerally, the reproduction number, R, quantifies the average number of secondary cases per case during the early ascending phase of an outbreak before the implementation of interventions or behavior changes (Anderson & May, 1991; Chowell et al., 2015; Yan & Chowell, 2019).", [["a parametric bootstrapping approach", "TREATMENT", 127, 162], ["interventions", "TREATMENT", 494, 507]]], ["Estimates of the effective R indicate if the disease transmission sustains (R>1) or the disease trend is declining (R<1).", [["the disease transmission sustains", "PROBLEM", 41, 74], ["the disease trend", "PROBLEM", 84, 101], ["disease", "OBSERVATION", 88, 95]]], ["Therefore, it is necessary to maintain R<1 to contain an outbreak.", [["an outbreak", "PROBLEM", 54, 65], ["outbreak", "OBSERVATION", 57, 65]]], ["Here, we estimate the reproduction number by characterizing the early growth phase (16 day) of local cases using the generalized-growth model (Viboud et al., 2016) and modeling the generation interval of SARS-CoV-2 assuming a gamma distribution with a mean of 4.41 days and a standard deviation of 3.17 days (Nishiura, Linton, & Akhmetzhanov, 2020; You et al., 2020).", [["SARS", "DISEASE", 204, 208], ["SARS-CoV", "SPECIES", 204, 212], ["SARS", "PROBLEM", 204, 208]]], ["We simulate the progression of local incident cases by onset dates using the calibrated GGM model and account for the daily series of imported cases into a renewal equation given as (Nishiura & Chowell, 2009, 2014; Paine et al., 2010):Rti=Ii\u2211j=0i(Ii\u2212j+\u03b1Ji\u2212j)\u03c1iWe denote the local incidence at calendar time ti by Ii, which is characterized using the generalized-growth model, the imported cases at calendar time ti by Ji, and the discretized probability distribution of the generation interval by \u03c1i.", [["Ii", "PROTEIN", 313, 315], ["the calibrated GGM model", "TREATMENT", 73, 97], ["Rti", "TEST", 235, 238], ["progression", "OBSERVATION_MODIFIER", 16, 27]]], ["In this equation the numerator represents the total new cases Ii, and the denominator represents the total number of cases that contribute to the new cases Ii at time ti.", [["Ii", "GENE_OR_GENE_PRODUCT", 62, 64], ["Ii", "GENE_OR_GENE_PRODUCT", 156, 158], ["Ii", "PROTEIN", 62, 64], ["Ii", "PROTEIN", 156, 158]]], ["The relative contribution of imported cases to the secondary disease transmission is represented by the parameter 0\u2264r\u03b1 ran.", [["the secondary disease transmission", "PROBLEM", 47, 81], ["secondary disease", "OBSERVATION", 51, 68]]], ["We perform a sensitivity analyses by setting \u03b1 = 0.15 and \u03b1 = 1.0 to assess the relative contribution of imported cases to the secondary disease transmission (Nishiura & Roberts, 2010).", [["a sensitivity analyses", "TEST", 11, 33], ["the secondary disease transmission", "PROBLEM", 123, 157], ["secondary disease", "OBSERVATION", 127, 144]]], ["This is followed by the derivation of the uncertainty bounds around the curve of R directly from the uncertainty associated with the parameter estimates (r, p).", [["the uncertainty bounds", "PROBLEM", 38, 60]]], ["This method to derive early estimates of the reproduction number, R, has been employed in several prior studies as in refs (Chowell, 2017; Tariq et al., 2020).COVID-19 testing and positivity rates ::: ResultsFigure 1 shows the daily number of positive and negative laboratory test results and the positivity rate during the reporting period, March 4th\u2013March 30th, 2020.", [["COVID", "TEST", 159, 164], ["positivity rates", "TEST", 180, 196], ["the positivity rate", "TEST", 293, 312]]], ["The total number of PCR tests performed for this time period were 11518 (1127 positive results and 10307 negative results).", [["PCR tests", "TEST", 20, 29]]], ["The average daily number of PCR tests performed in Lima was estimated at ~188 between March 4th\u2013March 15th, 2020 whereas the number of tests performed between March 16th\u2013March 30th, 2020 increased to ~617 tests per day, an increase of 228 % in the testing rates, perhaps reflecting an increase number of suspected cases with respiratory symptoms.", [["respiratory", "ANATOMY", 325, 336], ["respiratory symptoms", "DISEASE", 325, 345], ["PCR tests", "TEST", 28, 37], ["tests", "TEST", 135, 140], ["the testing rates", "TEST", 244, 261], ["respiratory symptoms", "PROBLEM", 325, 345], ["increase", "OBSERVATION_MODIFIER", 223, 231], ["increase", "OBSERVATION_MODIFIER", 285, 293]]], ["The positivity rate (percentage of positive cases among the positive and negative cases) has ranged from 0.6\u201323.9 % between March 4 th\u2013March 30th, 2020.Local and imported incidence trends ::: ResultsThe COVID-19 epidemic curve by the date of symptoms onset, stratified by the local and imported incidence case counts is shown in Figure 2.", [["The positivity rate", "TEST", 0, 19], ["positive cases", "PROBLEM", 35, 49], ["The COVID", "TEST", 199, 208], ["symptoms", "PROBLEM", 242, 250]]], ["On average ~6 imported cases and ~162 local cases have been reported daily between March 16th\u2013March 30th, 2020 in Lima.", [["Lima", "ANATOMY", 114, 118]]], ["A total of 2783 autochthonous cases and 151 imported cases have been reported in Lima as of March 30th, 2020.Reproduction number, R ::: ResultsWe estimated the reproduction number from the epidemic\u2019s early growth phase comprising the first 16 epidemic days prior to the implementation of social distancing interventions which includes the national emergency declaration on March 16th 2020.", [["social distancing interventions", "TREATMENT", 288, 319]]], ["The local incidence curve by the date of symptoms onset displays near exponential growth dynamics with the scaling of growth parameter, p, estimated at 0.9 (95% CI: 0.9, 1.0) and the intrinsic growth rate, r, estimated at 0.3 (95% CI: 0.3, 0.5).", [["The local incidence curve", "PROBLEM", 0, 25], ["symptoms", "PROBLEM", 41, 49], ["near exponential growth dynamics", "PROBLEM", 65, 97], ["CI", "TEST", 161, 163], ["the intrinsic growth rate", "TEST", 179, 204], ["CI", "TEST", 231, 233], ["growth", "OBSERVATION_MODIFIER", 193, 199]]], ["The estimate of the reproduction number was estimated at 2.3 (95% CI: 2.0, 2.5) when \u03b1 = 0.15 (Figure 3).", [["CI", "TEST", 66, 68]]], ["When \u03b1 = 1.0, the reproduction number slightly decreases to 2.0 (95% CI: 1.7, 2.3) (Table 1).Assessing the impact of social distancing interventions ::: ResultsIn order to assess the impact of social distancing interventions in Lima, including school closures on March 11th, 2020 and the declaration of national emergency on March 16th, 2020, we generate a 20-day ahead forecast for Lima based on the daily incidence curve up until the declaration of the national emergency in Lima.", [["CI", "TEST", 69, 71], ["social distancing interventions", "TREATMENT", 193, 224], ["Lima", "TREATMENT", 383, 387]]], ["The 16-day calibration period of the model yields an estimated growth rate, r, at 0.8 (95% CI: 0.6, 1.1) and a scaling of growth rate parameter, p, at 0.8 (95%CI: 0.7,0.9).", [["an estimated growth rate", "TEST", 50, 74], ["CI", "TEST", 91, 93], ["a scaling of growth rate parameter", "PROBLEM", 109, 143], ["CI", "TEST", 159, 161], ["growth", "OBSERVATION_MODIFIER", 63, 69]]], ["The 20-day ahead forecast suggests that the effect of the school closure and the national emergency declaration slowed down the spread of the virus as shown in Figure 4.", [["the school closure", "TREATMENT", 54, 72], ["the virus", "PROBLEM", 138, 147]]], ["Indeed, the scaling of growth parameter declined to 0.53 (95% CI: 0.48, 0.58), consistent with an approximately linear incidence growth trend during the period affected by the intervention.DiscussionOur estimate of the transmission potential in Lima for the first 16 days of the epidemic indicates sustained local transmission in the region after accounting for multiple case importations with the estimate of reproduction number, R, at ~2.3 (95% CI: 2.0, 2.5) which is comparable to estimates of the reproduction number for China, Korea, and Iran that lie in the range of 1.5\u20137.1 (Hwang, Park, Kim, Jung, & Kim, 2020; Mizumoto, Kagaya, & Chowell, 2020; Muniz-Rodriguez et al., 2020; Read, Bridgen, Cummings, Ho, & Jewell, 2020; Shim, Tariq, Choi, Lee, & Chowell, 2020; Wu, Leung, & Leung, 2020).", [["CI", "TEST", 62, 64], ["an approximately linear incidence growth", "PROBLEM", 95, 135], ["the intervention", "TREATMENT", 172, 188], ["CI", "TEST", 447, 449], ["Mizumoto", "TEST", 619, 627], ["scaling", "OBSERVATION_MODIFIER", 12, 19], ["growth", "OBSERVATION_MODIFIER", 23, 29], ["consistent with", "UNCERTAINTY", 79, 94], ["approximately", "OBSERVATION_MODIFIER", 98, 111], ["linear", "OBSERVATION_MODIFIER", 112, 118], ["incidence", "OBSERVATION_MODIFIER", 119, 128], ["growth", "OBSERVATION_MODIFIER", 129, 135], ["trend", "OBSERVATION_MODIFIER", 136, 141]]], ["In contrast, a recent study on Singapore\u2019s COVID-19 transmission reported a lower estimate of R at ~0.7, which has been explained as a result of the early implementation of sweeping social distancing interventions (Tariq et al., 2020).DiscussionThe initial scaling of growth parameter in Lima indicates a nearly exponential growth pattern, consistent with the early spread of the COVID-19 epidemic in Iran and the exponential growth pattern of COVID-19 displayed by the Chinese province of Hubei (Muniz-Rodriguez et al., 2020; Roosa et al., 2020).", [["COVID-19", "CHEMICAL", 444, 452], ["Singapore\u2019s COVID-19", "SPECIES", 31, 51], ["a recent study", "TEST", 13, 27], ["COVID", "TEST", 43, 48], ["a nearly exponential growth pattern", "PROBLEM", 303, 338], ["the COVID", "TEST", 376, 385], ["COVID", "TEST", 444, 449], ["consistent with", "UNCERTAINTY", 340, 355], ["early", "OBSERVATION_MODIFIER", 360, 365], ["spread", "OBSERVATION_MODIFIER", 366, 372]]], ["In comparison sub-exponential growth patterns of COVID-19 have been observed in Singapore (p~0.7), Korea (p~0.76) and other Chinese provinces excluding Hubei (p~0.67) as described in recent studies (Roosa et al., 2020; Shim et al., 2020; Tariq et al., 2020).DiscussionAlthough Lima has been quick to take aggressive measures against COVID-19, Peru remains one of the hardest hit countries in Latin America (Tegel, 2020).", [["COVID-19", "DNA", 49, 57], ["COVID", "TEST", 49, 54], ["aggressive measures", "TREATMENT", 305, 324], ["COVID", "TEST", 333, 338]]], ["Despite the closure of country borders on March 16th, 2020, the number of imported ~6 cases in Lima has increased with an average of imported cases reported between March 16th\u2013March 30th, 2020 compared to an average of ~4 imported cases per day before March 16th, 2020.", [["closure", "OBSERVATION", 12, 19], ["increased", "OBSERVATION_MODIFIER", 104, 113]]], ["However, the 20-day ahead forecast of our GGM model calibrated to first 16 epidemic days suggest that the social distancing measures, including closure of schools and the declaration of national emergency are slowing down the virus spread in Lima.", [["closure of schools", "TREATMENT", 144, 162], ["Lima", "ANATOMY", 242, 246]]], ["The scaling of growth parameter, p, was estimated at ~0.5 (95%CI: 0.5,0.6) after the implementation of social distancing measures, consistent with a linear incidence growth trend.", [["CI", "TEST", 62, 64], ["social distancing measures", "TREATMENT", 103, 129], ["a linear incidence growth trend", "PROBLEM", 147, 178], ["scaling", "OBSERVATION_MODIFIER", 4, 11], ["growth", "OBSERVATION_MODIFIER", 15, 21], ["consistent with", "UNCERTAINTY", 131, 146]]], ["However, the COVID-19 case incidence continues to accumulate despite the quarantine and lockdowns in the region highlighting the need to enhance social distancing measures to further contain the outbreak.DiscussionThe average positivity rate of COVID-19 in Lima was ~8.6% between March 4th\u2013March 30th, 2020.", [["the quarantine and lockdowns", "TREATMENT", 69, 97], ["social distancing measures", "TREATMENT", 145, 171], ["COVID", "TEST", 245, 250]]], ["This positivity rate for Lima, Peru, corresponds to the positivity rates derived from Denmark, Germany and Canada (6\u20138%) (Meyer & C.Madrigal, 2020).", [["the positivity rates", "PROBLEM", 52, 72]]], ["In comparison countries like New Zealand, South Korea and Australia have tested widely and exhibit lower positivity rates (2%) whereas Italy and the US have shown much higher positivity rates (15\u201320%) for COVID-19 indicating suboptimal testing capacity in these countries (Meyer & C.Madrigal, 2020; Project, 2020).", [["lower positivity rates", "PROBLEM", 99, 121], ["the US", "TEST", 145, 151], ["much higher positivity rates", "PROBLEM", 163, 191], ["COVID", "TEST", 205, 210], ["suboptimal testing capacity", "PROBLEM", 225, 252], ["New", "OBSERVATION_MODIFIER", 29, 32], ["Zealand", "OBSERVATION_MODIFIER", 33, 40], ["lower", "OBSERVATION_MODIFIER", 99, 104], ["positivity", "OBSERVATION", 105, 115]]], ["A recent study has shown that changes in testing rates over the course of the epidemic can mask the epidemic growth rate resulting in biased epidemic trends (Omori, Mizumoto, & Chowell, 2020).", [["A recent study", "TEST", 0, 14], ["testing rates", "TEST", 41, 54]]], ["Moreover, there is a substantial fraction of asymptomatic COVID-19 cases, which could have underestimated the reproduction number derived from the daily incidence\u2019s growth trend of symptomatic cases (Mizumoto, Kagaya, Zarebski, & Chowell, 2020; Wei et al., 2020).", [["asymptomatic COVID", "TEST", 45, 63], ["substantial", "OBSERVATION_MODIFIER", 21, 32], ["fraction", "OBSERVATION_MODIFIER", 33, 41]]], ["Our study underscores the need for active contact tracing efforts that targets symptomatic and asymptomatic cases, rapid isolation of infectious individuals, quarantined contacts and strict social distancing measures to curb the spread of the virus.ConclusionIn this study we estimate the early transmission potential of SARS-CoV-2 in Lima, Peru.", [["SARS", "DISEASE", 321, 325], ["SARS-CoV-2", "ORGANISM", 321, 331], ["SARS-CoV", "SPECIES", 321, 329], ["Our study", "TEST", 0, 9], ["symptomatic and asymptomatic cases", "PROBLEM", 79, 113], ["infectious individuals", "PROBLEM", 134, 156], ["strict social distancing measures", "TREATMENT", 183, 216], ["the virus", "PROBLEM", 239, 248], ["this study", "TEST", 262, 272], ["SARS", "PROBLEM", 321, 325], ["CoV", "TEST", 326, 329], ["infectious", "OBSERVATION_MODIFIER", 134, 144], ["Lima", "ANATOMY", 335, 339]]], ["Our current findings point to sustained transmission of SARS-CoV-2 in the early phase of the outbreak, with our estimate of the mean reproduction number ~2.3.", [["SARS", "DISEASE", 56, 60], ["SARS-CoV-2", "ORGANISM", 56, 66], ["SARS-CoV", "SPECIES", 56, 64], ["SARS", "PROBLEM", 56, 60], ["CoV", "TEST", 61, 64], ["SARS", "OBSERVATION", 56, 60], ["early phase", "OBSERVATION_MODIFIER", 74, 85]]], ["The COVID-19 epidemic in Lima followed an early exponential growth trend, which slowed down and turned into an almost linear growth trend (p~0.5), which appears to be tied to broad scale social distancing interventions put in place by the government.", [["The COVID", "TEST", 0, 9], ["broad scale social distancing interventions", "TREATMENT", 175, 218], ["Lima", "ANATOMY", 25, 29], ["linear", "OBSERVATION_MODIFIER", 118, 124], ["growth", "OBSERVATION_MODIFIER", 125, 131]]], ["While the interventions appear to have slowed the transmission rate, the number of new COVID-19 cases continue to accumulate, highlighting the need to continue social distancing and active case finding efforts to mitigate disease transmission in the region.", [["new COVID", "TEST", 83, 92], ["disease transmission in the region", "PROBLEM", 222, 256]]]], "f808fc130cc1ae282a1905872d2dba803d5ff1de": [["The Y2H system as the standard assay for the evaluation of interactomes Essentially all high-throughput approaches to identify binary protein interactions on a genome-scale currently rely on the Gal4-based yeast-two-hybrid (Y2H) system ( Figure 1 ) developed in 1989 [1] .", [["Gal4", "GENE_OR_GENE_PRODUCT", 195, 199], ["Gal4", "PROTEIN", 195, 199], ["yeast", "SPECIES", 206, 211], ["The Y2H system", "TEST", 0, 14], ["the evaluation", "TEST", 41, 55], ["interactomes", "TEST", 59, 71], ["binary protein interactions", "PROBLEM", 127, 154], ["a genome-scale", "TREATMENT", 158, 172], ["the Gal4", "TEST", 191, 199]]], ["In principle, two proteins are fused to separately expressed and nonfunctional domains of the Gal4 transcription factor, either the Gal4 DNA binding domain (bait) or the Gal4 activation domain (prey).", [["Gal4", "GENE_OR_GENE_PRODUCT", 94, 98], ["Gal4", "GENE_OR_GENE_PRODUCT", 132, 136], ["DNA", "CELLULAR_COMPONENT", 137, 140], ["Gal4", "GENE_OR_GENE_PRODUCT", 170, 174], ["nonfunctional domains", "PROTEIN", 65, 86], ["Gal4 transcription factor", "PROTEIN", 94, 119], ["Gal4 DNA binding domain", "PROTEIN", 132, 155], ["bait", "PROTEIN", 157, 161], ["Gal4 activation domain", "PROTEIN", 170, 192], ["the Gal4 transcription factor", "PROBLEM", 90, 119], ["the Gal4 DNA binding domain", "PROBLEM", 128, 155], ["the Gal4 activation domain", "PROBLEM", 166, 192]]], ["Upon interaction of the two proteins of interest, the transcription factor activity is reconstituted in the yeast nucleus leading to the activation of one or several reporter genes.", [["yeast nucleus", "ANATOMY", 108, 121], ["yeast nucleus", "CELLULAR_COMPONENT", 108, 121], ["transcription factor", "PROTEIN", 54, 74], ["reporter genes", "DNA", 166, 180], ["yeast", "SPECIES", 108, 113], ["yeast", "SPECIES", 108, 113], ["the yeast nucleus", "PROBLEM", 104, 121], ["yeast nucleus", "OBSERVATION", 108, 121]]], ["A major improvement was the introduction of a mating protocol in which pretransformed haploid yeast cells form diploids that carry both the bait and prey vector [2] .", [["cells", "ANATOMY", 100, 105], ["yeast cells", "CELL", 94, 105], ["diploids", "CELL", 111, 119], ["pretransformed haploid yeast cells", "CELL_LINE", 71, 105], ["yeast", "SPECIES", 94, 99], ["yeast", "SPECIES", 94, 99], ["a mating protocol", "TREATMENT", 44, 61], ["pretransformed haploid yeast cells", "TREATMENT", 71, 105], ["major", "OBSERVATION_MODIFIER", 2, 7], ["improvement", "OBSERVATION_MODIFIER", 8, 19], ["yeast cells", "OBSERVATION", 94, 105]]], ["Compared to the previously used transformation protocol, this novel strategy is easier to perform and allows automated screening and the crosscombination of a large number of pretransformed bait and prey pairs.", [["transformation protocol", "TREATMENT", 32, 55], ["automated screening", "TEST", 109, 128], ["large", "OBSERVATION_MODIFIER", 159, 164]]], ["Another major improvement that further boosted genome-scale Y2H approaches was the combination with the highly efficient Gateway recombinational cloning system for the generation of larger clone collections [3] .", [["clone", "CELL", 189, 194], ["Y2H approaches", "TREATMENT", 60, 74], ["larger clone collections", "PROBLEM", 182, 206], ["major", "OBSERVATION_MODIFIER", 8, 13], ["improvement", "OBSERVATION_MODIFIER", 14, 25], ["larger", "OBSERVATION_MODIFIER", 182, 188], ["clone collections", "OBSERVATION", 189, 206]]], ["Over the last 10 years, the interactomes of several previously sequenced organisms like H. pylori [4] , C. jejuni [5] , M. tuberculosis [6] , P. falciparum [7] , T. pallidum [8] , S. cerevisiae [9, 10] , C. elegans [11] , D. melanogaster [12] , and humans [13, 14] could be generated using the Y2H system.", [["tuberculosis", "DISEASE", 123, 135], ["P. falciparum", "DISEASE", 142, 155], ["H. pylori", "ORGANISM", 88, 97], ["[4]", "ORGANISM", 98, 101], ["C. jejuni", "ORGANISM", 104, 113], ["5]", "ORGANISM", 115, 117], ["M. tuberculosis [6]", "ORGANISM", 120, 139], ["P. falciparum", "ORGANISM", 142, 155], ["T.", "ORGANISM", 162, 164], ["pallidum [8]", "ORGANISM", 165, 177], ["S. cerevisiae", "ORGANISM", 180, 193], ["C. elegans", "ORGANISM", 204, 214], ["D. melanogaster", "ORGANISM", 222, 237], ["humans", "ORGANISM", 249, 255], ["H. pylori", "SPECIES", 88, 97], ["C. jejuni", "SPECIES", 104, 113], ["M. tuberculosis", "SPECIES", 120, 135], ["P. falciparum", "SPECIES", 142, 155], ["T. pallidum", "SPECIES", 162, 173], ["S. cerevisiae", "SPECIES", 180, 193], ["C. elegans", "SPECIES", 204, 214], ["D. melanogaster", "SPECIES", 222, 237], ["humans", "SPECIES", 249, 255], ["H. pylori", "SPECIES", 88, 97], ["C. jejuni", "SPECIES", 104, 113], ["M. tuberculosis", "SPECIES", 120, 135], ["P. falciparum", "SPECIES", 142, 155], ["T. pallidum", "SPECIES", 162, 173], ["S. cerevisiae", "SPECIES", 180, 193], ["C. elegans", "SPECIES", 204, 214], ["D. melanogaster", "SPECIES", 222, 237], ["humans", "SPECIES", 249, 255], ["several previously sequenced organisms", "PROBLEM", 44, 82], ["H. pylori", "PROBLEM", 88, 97], ["C. jejuni", "PROBLEM", 104, 113], ["M. tuberculosis", "PROBLEM", 120, 135], ["P. falciparum", "PROBLEM", 142, 155], ["pylori", "ANATOMY", 91, 97], ["jejuni", "ANATOMY", 107, 113]]], ["In most cases arrays were generated to test either individual or defined pools of open reading frames (ORFs) for interaction with each other (matrix screens).", [["matrix", "CELLULAR_COMPONENT", 142, 148], ["open reading frames", "DNA", 82, 101], ["ORFs", "DNA", 103, 107]]], ["Alternatively, a number of individual baits were used to screen cDNA libraries.", [["cDNA libraries", "DNA", 64, 78]]], ["More recently, several viral interactomes with the herpesvirus family being by far the largest group analyzed have been generated (refs.", [["herpesvirus", "ORGANISM", 51, 62], ["several viral interactomes", "PROBLEM", 15, 41], ["viral interactomes", "OBSERVATION", 23, 41]]], ["[15 ,16 ,17 ,18 ,19 ] and (E Fossum et al., in revision).Limitations of the Y2H systemThe reliability and the biological relevance of the Y2H system in general have been challenged repeatedly.", [["[15 ,16 ,17 ,18 ,19", "SIMPLE_CHEMICAL", 0, 19], ["Y2H", "PROTEIN", 138, 141], ["revision", "TREATMENT", 47, 55], ["the Y2H system", "TEST", 72, 86], ["the Y2H system", "TEST", 134, 148], ["revision", "OBSERVATION", 47, 55]]], ["Despite certain limitations the Y2H system is used by the majority of groups because of its enormous efficacy and the data discussed in this review are all based on Y2H screens as all currently published large-scale studies on intraviral or virus-host protein interactions are based on them.", [["the Y2H system", "TEST", 28, 42], ["Y2H screens", "TEST", 165, 176], ["intraviral", "TREATMENT", 227, 237], ["virus", "TREATMENT", 241, 246], ["host protein interactions", "TREATMENT", 247, 272]]], ["Clearly, since based on the nuclear localization of a transcriptional reporter system, it is limited in the analysis of transcriptional activators and proteins localized to membrane compartments.", [["nuclear", "ANATOMY", 28, 35], ["membrane compartments", "ANATOMY", 173, 194], ["nuclear", "CELLULAR_COMPONENT", 28, 35], ["membrane compartments", "CELLULAR_COMPONENT", 173, 194], ["transcriptional activators", "PROTEIN", 120, 146], ["transcriptional activators", "PROBLEM", 120, 146]]], ["However, although the proteins to be tested are forced into the yeast nucleus for interaction, no bias between nuclear or non-nuclear proteins was observed [20 ] .", [["nucleus", "ANATOMY", 70, 77], ["nuclear", "ANATOMY", 111, 118], ["yeast nucleus", "CELLULAR_COMPONENT", 64, 77], ["nuclear", "CELLULAR_COMPONENT", 111, 118], ["nuclear or non-nuclear proteins", "PROTEIN", 111, 142], ["yeast", "SPECIES", 64, 69], ["yeast", "SPECIES", 64, 69], ["the proteins", "TEST", 18, 30], ["bias between nuclear or non-nuclear proteins", "PROBLEM", 98, 142], ["yeast nucleus", "OBSERVATION", 64, 77]]], ["Interestingly, while the yeast system is not expected to provide translational modifications comparable to the mammalian cell, it is nonetheless able to introduce and report modificationdependent interactions up to a certain extent.", [["cell", "ANATOMY", 121, 125], ["cell", "CELL", 121, 125], ["mammalian cell", "CELL_TYPE", 111, 125], ["yeast", "SPECIES", 25, 30], ["yeast", "SPECIES", 25, 30], ["the yeast system", "TEST", 21, 37], ["translational modifications", "TREATMENT", 65, 92], ["mammalian cell", "OBSERVATION", 111, 125]]], ["Thus, the yeast cell offers an environment sufficiently natural for the analysis of protein interactions of other species [20 ] .Limitations of the Y2H systemA major concern of the Y2H system particularly in its high-throughput application is the small overlap of identified interactions in comparative studies.", [["cell", "ANATOMY", 16, 20], ["yeast cell", "CELL", 10, 20], ["yeast", "SPECIES", 10, 15], ["yeast", "SPECIES", 10, 15], ["the yeast cell", "PROBLEM", 6, 20], ["other species", "PROBLEM", 108, 121], ["the Y2H systemA", "TEST", 144, 159], ["the Y2H system", "TEST", 177, 191], ["comparative studies", "TEST", 291, 310], ["yeast cell", "OBSERVATION", 10, 20], ["high", "OBSERVATION_MODIFIER", 212, 216], ["small", "OBSERVATION_MODIFIER", 247, 252]]], ["This is exemplified by two S. cerevisiae proteome-wide Y2H approaches in which the screening of 6000 gene products identified 682 (Uetz-screen) and 843 (Ito-core) binary interactions [9, 10] .", [["S. cerevisiae", "ORGANISM", 27, 40], ["6000 gene products", "PROTEIN", 96, 114], ["S. cerevisiae", "SPECIES", 27, 40], ["S. cerevisiae", "SPECIES", 27, 40], ["the screening", "TEST", 79, 92]]], ["However, only 19% of the Uetz-screen and 15% of the Ito-core interactions were found in the respective other screen [9, 10] .", [["Uetz-screen", "CANCER", 25, 36], ["the Uetz-screen", "TEST", 21, 36]]], ["A similarly small overlap was observed in several independently performed genome-wide herpesviral protein interaction screens [15 ,16 ,19 ,21,22 ] (E Fossum et al., in revision).", [["A similarly small overlap", "PROBLEM", 0, 25], ["wide herpesviral protein interaction screens", "TEST", 81, 125], ["revision", "TREATMENT", 168, 176], ["small", "OBSERVATION_MODIFIER", 12, 17], ["overlap", "OBSERVATION", 18, 25]]], ["Recent large-scale efforts demonstrated by reinvestigating a set of random protein interactions of the S. cerevisiae and human interactomes that the low coverage is the result of low sensitivity rather than low specificity [20 ,23 ,24 ].", [["S. cerevisiae", "ORGANISM", 103, 116], ["human", "ORGANISM", 121, 126], ["S. cerevisiae", "SPECIES", 103, 116], ["human", "SPECIES", 121, 126], ["S. cerevisiae", "SPECIES", 103, 116], ["human", "SPECIES", 121, 126], ["Recent large-scale efforts", "PROBLEM", 0, 26], ["the S. cerevisiae", "TREATMENT", 99, 116], ["human interactomes", "TREATMENT", 121, 139], ["the low coverage", "TREATMENT", 145, 161], ["low sensitivity", "PROBLEM", 179, 194], ["low specificity", "PROBLEM", 207, 222], ["large", "OBSERVATION_MODIFIER", 7, 12], ["-scale", "OBSERVATION_MODIFIER", 12, 18]]], ["Several validation protocols performed in parallel (see below) confirmed 25-30% of the Y2H interactions suggesting that the Y2H approach does not yield more false positives than other assays that detect binary interactions and is comparable in quality to literature-curated data [25 ] .Limitations of the Y2H systemSeveral reasons are likely to account for the low sensitivity of Y2H approaches [23 ] .", [["Y2H", "GENE_OR_GENE_PRODUCT", 87, 90], ["Several validation protocols", "TEST", 0, 28], ["the Y2H approach", "TEST", 120, 136]]], ["Second, depending on the assay or screening protocol applied different spaces are screened.", [["the assay", "TEST", 21, 30], ["screening protocol", "TEST", 34, 52]]], ["This is demonstrated by studies on Hepatitis C virus (HCV) where the same set of proteins was screened by a yeast mating (IMAPI) as well as a transformation protocol (IMAPII) using two different human cDNA libraries [18 ] .", [["Hepatitis C", "DISEASE", 35, 46], ["Hepatitis C virus", "ORGANISM", 35, 52], ["HCV", "ORGANISM", 54, 57], ["human", "ORGANISM", 195, 200], ["human cDNA libraries", "DNA", 195, 215], ["Hepatitis C virus", "SPECIES", 35, 52], ["yeast", "SPECIES", 108, 113], ["human", "SPECIES", 195, 200], ["Hepatitis C virus", "SPECIES", 35, 52], ["HCV", "SPECIES", 54, 57], ["yeast", "SPECIES", 108, 113], ["human", "SPECIES", 195, 200], ["Hepatitis C virus", "PROBLEM", 35, 52], ["HCV", "PROBLEM", 54, 57], ["a transformation protocol", "TREATMENT", 140, 165], ["two different human cDNA libraries", "TREATMENT", 181, 215]]], ["Although performed in the same laboratory, IMAPI and IMAPII shared only 22 interactions indicating that different screening protocols, vectors, and yeast strains as well as the quality and composition of cDNA libraries have a greater impact on the screening success than generally assumed.", [["IMAPI", "DNA", 43, 48], ["IMAPII", "DNA", 53, 59], ["cDNA libraries", "DNA", 204, 218], ["yeast", "SPECIES", 148, 153], ["yeast", "SPECIES", 148, 153], ["different screening protocols", "TEST", 104, 133], ["vectors", "TREATMENT", 135, 142], ["yeast strains", "PROBLEM", 148, 161], ["cDNA libraries", "PROBLEM", 204, 218]]], ["Third, high-throughput approaches are often hampered by technical limitations that can be improved for example by multiple screenings of the same set of proteins.", [["multiple screenings", "TEST", 114, 133], ["high", "OBSERVATION_MODIFIER", 7, 11]]], ["Multiple sampling of the same search space allowed the identification of 80-90% while a single round revealed only 60% of all possible Y2H interactions [23 ] .", [["Y2H", "GENE_OR_GENE_PRODUCT", 135, 138], ["the identification", "TEST", 51, 69]]], ["The ORFeomes of five evolutionarily related herpesviruses were used to systematically address the low coverage of Y2H screens by comparing the interactions identified in individual species followed by secondary methods [15 ] (E Fossum et al., in revision).", [["herpesviruses", "ORGANISM", 44, 57], ["Y2H", "PROTEIN", 114, 117], ["herpesviruses", "PROBLEM", 44, 57], ["Y2H screens", "TEST", 114, 125], ["individual species", "PROBLEM", 170, 188], ["E Fossum et al., in revision", "TREATMENT", 226, 254]]], ["In the initial Y2H screens 283 interactions of the 41 core orthologous proteins were observed and 113 interactions High-throughput technologies to detect protein interactions.", [["41 core orthologous proteins", "PROTEIN", 51, 79], ["orthologous proteins", "TEST", 59, 79], ["protein interactions", "PROBLEM", 154, 174]]], ["Graphic depiction of several approaches for the detection of binary protein interaction including the yeast-two-hybrid (Y2H) system, the nucleic acid programmable protein array (NAPPA), the LUMIER (luminescence-based mammalian interactome mapping), the protein fragment complementation assay (PCA), and the MAPPIT (mammalian protein-protein interaction trap).", [["nucleic acid", "CHEMICAL", 137, 149], ["Y2H", "PROTEIN", 120, 123], ["nucleic acid programmable protein array", "PROTEIN", 137, 176], ["NAPPA", "PROTEIN", 178, 183], ["LUMIER", "PROTEIN", 190, 196], ["MAPPIT", "PROTEIN", 307, 313], ["mammalian protein-protein interaction trap", "PROTEIN", 315, 357], ["yeast", "SPECIES", 102, 107], ["binary protein interaction", "PROBLEM", 61, 87], ["the yeast", "TEST", 98, 107], ["the nucleic acid", "TEST", 133, 149], ["the LUMIER (luminescence", "TREATMENT", 186, 210], ["mammalian interactome mapping", "TREATMENT", 217, 246], ["the protein fragment complementation assay", "TEST", 249, 291], ["PCA", "TEST", 293, 296], ["the MAPPIT", "TEST", 303, 313], ["mammalian protein-protein interaction trap", "TREATMENT", 315, 357]]], ["Multicomponent protein interactions can be analyzed by the TAP (tandem affinity purification) of ProtA-tagged bait proteins followed by mass spectrometry of associated proteins.", [["TAP", "GENE_OR_GENE_PRODUCT", 59, 62], ["ProtA", "SIMPLE_CHEMICAL", 97, 102], ["TAP", "PROTEIN", 59, 62], ["ProtA", "PROTEIN", 97, 102], ["tagged bait proteins", "PROTEIN", 103, 123], ["associated proteins", "PROTEIN", 157, 176], ["Multicomponent protein interactions", "PROBLEM", 0, 35], ["the TAP (tandem affinity purification", "TREATMENT", 55, 92], ["ProtA", "TEST", 97, 102], ["tagged bait proteins", "PROBLEM", 103, 123], ["mass spectrometry of associated proteins", "PROBLEM", 136, 176]]], ["Bait (x) and prey (y) proteins are indicated, fusion tags are shown in orange (AD: activation domain; DBD: DNA binding protein; ATG: start codon).Limitations of the Y2H systemwere found in more than one species (E Fossum et al., in revision).", [["DNA", "CELLULAR_COMPONENT", 107, 110], ["ATG", "GENE_OR_GENE_PRODUCT", 128, 131], ["Bait (x) and prey (y) proteins", "PROTEIN", 0, 30], ["AD: activation domain", "PROTEIN", 79, 100], ["DBD", "PROTEIN", 102, 105], ["DNA binding protein", "PROTEIN", 107, 126], ["ATG: start codon", "DNA", 128, 144], ["Y2H systemwere", "PROTEIN", 165, 179], ["prey (y) proteins", "TREATMENT", 13, 30], ["fusion tags", "TEST", 46, 57], ["DNA binding protein", "PROBLEM", 107, 126], ["the Y2H systemwere", "TEST", 161, 179], ["revision", "TREATMENT", 232, 240]]], ["On the basis of 55 Y2H interactions detected in KSHV, 59 of 92 interactions predicted for the corresponding orthologs in HSV-1, mCMV, and EBV could be identified by coprecipitation.", [["Y2H", "GENE_OR_GENE_PRODUCT", 19, 22], ["KSHV", "ORGANISM", 48, 52], ["HSV-1", "ORGANISM", 121, 126], ["mCMV", "GENE_OR_GENE_PRODUCT", 128, 132], ["EBV", "ORGANISM", 138, 141], ["KSHV", "SPECIES", 48, 52], ["HSV-1", "SPECIES", 121, 126], ["mCMV", "SPECIES", 128, 132], ["EBV", "SPECIES", 138, 141], ["HSV", "TEST", 121, 124], ["mCMV", "PROBLEM", 128, 132], ["EBV", "PROBLEM", 138, 141]]], ["In conclusion, the low coverage of the Y2H system -currently its major drawback -can be addressed either by technical improvements or the combination with other assays.Alternative technologiesTo address the biological significance of an interaction identified by Y2H, validation by one or more biochemical methods is required ( Figure 1 ).", [["Y2H", "PROTEIN", 263, 266], ["the Y2H system", "TEST", 35, 49], ["other assays", "TEST", 155, 167], ["Alternative technologies", "TREATMENT", 168, 192]]], ["Technologies similar to the Y2H, for example an assay based on closeness of two proteins if not their direct interaction likely leads to high confirmation rates, however be little complementary [20 ] .", [["Y2H", "GENE_OR_GENE_PRODUCT", 28, 31], ["Y2H", "PROTEIN", 28, 31], ["the Y2H", "TEST", 24, 31], ["an assay", "TEST", 45, 53]]], ["Coexpression in mammalian cells of two proteins fused to distinct tags followed by immuno-coprecipitation or affinity-coprecipitation (CoP) was successfully applied to validate several Y2H studies [15 ,17 ] (E Fossum et al., in revision).", [["mammalian cells", "ANATOMY", 16, 31], ["mammalian cells", "CELL", 16, 31], ["mammalian cells", "CELL_TYPE", 16, 31], ["Coexpression in mammalian cells", "PROBLEM", 0, 31], ["two proteins", "PROBLEM", 35, 47], ["distinct tags", "PROBLEM", 57, 70], ["immuno-coprecipitation", "TREATMENT", 83, 105], ["affinity-coprecipitation (CoP)", "TREATMENT", 109, 139], ["several Y2H studies", "TEST", 177, 196], ["mammalian cells", "OBSERVATION", 16, 31]]], ["Recently, a tool-box for high-throughput validation of Y2H interactions was developed (Figure 1; [20 ]).", [["Y2H", "GENE_OR_GENE_PRODUCT", 55, 58], ["Y2H", "PROTEIN", 55, 58], ["a tool", "TEST", 10, 16]]], ["Expression of proteins on array-printed template DNA using a coupled in vitro transcription-translation reaction (nucleic acid programmable protein array, NAPPA, [26] ) follows a principle similar to the CoP.", [["nucleic acid", "CHEMICAL", 114, 126], ["DNA", "CELLULAR_COMPONENT", 49, 52], ["array-printed template DNA", "DNA", 26, 52], ["NAPPA", "PROTEIN", 155, 160], ["printed template DNA", "TREATMENT", 32, 52], ["a coupled in vitro transcription", "TREATMENT", 59, 91], ["translation reaction", "PROBLEM", 92, 112], ["nucleic acid programmable protein array", "TEST", 114, 153], ["NAPPA", "TEST", 155, 160]]], ["A second method used on a rather large scale is the LUMIER (luminescence-based mammalian interactome mapping) pull-down assay where two proteins are expressed in mammalian cells.", [["cells", "ANATOMY", 172, 177], ["mammalian cells", "CELL", 162, 177], ["mammalian cells", "CELL_TYPE", 162, 177], ["A second method", "TREATMENT", 0, 15], ["mammalian cells", "OBSERVATION", 162, 177]]], ["While the bait protein is expressed as a fusion to the protein A-tag or Flag-tag to immobilize the complex, the prey protein is expressed as a fusion with luciferase allowing the detection of the coisolated prey [27] .", [["Flag", "GENE_OR_GENE_PRODUCT", 72, 76], ["luciferase", "GENE_OR_GENE_PRODUCT", 155, 165], ["bait protein", "PROTEIN", 10, 22], ["protein A-tag", "PROTEIN", 55, 68], ["Flag", "PROTEIN", 72, 76], ["prey protein", "PROTEIN", 112, 124], ["luciferase", "PROTEIN", 155, 165], ["a fusion", "TREATMENT", 39, 47], ["Flag-tag", "TREATMENT", 72, 80], ["a fusion with luciferase", "TREATMENT", 141, 165]]], ["Protein fragment complementation assays (PCA), for example the split-YFP system in which interacting bait and prey proteins are fused to YFP domains, reconstitute an enzyme or a fluorescent protein and generally do not require an enrichment of the interactors.", [["YFP", "GENE_OR_GENE_PRODUCT", 137, 140], ["interacting bait and prey proteins", "PROTEIN", 89, 123], ["YFP domains", "PROTEIN", 137, 148], ["enzyme", "PROTEIN", 166, 172], ["fluorescent protein", "PROTEIN", 178, 197], ["Protein fragment complementation assays", "TEST", 0, 39], ["the split-YFP system", "PROBLEM", 59, 79], ["YFP domains", "TEST", 137, 148], ["an enzyme", "TEST", 163, 172], ["a fluorescent protein", "PROBLEM", 176, 197], ["enrichment", "OBSERVATION", 230, 240]]], ["Finally, the MAPPIT (mammalian protein-protein interaction trap) uses a bait protein fused to a hybrid erythropoietin-leptin receptor located to the plasmamembrane and a prey protein fused to gp130, which drives a signaling cascade resulting in the read-out of an endogenous transcriptional reporter [29] .Alternative technologiesProteomic approaches that are able to detect indirect interactions are complementary to the Y2H system rather than confirmatory, and are therefore well suited to increase the coverage of a Y2H interactome.", [["plasmamembrane", "ANATOMY", 149, 163], ["MAPPIT", "GENE_OR_GENE_PRODUCT", 13, 19], ["erythropoietin", "GENE_OR_GENE_PRODUCT", 103, 117], ["leptin", "GENE_OR_GENE_PRODUCT", 118, 124], ["plasmamembrane", "GENE_OR_GENE_PRODUCT", 149, 163], ["gp130", "GENE_OR_GENE_PRODUCT", 192, 197], ["Y2H", "GENE_OR_GENE_PRODUCT", 519, 522], ["MAPPIT", "PROTEIN", 13, 19], ["mammalian protein-protein interaction trap", "PROTEIN", 21, 63], ["bait protein", "PROTEIN", 72, 84], ["erythropoietin", "PROTEIN", 103, 117], ["leptin receptor", "PROTEIN", 118, 133], ["plasmamembrane", "PROTEIN", 149, 163], ["gp130", "PROTEIN", 192, 197], ["the MAPPIT (mammalian protein-protein interaction trap", "TREATMENT", 9, 63], ["a bait protein", "TREATMENT", 70, 84], ["a hybrid erythropoietin-leptin receptor", "TREATMENT", 94, 133]]], ["In the tandem affinity purification (TAP) approach individual proteins are fused to a cleavable tandem tag composed for example of protein A or G and a calmodulin binding peptide (CBP), and the isolated proteins present in the pulled-down complex are subsequently identified by mass spectrometry as done for yeast ( Figure 1 ; [30] [31] [32] ).", [["protein A", "GENE_OR_GENE_PRODUCT", 131, 140], ["G", "GENE_OR_GENE_PRODUCT", 144, 145], ["calmodulin binding peptide", "GENE_OR_GENE_PRODUCT", 152, 178], ["CBP", "GENE_OR_GENE_PRODUCT", 180, 183], ["TAP", "PROTEIN", 37, 40], ["cleavable tandem tag", "PROTEIN", 86, 106], ["protein A", "PROTEIN", 131, 140], ["G", "PROTEIN", 144, 145], ["calmodulin", "PROTEIN", 152, 162], ["CBP", "PROTEIN", 180, 183], ["pulled-down complex", "PROTEIN", 227, 246], ["yeast", "SPECIES", 308, 313], ["yeast", "SPECIES", 308, 313], ["the tandem affinity purification (TAP", "TREATMENT", 3, 40], ["approach individual proteins", "PROBLEM", 42, 70], ["a cleavable tandem tag", "PROBLEM", 84, 106], ["protein A", "PROBLEM", 131, 140], ["a calmodulin binding peptide", "TEST", 150, 178], ["CBP", "TEST", 180, 183], ["the isolated proteins", "PROBLEM", 190, 211], ["mass spectrometry", "TEST", 278, 295], ["yeast ( Figure", "TEST", 308, 322]]], ["Similarly, smaller subsets of human proteins have been analyzed in higher eukaryotic cells [33] [34] [35] .", [["cells", "ANATOMY", 85, 90], ["human", "ORGANISM", 30, 35], ["cells", "CELL", 85, 90], ["human proteins", "PROTEIN", 30, 44], ["human", "SPECIES", 30, 35], ["human", "SPECIES", 30, 35], ["human proteins", "TEST", 30, 44], ["smaller", "OBSERVATION_MODIFIER", 11, 18]]], ["Since the systematic tagging of chromosomal genes is currently not feasible in these cells, tagged proteins have been introduced in addition to the endogenous proteins and thus compete with them in the pull-down analysis.", [["chromosomal", "ANATOMY", 32, 43], ["cells", "ANATOMY", 85, 90], ["chromosomal", "CELLULAR_COMPONENT", 32, 43], ["cells", "CELL", 85, 90], ["chromosomal genes", "DNA", 32, 49], ["tagged proteins", "PROTEIN", 92, 107], ["endogenous proteins", "PROTEIN", 148, 167], ["chromosomal genes", "PROBLEM", 32, 49], ["tagged proteins", "TEST", 92, 107], ["the endogenous proteins", "PROBLEM", 144, 167], ["the pull-down analysis", "TEST", 198, 220], ["chromosomal genes", "OBSERVATION", 32, 49]]], ["Genetic systems are now available for many viral genomes (including large DNA viruses), and systematic functional TAP-tagging of viral proteins might be addressed in the near future.", [["DNA", "CELLULAR_COMPONENT", 74, 77], ["TAP", "GENE_OR_GENE_PRODUCT", 114, 117], ["viral genomes", "DNA", 43, 56], ["TAP", "PROTEIN", 114, 117], ["viral proteins", "PROTEIN", 129, 143], ["Genetic systems", "TEST", 0, 15], ["many viral genomes", "PROBLEM", 38, 56], ["large DNA viruses", "PROBLEM", 68, 85], ["systematic functional TAP", "TREATMENT", 92, 117], ["viral proteins", "TREATMENT", 129, 143]]], ["Proteomic analyses of purified virus particles have recently been performed for a few virus species and may provide further evidence for the interaction between viral proteins, particularly in conjunction with Y2H data (Figure 2) [36, 37] .Protein interaction networks in virusesInitial 'genome-wide' studies concentrated on intraviral protein interactions of small RNA and DNA viruses.", [["DNA", "CELLULAR_COMPONENT", 374, 377], ["viral proteins", "PROTEIN", 161, 175], ["Y2H", "PROTEIN", 210, 213], ["Protein interaction networks", "PROTEIN", 240, 268], ["small RNA", "RNA", 360, 369], ["Proteomic analyses", "TEST", 0, 18], ["purified virus particles", "PROBLEM", 22, 46], ["a few virus species", "PROBLEM", 80, 99], ["the interaction between viral proteins", "PROBLEM", 137, 175], ["Y2H data", "TEST", 210, 218], ["Protein interaction networks", "PROBLEM", 240, 268], ["wide' studies", "TEST", 295, 308], ["small RNA and DNA viruses", "PROBLEM", 360, 385], ["purified virus", "OBSERVATION", 22, 36], ["small RNA", "OBSERVATION", 360, 369], ["DNA viruses", "OBSERVATION", 374, 385]]], ["However, owing to the rather small number of proteins and protein interactions identified (Figure 3) , a detailed network analysis could not be applied (reviewed by [38] ).", [["protein interactions", "PROBLEM", 58, 78], ["a detailed network analysis", "TEST", 103, 130], ["small", "OBSERVATION_MODIFIER", 29, 34]]], ["More recent approaches on intraviral interactomes include several members of the herpesvirus family [15 ,16 ,19 Scheme of HSV-1 virus particle with protein interactions detected in a genome-wide Y2H screen.", [["herpesvirus", "ORGANISM", 81, 92], ["HSV-1 virus particle", "ORGANISM", 122, 142], ["HSV-1 virus", "SPECIES", 122, 133], ["HSV-1 virus", "SPECIES", 122, 133], ["HSV", "TEST", 122, 125], ["protein interactions", "PROBLEM", 148, 168]]], ["Capsid, tegument, and glycoproteins are indicated depending on their localization in the virus particle.", [["tegument", "ANATOMY", 8, 16], ["Capsid", "GENE_OR_GENE_PRODUCT", 0, 6], ["tegument", "CELLULAR_COMPONENT", 8, 16], ["Capsid, tegument, and glycoproteins", "PROTEIN", 0, 35], ["glycoproteins", "TREATMENT", 22, 35], ["tegument", "ANATOMY", 8, 16]]], ["Proteins are colored according to their conservation, purple: conserved in all herpesviruses, red: in alpha herpesviruses, grey: in Herpes simplex virus, pink: in alpha and gamma herpesviruses.Protein interaction networks in virusesfirst combined virus-host interactomes were investigated in HCV [18 ], EBV [16 ] , VZV and KSHV (Haas and collaborators).", [["Herpes simplex virus", "DISEASE", 132, 152], ["herpesviruses", "ORGANISM", 79, 92], ["alpha herpesviruses", "ORGANISM", 102, 121], ["Herpes simplex virus", "ORGANISM", 132, 152], ["alpha", "GENE_OR_GENE_PRODUCT", 163, 168], ["gamma herpesviruses", "ORGANISM", 173, 192], ["virusesfirst combined virus", "ORGANISM", 225, 252], ["HCV [18", "ORGANISM", 292, 299], ["EBV", "ORGANISM", 303, 306], ["VZV", "ORGANISM", 315, 318], ["KSHV", "ORGANISM", 323, 327], ["alpha and gamma herpesviruses", "PROTEIN", 163, 192], ["Protein interaction networks", "PROTEIN", 193, 221], ["Herpes simplex virus", "SPECIES", 132, 152], ["Herpes simplex virus", "SPECIES", 132, 152], ["HCV", "SPECIES", 292, 295], ["VZV", "SPECIES", 315, 318], ["KSHV", "SPECIES", 323, 327], ["Herpes simplex virus", "PROBLEM", 132, 152], ["Protein interaction networks", "PROBLEM", 193, 221], ["combined virus", "PROBLEM", 238, 252], ["HCV", "TEST", 292, 295], ["EBV", "TEST", 303, 306], ["VZV", "PROBLEM", 315, 318], ["colored", "OBSERVATION", 13, 20], ["all herpesviruses", "OBSERVATION_MODIFIER", 75, 92], ["alpha herpesviruses", "ANATOMY", 102, 121], ["grey", "ANATOMY", 123, 127], ["Herpes simplex virus", "OBSERVATION", 132, 152], ["alpha", "ANATOMY", 163, 168], ["gamma herpesviruses", "OBSERVATION", 173, 192]]], ["Virus-host protein interactions have been included into several public databases, or novel databases specific for virus-host interactions like VirHostNet have been set up [39] .Hepatitis C virus (HCV)In a systematic screen of 27 full-length proteins or domains of HCV against two human cDNA libraries, 314 virus-host interactions were identified [18 ].", [["Hepatitis C", "DISEASE", 177, 188], ["Virus", "ORGANISM", 0, 5], ["Hepatitis C virus", "ORGANISM", 177, 194], ["HCV", "ORGANISM", 196, 199], ["HCV", "ORGANISM", 264, 267], ["human", "ORGANISM", 280, 285], ["27 full-length proteins", "PROTEIN", 226, 249], ["human cDNA libraries", "DNA", 280, 300], ["Hepatitis C virus", "SPECIES", 177, 194], ["human", "SPECIES", 280, 285], ["Hepatitis C virus", "SPECIES", 177, 194], ["HCV", "SPECIES", 196, 199], ["HCV", "SPECIES", 264, 267], ["human", "SPECIES", 280, 285], ["Virus", "PROBLEM", 0, 5], ["host protein interactions", "PROBLEM", 6, 31], ["novel databases", "TEST", 85, 100], ["virus", "PROBLEM", 114, 119], ["Hepatitis C virus", "PROBLEM", 177, 194], ["HCV", "PROBLEM", 196, 199], ["a systematic screen", "TEST", 203, 222], ["domains of HCV", "PROBLEM", 253, 267]]], ["Taking published interactions into account, this is the first analysis on RNA viruses producing a large enough dataset to constitute a virus-human interaction network composed of 481 interactions involving 11 HCV and 421 human proteins.", [["human", "ORGANISM", 141, 146], ["HCV", "ORGANISM", 209, 212], ["human", "ORGANISM", 221, 226], ["HCV and 421 human proteins", "PROTEIN", 209, 235], ["human", "SPECIES", 141, 146], ["human", "SPECIES", 221, 226], ["human", "SPECIES", 141, 146], ["HCV", "SPECIES", 209, 212], ["human", "SPECIES", 221, 226], ["RNA viruses", "PROBLEM", 74, 85], ["a virus", "PROBLEM", 133, 140]]], ["The most highly connected proteins were the NS3, NS5A, and core proteins with 214, 96, 76 interactors, respectively.", [["NS3", "GENE_OR_GENE_PRODUCT", 44, 47], ["NS5A", "GENE_OR_GENE_PRODUCT", 49, 53], ["NS3", "PROTEIN", 44, 47], ["NS5A", "PROTEIN", 49, 53], ["core proteins", "PROTEIN", 59, 72], ["214, 96, 76 interactors", "PROTEIN", 78, 101], ["the NS3", "TREATMENT", 40, 47], ["NS5A", "TEST", 49, 53], ["core proteins", "TEST", 59, 72]]], ["Intriguingly, the insulin, Jak/ STAT, and TGFb signaling pathways were particularly enriched, which might be consistent with the metabolic disorders observed during chronic HCV infection.", [["metabolic disorders", "DISEASE", 129, 148], ["HCV infection", "DISEASE", 173, 186], ["insulin", "GENE_OR_GENE_PRODUCT", 18, 25], ["Jak", "GENE_OR_GENE_PRODUCT", 27, 30], ["STAT", "GENE_OR_GENE_PRODUCT", 32, 36], ["TGFb", "GENE_OR_GENE_PRODUCT", 42, 46], ["HCV", "ORGANISM", 173, 176], ["Jak", "PROTEIN", 27, 30], ["STAT", "PROTEIN", 32, 36], ["TGFb", "PROTEIN", 42, 46], ["HCV", "SPECIES", 173, 176], ["the insulin", "TREATMENT", 14, 25], ["TGFb signaling pathways", "TEST", 42, 65], ["the metabolic disorders", "PROBLEM", 125, 148], ["chronic HCV infection", "PROBLEM", 165, 186], ["might be consistent with", "UNCERTAINTY", 100, 124], ["metabolic disorders", "OBSERVATION", 129, 148], ["chronic", "OBSERVATION_MODIFIER", 165, 172], ["HCV", "OBSERVATION_MODIFIER", 173, 176], ["infection", "OBSERVATION", 177, 186]]], ["Focal adhesion complexes could represent a novel target of HCV suggesting a role of several HCV proteins in viral spreading, cell-cell interaction, and tissue reorganization.", [["cell", "ANATOMY", 125, 129], ["cell", "ANATOMY", 130, 134], ["tissue", "ANATOMY", 152, 158], ["Focal adhesion complexes", "GENE_OR_GENE_PRODUCT", 0, 24], ["HCV", "ORGANISM", 59, 62], ["cell", "CELL", 125, 129], ["cell", "CELL", 130, 134], ["tissue", "TISSUE", 152, 158], ["Focal adhesion complexes", "PROTEIN", 0, 24], ["HCV proteins", "PROTEIN", 92, 104], ["HCV", "SPECIES", 59, 62], ["HCV", "SPECIES", 92, 95], ["Focal adhesion complexes", "PROBLEM", 0, 24], ["HCV", "PROBLEM", 59, 62], ["several HCV proteins", "PROBLEM", 84, 104], ["viral spreading", "PROBLEM", 108, 123], ["tissue reorganization", "PROBLEM", 152, 173], ["adhesion complexes", "OBSERVATION", 6, 24], ["HCV", "OBSERVATION", 59, 62], ["several", "OBSERVATION_MODIFIER", 84, 91], ["HCV", "OBSERVATION", 92, 95], ["viral", "OBSERVATION_MODIFIER", 108, 113], ["spreading", "OBSERVATION_MODIFIER", 114, 123], ["cell-cell interaction", "OBSERVATION", 125, 146], ["tissue", "OBSERVATION_MODIFIER", 152, 158], ["reorganization", "OBSERVATION_MODIFIER", 159, 173]]], ["This analysis may thus help to identify potential new targets for HCV therapy.HerpesvirusesThe largest high-throughput approaches involving viruses have been performed with herpesviruses.", [["HCV", "ORGANISM", 66, 69], ["herpesviruses", "ORGANISM", 173, 186], ["HCV", "SPECIES", 66, 69], ["This analysis", "TEST", 0, 13], ["HCV therapy", "TREATMENT", 66, 77], ["Herpesviruses", "PROBLEM", 78, 91], ["viruses", "PROBLEM", 140, 147], ["herpesviruses", "PROBLEM", 173, 186], ["largest", "OBSERVATION_MODIFIER", 95, 102], ["high", "OBSERVATION_MODIFIER", 103, 107], ["viruses", "OBSERVATION", 140, 147]]], ["Equipped with moderately large-sized genomes encoding a manageable but complex set of genes these viruses represent the ideal candidates for genome-wide Y2H approaches followed by bioinformatical analysis.", [["moderately large-sized genomes", "PROBLEM", 14, 44], ["genes these viruses", "PROBLEM", 86, 105], ["bioinformatical analysis", "TEST", 180, 204], ["moderately", "OBSERVATION_MODIFIER", 14, 24], ["large", "OBSERVATION_MODIFIER", 25, 30], ["-sized", "OBSERVATION_MODIFIER", 30, 36], ["genomes", "OBSERVATION", 37, 44]]], ["Intraviral interactomes have been generated for several herpesviruses including the a-herpesviruses Global view of the interaction of two herpesviruses, VZV and KSHV, with the human proteome.", [["herpesviruses", "ORGANISM", 138, 151], ["VZV", "ORGANISM", 153, 156], ["KSHV", "ORGANISM", 161, 165], ["human", "ORGANISM", 176, 181], ["human", "SPECIES", 176, 181], ["VZV", "SPECIES", 153, 156], ["KSHV", "SPECIES", 161, 165], ["human", "SPECIES", 176, 181], ["Intraviral interactomes", "PROBLEM", 0, 23], ["several herpesviruses", "PROBLEM", 48, 69], ["VZV", "PROBLEM", 153, 156]]], ["Two experimental Y2H datasets were used to connect the two viral interactomes of VZV (red) and KSHV (pink) into a predicted high-confidence human interaction network consisting of 10 636 edges between 3169 nodes.", [["3169 nodes", "ANATOMY", 201, 211], ["VZV", "ORGANISM", 81, 84], ["KSHV", "ORGANISM", 95, 99], ["human", "ORGANISM", 140, 145], ["human", "SPECIES", 140, 145], ["VZV", "SPECIES", 81, 84], ["KSHV", "SPECIES", 95, 99], ["human", "SPECIES", 140, 145], ["Two experimental Y2H datasets", "TREATMENT", 0, 29], ["VZV", "PROBLEM", 81, 84], ["KSHV", "TEST", 95, 99], ["Y2H datasets", "OBSERVATION", 17, 29], ["viral interactomes", "OBSERVATION", 59, 77], ["VZV", "OBSERVATION", 81, 84], ["KSHV", "ANATOMY", 95, 99], ["nodes", "OBSERVATION", 206, 211]]], ["Interactions between viral proteins are depicted in red or orange, interactions to cellular proteins in blue.Herpesvirusesof five herpesviral species including 1007 intraviral interactions a core set of highly conserved protein interactions has been identified.", [["cellular", "ANATOMY", 83, 91], ["cellular", "CELL", 83, 91], ["viral proteins", "PROTEIN", 21, 35], ["cellular proteins", "PROTEIN", 83, 100], ["viral proteins", "PROBLEM", 21, 35], ["Herpesvirusesof five herpesviral species", "PROBLEM", 109, 149], ["herpesviral species", "OBSERVATION", 130, 149], ["protein interactions", "OBSERVATION", 220, 240]]], ["Intriguingly, the interactions between the orthologous proteins were found to be conserved independent of their sequence homology.", [["orthologous proteins", "PROTEIN", 43, 63], ["the orthologous proteins", "TEST", 39, 63]]], ["The topology of all herpesviral networks differed from cellular networks; however, it is difficult to judge whether this really reflects biological differences or artefacts caused by different setups used to evaluate them.", [["herpesviral networks", "ANATOMY", 20, 40], ["cellular networks", "ANATOMY", 55, 72], ["herpesviral networks", "MULTI-TISSUE_STRUCTURE", 20, 40], ["cellular networks", "MULTI-TISSUE_STRUCTURE", 55, 72], ["herpesviral networks", "PROTEIN", 20, 40], ["all herpesviral networks", "PROBLEM", 16, 40], ["artefacts", "PROBLEM", 163, 172], ["cellular networks", "OBSERVATION", 55, 72]]], ["In EBV [16 ] , HCV [18 ], VZV and KSHV (Haas and collaborators), and KSHV (Haas and collaborators) viral proteins tend to interact with highly connected cellular proteins, which could be a general hallmark of many pathogen-host interactions [40 ] .", [["cellular", "ANATOMY", 153, 161], ["EBV", "ORGANISM", 3, 6], ["HCV [18", "ORGANISM", 15, 22], ["VZV", "ORGANISM", 26, 29], ["KSHV", "ORGANISM", 34, 38], ["KSHV", "ORGANISM", 69, 73], ["cellular", "CELL", 153, 161], ["KSHV (Haas and collaborators) viral proteins", "PROTEIN", 69, 113], ["cellular proteins", "PROTEIN", 153, 170], ["HCV", "SPECIES", 15, 18], ["VZV", "SPECIES", 26, 29], ["KSHV", "SPECIES", 34, 38], ["KSHV", "SPECIES", 69, 73], ["HCV", "PROBLEM", 15, 18], ["VZV", "PROBLEM", 26, 29], ["KSHV", "PROBLEM", 34, 38], ["KSHV", "PROBLEM", 69, 73], ["viral proteins", "PROBLEM", 99, 113], ["highly connected cellular proteins", "PROBLEM", 136, 170], ["cellular proteins", "OBSERVATION", 153, 170]]], ["The datasets available to date are hampered by the low coverage of the Y2H screens performed, which makes it difficult to draw general biological conclusions.", [["the Y2H screens", "TEST", 67, 82]]], ["To reveal significant differences how different pathogens interact with the host proteome, protein interaction data with a considerably higher coverage of the screening space have to be generated.HerpesvirusesTo provide an example of the power of this approach, a comparison of the five herpesviral core networks identified the highly connected HSV-1 UL33 ortholog (VZV Orf25, mCMV M51, EBV BFRF4, and KSHV Orf67.5), which interacted with 14 tegument proteins (Figure 2 , E Fossum et al., in revision).", [["HSV-1", "ORGANISM", 345, 350], ["UL33", "GENE_OR_GENE_PRODUCT", 351, 355], ["VZV", "ORGANISM", 366, 369], ["Orf25", "GENE_OR_GENE_PRODUCT", 370, 375], ["mCMV M51", "ORGANISM", 377, 385], ["EBV", "ORGANISM", 387, 390], ["BFRF4", "GENE_OR_GENE_PRODUCT", 391, 396], ["herpesviral core networks", "PROTEIN", 287, 312], ["HSV-1 UL33 ortholog", "DNA", 345, 364], ["VZV Orf25", "PROTEIN", 366, 375], ["mCMV M51", "PROTEIN", 377, 385], ["EBV BFRF4", "DNA", 387, 396], ["tegument proteins", "PROTEIN", 442, 459], ["HSV-1", "SPECIES", 345, 350], ["HSV-1", "SPECIES", 345, 350], ["VZV", "SPECIES", 366, 369], ["mCMV", "SPECIES", 377, 381], ["significant differences how different pathogens", "PROBLEM", 10, 57], ["protein interaction data", "TEST", 91, 115], ["the screening space", "PROBLEM", 155, 174], ["HSV", "TEST", 345, 348], ["VZV", "TEST", 366, 369], ["mCMV", "TEST", 377, 381], ["EBV BFRF4", "TEST", 387, 396], ["KSHV Orf", "TEST", 402, 410], ["revision", "TREATMENT", 492, 500], ["significant", "OBSERVATION_MODIFIER", 10, 21]]], ["In addition, the interaction between UL33 orthologs and the HSV-1 UL31 orthologs (VZV Orf27, mCMV M53, EBV BFLF2, and KSHV Orf69) which in turn were found and previously published to interact with the HSV-1 UL34 orthologs (VZV Orf24, mCMV M50, EBV BFRF1, and KSHV Orf67) was highly conserved [41] [42] [43] [44] [45] .", [["UL33", "GENE_OR_GENE_PRODUCT", 37, 41], ["HSV-1", "ORGANISM", 60, 65], ["UL31", "GENE_OR_GENE_PRODUCT", 66, 70], ["VZV", "ORGANISM", 82, 85], ["Orf27", "GENE_OR_GENE_PRODUCT", 86, 91], ["mCMV M53", "ORGANISM", 93, 101], ["EBV", "ORGANISM", 103, 106], ["BFLF2", "GENE_OR_GENE_PRODUCT", 107, 112], ["KSHV", "ORGANISM", 118, 122], ["Orf69", "GENE_OR_GENE_PRODUCT", 123, 128], ["HSV-1", "ORGANISM", 201, 206], ["UL34", "GENE_OR_GENE_PRODUCT", 207, 211], ["VZV", "ORGANISM", 223, 226], ["Orf24", "GENE_OR_GENE_PRODUCT", 227, 232], ["mCMV M50", "GENE_OR_GENE_PRODUCT", 234, 242], ["EBV", "ORGANISM", 244, 247], ["BFRF1", "GENE_OR_GENE_PRODUCT", 248, 253], ["KSHV", "ORGANISM", 259, 263], ["Orf67", "GENE_OR_GENE_PRODUCT", 264, 269], ["UL33 orthologs", "DNA", 37, 51], ["HSV-1 UL31 orthologs", "DNA", 60, 80], ["VZV Orf27", "DNA", 82, 91], ["mCMV M53", "DNA", 93, 101], ["EBV BFLF2", "DNA", 103, 112], ["KSHV Orf69", "DNA", 118, 128], ["HSV-1 UL34 orthologs", "DNA", 201, 221], ["VZV Orf24", "DNA", 223, 232], ["mCMV M50", "DNA", 234, 242], ["EBV BFRF1", "DNA", 244, 253], ["KSHV Orf67", "DNA", 259, 269], ["HSV-1", "SPECIES", 60, 65], ["HSV-1", "SPECIES", 60, 65], ["VZV", "SPECIES", 82, 85], ["mCMV", "SPECIES", 93, 97], ["KSHV", "SPECIES", 118, 122], ["HSV-1", "SPECIES", 201, 206], ["VZV", "SPECIES", 223, 226], ["mCMV", "SPECIES", 234, 238], ["UL33 orthologs", "TEST", 37, 51], ["the HSV", "TEST", 56, 63], ["UL31 orthologs", "TEST", 66, 80], ["VZV", "TEST", 82, 85], ["Orf27", "TEST", 86, 91], ["mCMV", "TEST", 93, 97], ["EBV BFLF2", "TEST", 103, 112], ["KSHV Orf69", "TEST", 118, 128], ["the HSV", "TEST", 197, 204], ["VZV", "TEST", 223, 226], ["Orf24", "TEST", 227, 232], ["mCMV", "TEST", 234, 238], ["EBV BFRF1", "TEST", 244, 253], ["KSHV Orf67", "TEST", 259, 269]]], ["Likely these proteins form a large protein complex that mediates budding of capsids at the inner nuclear membrane of the host (Figure 4 ).", [["inner nuclear membrane", "ANATOMY", 91, 113], ["inner nuclear membrane", "CELLULAR_COMPONENT", 91, 113], ["protein complex", "PROTEIN", 35, 50], ["these proteins", "PROBLEM", 7, 21], ["a large protein complex", "PROBLEM", 27, 50], ["proteins", "OBSERVATION", 13, 21], ["large", "OBSERVATION_MODIFIER", 29, 34], ["protein complex", "OBSERVATION", 35, 50], ["capsids", "OBSERVATION_MODIFIER", 76, 83], ["inner", "ANATOMY_MODIFIER", 91, 96], ["nuclear membrane", "ANATOMY", 97, 113]]], ["The role of UL33 in DNA packaging and cleavage could point to a role in connecting capsid maturation with nuclear egress [46] .", [["nuclear", "ANATOMY", 106, 113], ["UL33", "GENE_OR_GENE_PRODUCT", 12, 16], ["DNA", "CELLULAR_COMPONENT", 20, 23], ["capsid", "CELLULAR_COMPONENT", 83, 89], ["nuclear", "CELLULAR_COMPONENT", 106, 113], ["UL33", "PROTEIN", 12, 16], ["UL33 in DNA packaging", "TREATMENT", 12, 33]]], ["This is in line with these proteins being crucial for capsid formation and nuclear egress [41, [46] [47] [48] [49] .", [["nuclear", "ANATOMY", 75, 82], ["capsid", "CELLULAR_COMPONENT", 54, 60], ["nuclear", "CELLULAR_COMPONENT", 75, 82], ["nuclear egress", "TEST", 75, 89]]], ["The identification of this protein complex thus demonstrates the potential of systems virology to reveal targets for alternative herpesviral therapies.", [["herpesviral", "ANATOMY", 129, 140], ["protein complex", "PROTEIN", 27, 42], ["this protein complex", "PROBLEM", 22, 42], ["alternative herpesviral therapies", "TREATMENT", 117, 150]]], ["This could be achieved by peptides or other small molecules introduced to interfere with targeting or assembly of the complex components.", [["complex components", "PROTEIN", 118, 136], ["other small molecules", "PROBLEM", 38, 59], ["small", "OBSERVATION_MODIFIER", 44, 49], ["molecules", "OBSERVATION", 50, 59], ["complex", "OBSERVATION_MODIFIER", 118, 125], ["components", "OBSERVATION_MODIFIER", 126, 136]]], ["Nuclear egress of HSV-1 capsids.", [["Nuclear", "ANATOMY", 0, 7], ["Nuclear", "CELLULAR_COMPONENT", 0, 7], ["HSV-1 capsids", "ORGANISM", 18, 31], ["HSV-1", "SPECIES", 18, 23], ["HSV-1", "SPECIES", 18, 23], ["Nuclear egress", "TEST", 0, 14], ["HSV", "TEST", 18, 21]]], ["Herpesviral capsids are formed in the host nucleus and released to the cytoplasm by budding through the nuclear envelope.", [["nucleus", "ANATOMY", 43, 50], ["cytoplasm", "ANATOMY", 71, 80], ["nuclear envelope", "ANATOMY", 104, 120], ["nucleus", "CELLULAR_COMPONENT", 43, 50], ["cytoplasm", "ORGANISM_SUBSTANCE", 71, 80], ["nuclear", "CELLULAR_COMPONENT", 104, 111], ["Herpesviral capsids", "PROBLEM", 0, 19], ["capsids", "OBSERVATION", 12, 19], ["host nucleus", "ANATOMY", 38, 50]]], ["Primary envelopment at the inner nuclear membrane (INM) requires the membrane anchored UL34/UL31 family of proteins.", [["inner nuclear membrane", "ANATOMY", 27, 49], ["INM", "ANATOMY", 51, 54], ["membrane", "ANATOMY", 69, 77], ["inner nuclear membrane", "CELLULAR_COMPONENT", 27, 49], ["INM", "CELLULAR_COMPONENT", 51, 54], ["membrane", "CELLULAR_COMPONENT", 69, 77], ["UL34", "GENE_OR_GENE_PRODUCT", 87, 91], ["UL31", "GENE_OR_GENE_PRODUCT", 92, 96], ["UL34", "PROTEIN", 87, 91], ["UL31 family", "PROTEIN", 92, 103], ["inner", "ANATOMY_MODIFIER", 27, 32], ["nuclear membrane", "ANATOMY", 33, 49]]], ["The UL33 protein family interacts with this nuclear egress complex and may connect capsid packaging and nuclear egress (ER: endoplasmic reticulum; INM: inner nuclear membrane; ONM: outer nuclear membrane; NPC: nuclear pore complex). these could be confirmed by CoP.", [["nuclear", "ANATOMY", 44, 51], ["nuclear", "ANATOMY", 104, 111], ["endoplasmic reticulum", "ANATOMY", 124, 145], ["INM", "ANATOMY", 147, 150], ["inner nuclear membrane", "ANATOMY", 152, 174], ["ONM", "ANATOMY", 176, 179], ["outer nuclear membrane", "ANATOMY", 181, 203], ["NPC", "ANATOMY", 205, 208], ["nuclear pore complex", "ANATOMY", 210, 230], ["UL33", "GENE_OR_GENE_PRODUCT", 4, 8], ["nuclear", "CELLULAR_COMPONENT", 44, 51], ["nuclear", "CELLULAR_COMPONENT", 104, 111], ["ER", "GENE_OR_GENE_PRODUCT", 120, 122], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 124, 145], ["INM", "CELLULAR_COMPONENT", 147, 150], ["inner nuclear membrane", "CELLULAR_COMPONENT", 152, 174], ["ONM", "CELLULAR_COMPONENT", 176, 179], ["outer nuclear membrane", "CELLULAR_COMPONENT", 181, 203], ["NPC", "CELLULAR_COMPONENT", 205, 208], ["nuclear pore complex", "GENE_OR_GENE_PRODUCT", 210, 230], ["UL33 protein family", "PROTEIN", 4, 23], ["nuclear egress complex", "PROTEIN", 44, 66], ["ER", "PROTEIN", 120, 122], ["INM", "PROTEIN", 147, 150], ["ONM", "PROTEIN", 176, 179], ["NPC", "PROTEIN", 205, 208], ["nuclear pore complex", "PROTEIN", 210, 230], ["capsid packaging", "TREATMENT", 83, 99], ["endoplasmic reticulum", "ANATOMY", 124, 145], ["inner", "ANATOMY_MODIFIER", 152, 157], ["nuclear membrane", "ANATOMY", 158, 174], ["nuclear membrane", "ANATOMY", 187, 203]]], ["The intraviral interaction network revealed network parameters similar to herpesviruses [15 ] and the combined published and experimental virus-host interactions suggest that SAR-S-CoV targets host functions like apoptosis, cell communication, and signaling.OutlookLarge-scale protein interaction screens are able to provide large amounts of novel and unbiased data, but the extraction of biological implications from these screens is difficult, particularly if they are based on a technology with a rather low coverage as the Y2H system.", [["intraviral", "ANATOMY", 4, 14], ["cell", "ANATOMY", 224, 228], ["SAR-S-CoV", "ORGANISM", 175, 184], ["cell", "CELL", 224, 228], ["Y2H", "PROTEIN", 527, 530], ["The intraviral interaction network", "TEST", 0, 34], ["network parameters", "PROBLEM", 44, 62], ["herpesviruses", "PROBLEM", 74, 87], ["experimental virus", "PROBLEM", 125, 143], ["SAR", "TEST", 175, 178], ["apoptosis", "PROBLEM", 213, 222], ["OutlookLarge-scale protein interaction screens", "TEST", 258, 304], ["unbiased data", "TEST", 352, 365], ["these screens", "TEST", 418, 431], ["a rather low coverage", "TREATMENT", 498, 519]]], ["In the near future, however, improved 'deep' screening technologies will lead to more comprehensive interaction maps of both intraviral and virus-host protein interactions, which, in combination with other genome-scale technologies like siRNA knock-down screens, transcriptional profiling, and spatial/temporal distribution studies may allow to setup improved models of virus-infected cells.", [["cells", "ANATOMY", 385, 390], ["cells", "CELL", 385, 390], ["virus-infected cells", "CELL_TYPE", 370, 390], ["host protein interactions", "PROBLEM", 146, 171], ["siRNA knock", "TEST", 237, 248], ["transcriptional profiling", "TEST", 263, 288], ["spatial/temporal distribution studies", "PROBLEM", 294, 331], ["virus", "PROBLEM", 370, 375], ["infected cells", "PROBLEM", 376, 390], ["infected cells", "OBSERVATION", 376, 390]]], ["The comparison of different viruses and, possibly, other pathogens may allow the identification of common strategies for infection and replication used by divergent pathogen groups, and the identification of targets for novel broad-spectrum antibiotics.", [["infection", "DISEASE", 121, 130], ["different viruses", "PROBLEM", 18, 35], ["other pathogens", "PROBLEM", 51, 66], ["infection", "PROBLEM", 121, 130], ["replication", "TREATMENT", 135, 146], ["novel broad-spectrum antibiotics", "TREATMENT", 220, 252], ["different", "OBSERVATION_MODIFIER", 18, 27], ["viruses", "OBSERVATION", 28, 35], ["infection", "OBSERVATION", 121, 130]]], ["On the other hand, it might reveal strategies that are specific for individual pathogens and help explain the characteristics of the infection with this particular pathogen.", [["infection", "DISEASE", 133, 142], ["individual pathogens", "PROBLEM", 68, 88], ["the infection", "PROBLEM", 129, 142], ["this particular pathogen", "PROBLEM", 148, 172], ["infection", "OBSERVATION", 133, 142]]], ["In combination with a genetic profiling of the infected host this approach will be even more powerful and might potentially lead to a step change in our understanding of viral infections.", [["viral infections", "DISEASE", 170, 186], ["a step change", "PROBLEM", 132, 145], ["viral infections", "PROBLEM", 170, 186], ["infected", "OBSERVATION", 47, 55], ["viral", "OBSERVATION_MODIFIER", 170, 175], ["infections", "OBSERVATION", 176, 186]]], ["A tool-box of high-throughput methods was tested for the validation of Y2H interactions including the mammalian protein-protein interaction trap (MAPPIT), the luminescence-based mammalian interactome (LUMIER), the yellow fluorescent protein (YFP) protein complementation assay (PCA), and the nucleic acid programmable protein array (NAPPA).", [["Y2H", "GENE_OR_GENE_PRODUCT", 71, 74], ["yellow fluorescent protein", "GENE_OR_GENE_PRODUCT", 214, 240], ["YFP", "GENE_OR_GENE_PRODUCT", 242, 245], ["mammalian protein-protein interaction trap", "PROTEIN", 102, 144], ["MAPPIT", "PROTEIN", 146, 152], ["LUMIER", "PROTEIN", 201, 207], ["yellow fluorescent protein", "PROTEIN", 214, 240], ["YFP", "PROTEIN", 242, 245], ["nucleic acid programmable protein array", "PROTEIN", 292, 331], ["NAPPA", "PROTEIN", 333, 338], ["A tool", "TEST", 0, 6], ["the mammalian protein", "TREATMENT", 98, 119], ["the luminescence", "TEST", 155, 171], ["the yellow fluorescent protein", "TEST", 210, 240], ["protein complementation assay", "TEST", 247, 276], ["PCA", "TEST", 278, 281], ["the nucleic acid programmable protein array", "TREATMENT", 288, 331]]], ["This analysis aims at defining a confidence score for binary proteinprotein interactions.", [["proteinprotein", "GENE_OR_GENE_PRODUCT", 61, 75], ["This analysis", "TEST", 0, 13], ["a confidence score", "TEST", 31, 49], ["binary proteinprotein interactions", "PROBLEM", 54, 88]]], ["These two sets of data define high-quality binary interaction maps of yeast and human protein networks.", [["human", "ORGANISM", 80, 85], ["yeast and human protein networks", "PROTEIN", 70, 102], ["yeast", "SPECIES", 70, 75], ["human", "SPECIES", 80, 85], ["yeast", "SPECIES", 70, 75], ["human", "SPECIES", 80, 85], ["yeast and human protein networks", "PROBLEM", 70, 102]]], ["In particular, these datasets suggest that the Y2H data are more reliable than generally believed and that the Y2H screens currently performed suffer from low sensitivity rather than low specificity.", [["the Y2H data", "TEST", 43, 55], ["the Y2H screens", "TEST", 107, 122], ["low sensitivity", "PROBLEM", 155, 170]]], ["Moreover, the distinct nature of binary versus cocomplex derived interactions is pointed out.", [["cocomplex derived interactions", "PROBLEM", 47, 77], ["distinct", "OBSERVATION_MODIFIER", 14, 22], ["binary", "OBSERVATION_MODIFIER", 33, 39]]], ["These two sets of data define high-quality binary interaction maps of yeast and human protein networks.", [["human", "ORGANISM", 80, 85], ["yeast and human protein networks", "PROTEIN", 70, 102], ["yeast", "SPECIES", 70, 75], ["human", "SPECIES", 80, 85], ["yeast", "SPECIES", 70, 75], ["human", "SPECIES", 80, 85], ["yeast and human protein networks", "PROBLEM", 70, 102]]], ["In particular, these datasets suggest that the Y2H data are more reliable than generally believed and that the Y2H screens currently performed suffer from low sensitivity rather than low specificity.", [["the Y2H data", "TEST", 43, 55], ["the Y2H screens", "TEST", 107, 122], ["low sensitivity", "PROBLEM", 155, 170]]], ["Moreover, the distinct nature of binary versus cocomplex derived interactions is pointed out.", [["cocomplex derived interactions", "PROBLEM", 47, 77], ["distinct", "OBSERVATION_MODIFIER", 14, 22], ["binary", "OBSERVATION_MODIFIER", 33, 39]]], ["Curation of protein interactions from literature is a method applied to obtain comprehensive protein networks.", [["protein networks", "PROTEIN", 93, 109], ["a method", "TREATMENT", 52, 60], ["comprehensive protein networks", "TREATMENT", 79, 109]]], ["However this analysis critically evaluates the current literature curation and shows that it is more errorprone and possibly of lower quality than generally assumed.", [["this analysis", "TEST", 8, 21], ["lower quality", "OBSERVATION_MODIFIER", 128, 141]]]], "PMC7133792": [["IntroductionLes pathologies infectieuses respiratoires sont fr\u00e9quemment rencontr\u00e9es dans la communaut\u00e9 et g\u00e9n\u00e9ralement de gravit\u00e9 l\u00e9g\u00e8re ou mod\u00e9r\u00e9e.", [["IntroductionLes pathologies infectieuses", "PROBLEM", 0, 40]]], ["Les agents responsables sont, dans la plupart des cas, de type viral avec parmi eux : les virus influenza et para-influenza, le virus respiratoire syncytial, les rhinovirus, les coronavirus, et les ad\u00e9novirus ; les herp\u00e8s virus ne sont que tr\u00e8s rarement rencontr\u00e9s dans ce contexte.", [["les virus influenza et para-influenza", "PROBLEM", 86, 123], ["le virus respiratoire syncytial", "PROBLEM", 125, 156], ["les rhinovirus", "PROBLEM", 158, 172], ["les coronavirus", "PROBLEM", 174, 189], ["et les ad\u00e9novirus", "PROBLEM", 191, 208], ["les herp\u00e8s virus", "PROBLEM", 211, 227], ["les", "ANATOMY", 86, 89], ["le virus", "ANATOMY", 125, 133], ["les rhinovirus", "ANATOMY", 158, 172], ["les coronavirus", "ANATOMY", 174, 189]]], ["Parmi ces pathog\u00e8nes, seuls quelques uns sont capables d'induire des tableaux s\u00e9v\u00e8res dont le diagnostic comme la prise en charge sont assez difficiles \u00e0 r\u00e9aliser.", [["Parmi ces pathog\u00e8nes", "PROBLEM", 0, 20]]], ["S'il est relativement ais\u00e9 d'obtenir un diagnostic \u00e9tiologique pour une infection bact\u00e9rienne, cette \u00e9tape est d\u00e9licate en cas d'infection virale et rend d'autant plus difficile la prise en charge de ces pathologies.", [["infection bact\u00e9rienne", "DISEASE", 72, 93], ["pour une infection bact\u00e9rienne", "TREATMENT", 63, 93], ["cette \u00e9tape", "TREATMENT", 95, 106], ["infection", "PROBLEM", 129, 138], ["et rend d'autant", "TREATMENT", 146, 162], ["difficile la", "PROBLEM", 168, 180]]], ["Ces pneumonies restent malgr\u00e9 tout rares chez l'immunocomp\u00e9tent, et doivent syst\u00e9matiquement faire rechercher une pathologie ou un traitement immunosuppresseur si le diagnostic est confirm\u00e9 : en dehors de la grippe et de la pneumonie \u00e0 SRAS-coronavirus, une infection par un herp\u00e8s virus, un rhinovirus ou autre est relativement exceptionnelle chez l'immunocomp\u00e9tent.", [["infection", "DISEASE", 258, 267], ["Ces pneumonies", "PROBLEM", 0, 14], ["malgr\u00e9", "PROBLEM", 23, 29], ["SRAS", "PROBLEM", 236, 240], ["coronavirus", "PROBLEM", 241, 252], ["une infection par un herp\u00e8s virus", "PROBLEM", 254, 287], ["rhinovirus", "PROBLEM", 292, 302]]], ["Le r\u00f4le des virus dans les pneumonies graves est toujours difficile \u00e0 confirmer.", [["Le r\u00f4le des virus dans les pneumonies", "TEST", 0, 37], ["difficile", "PROBLEM", 58, 67]]], ["Cette revue va se focaliser sur les diff\u00e9rents agents pouvant \u00eatre impliqu\u00e9s et les caract\u00e9ristiques, tant cliniques que biologiques, permettant de les caract\u00e9riser.\u00c9pid\u00e9miologie ::: Le cytom\u00e9galovirus (CMV) ::: Les herp\u00e8s virusLe CMV est un membre de la famille des herp\u00e8s virus ; ce virus \u00e0 ADN poss\u00e8de un g\u00e9nome constitu\u00e9 de 230 kb qui en fait le plus important des herp\u00e8s virus.", [["Le cytom\u00e9galovirus", "ORGANISM", 183, 201], ["CMV", "ORGANISM", 203, 206], ["Les herp\u00e8s virusLe", "TEST", 212, 230], ["CMV est", "TEST", 231, 238], ["ce virus", "TEST", 282, 290]]], ["L'infection \u00e0 CMV est fr\u00e9quente dans la population g\u00e9n\u00e9rale avec un niveau de s\u00e9ropr\u00e9valence report\u00e9 entre 40 \u00e0 100 % ; la distribution en fonction de l'\u00e2ge est bimodale et deux pics sont d\u00e9crits : le premier dans la petite enfance t\u00e9moigne d'une transmission verticale qui peut \u00eatre rattach\u00e9e \u00e0 l'allaitement maternel [1], [2].", [["infection", "DISEASE", 2, 11], ["CMV", "ORGANISM", 14, 17], ["L'infection", "PROBLEM", 0, 11], ["CMV est", "TEST", 14, 21], ["entre", "TEST", 101, 106], ["est bimodale", "TEST", 157, 169], ["infection", "OBSERVATION", 2, 11]]], ["Le second pic de s\u00e9roconversion survient chez le jeune adulte, la transmission est essentiellement d'origine sexuelle [3].", [["Le second pic de s\u00e9roconversion survient chez le jeune adulte", "TREATMENT", 0, 61]]], ["La r\u00e9ponse \u00e0 l'infection li\u00e9e au CMV fait intervenir \u00e0 la fois l'immunit\u00e9 cellulaire et l'immunit\u00e9 humorale ; cependant l'absence d'immunit\u00e9 cellulaire repr\u00e9sente le facteur pr\u00e9disposant le plus important des infections li\u00e9es \u00e0 ce pathog\u00e8ne.", [["La r\u00e9ponse", "TEST", 0, 10], ["l'infection", "TEST", 13, 24], ["li\u00e9e", "TEST", 25, 29], ["CMV", "TEST", 33, 36], ["fait", "TEST", 37, 41], ["intervenir", "TEST", 42, 52], ["et l'immunit\u00e9 humorale", "TREATMENT", 85, 107], ["cependant l'absence", "TREATMENT", 110, 129]]], ["Pour cette raison, l'infection \u00e0 CMV est g\u00e9n\u00e9ralement rencontr\u00e9e en pathologie h\u00e9matologique, dans un contexte de transplantation ou en cas d'infection VIH \u00e9volu\u00e9e.", [["infection", "DISEASE", 142, 151], ["Pour cette raison, l'infection \u00e0 CMV est g\u00e9n\u00e9ralement rencontr\u00e9e en pathologie h\u00e9matologique, dans un contexte de transplantation ou en cas d'infection VIH \u00e9volu\u00e9e", "SPECIES", 0, 163], ["Pour cette raison", "TREATMENT", 0, 17], ["l'infection", "PROBLEM", 19, 30], ["CMV est g\u00e9n\u00e9ralement", "TREATMENT", 33, 53]]], ["Comme pour les autres infections \u00e0 herp\u00e8s virus, au d\u00e9cours de la primo-infection, le CMV demeure ind\u00e9finiment latent chez l'h\u00f4te, pouvant \u00eatre \u00e0 l'origine de r\u00e9activation et de r\u00e9infections successives dans le temps [4], [5].", [["Comme pour les autres infections", "PROBLEM", 0, 32], ["herp\u00e8s virus", "PROBLEM", 35, 47], ["dans le temps", "TEST", 203, 216]]], ["Le m\u00e9canisme exact de la r\u00e9activation n'est pas encore totalement \u00e9lucid\u00e9 mais r\u00e9sulte le plus souvent d'une alt\u00e9ration de la balance entre les d\u00e9fenses de l'h\u00f4te et le virus latent expliquant le caract\u00e8re exceptionnel des infections respiratoires \u00e0 CMV chez l'adulte immunocomp\u00e9tent [6].", [["infections", "DISEASE", 223, 233], ["pas", "TEST", 44, 47], ["souvent d'une alt\u00e9ration", "TREATMENT", 95, 119], ["et le virus", "TREATMENT", 163, 174], ["le caract\u00e8re exceptionnel des", "TREATMENT", 193, 222], ["infections", "PROBLEM", 223, 233], ["respiratoires", "TEST", 234, 247]]], ["Dans la greffe de moelle allog\u00e9nique, la pneumonie \u00e0 CMV survient dans 10 \u00e0 20 % des cas avec une mortalit\u00e9 estim\u00e9e \u00e0 50 % [7].CMV et r\u00e9animation ::: Le cytom\u00e9galovirus (CMV) ::: Les herp\u00e8s virusLe patient hospitalis\u00e9 en r\u00e9animation pose n\u00e9anmoins un probl\u00e8me particulier car ne pouvant \u00eatre consid\u00e9r\u00e9 comme totalement immunocomp\u00e9tent.", [["CMV", "ORGANISM", 127, 130], ["Le cytom\u00e9galovirus", "ORGANISM", 150, 168], ["CMV", "ORGANISM", 170, 173], ["patient", "ORGANISM", 198, 205], ["patient", "SPECIES", 198, 205], ["CMV", "SPECIES", 127, 130], ["la pneumonie", "TREATMENT", 38, 50], ["CMV survient dans", "TREATMENT", 53, 70]]], ["Diff\u00e9rentes \u00e9tudes ont essay\u00e9 d'\u00e9valuer la fr\u00e9quence de survenue des infections \u00e0 CMV au sein de ce sous-groupe de patients : Papazian et al. rapportent les r\u00e9sultats obtenus sur une s\u00e9rie de 60 n\u00e9cropsies et 26 biopsies pulmonaires de patients atteints de pneumonies nosocomiales ou pr\u00e9sentant une d\u00e9tresse respiratoire aigu\u00eb [8].", [["infections", "DISEASE", 69, 79], ["patients", "ORGANISM", 115, 123], ["patients", "ORGANISM", 236, 244], ["patients", "SPECIES", 115, 123], ["patients", "SPECIES", 236, 244]]], ["La pneumonie \u00e0 CMV a \u00e9t\u00e9 confirm\u00e9e chez 25 patients, la symptomatologie clinique \u00e9tait totalement atypique dans la plupart des cas, ce sous-groupe de patients pr\u00e9sentait n\u00e9anmoins une hypox\u00e9mie plus s\u00e9v\u00e8re et une atteinte radiologique plus importante.", [["CMV", "ORGANISM", 15, 18], ["patients", "ORGANISM", 43, 51], ["patients", "ORGANISM", 150, 158], ["patients", "SPECIES", 43, 51], ["patients", "SPECIES", 150, 158], ["La pneumonie", "PROBLEM", 0, 12], ["une hypox\u00e9mie", "PROBLEM", 180, 193], ["CMV", "OBSERVATION", 15, 18]]], ["La force de cette \u00e9tude repose sur l'utilisation de crit\u00e8res histologiques dans le diagnostic de l'infection \u00e0 CMV.", [["CMV", "ORGANISM", 111, 114], ["CMV", "PROBLEM", 111, 114]]], ["En concordance avec ces r\u00e9sultats, Heninger et al., dans une unit\u00e9 de r\u00e9animation chirurgicale ont suivi 56 patients porteurs d'IgG anti-CMV au cours de leur hospitalisation [9].", [["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116]]], ["Une fois par semaine, la recherche de CMV \u00e9tait r\u00e9alis\u00e9e par PCR et culture virale \u00e0 partir d'\u00e9chantillons sanguins et respiratoires.", [["CMV", "ORGANISM", 38, 41], ["Une fois par semaine", "TEST", 0, 20], ["la recherche", "TEST", 22, 34], ["CMV", "TEST", 38, 41], ["par PCR", "TEST", 57, 64], ["et culture", "TEST", 65, 75], ["virale", "TEST", 76, 82], ["\u00e0", "TEST", 83, 84], ["partir", "TEST", 85, 91]]], ["Vingt patients ont d\u00e9velopp\u00e9 une infection active ; pour sept d'entre eux, le virus fut isol\u00e9 des s\u00e9cr\u00e9tions respiratoires.", [["infection", "DISEASE", 33, 42], ["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["patients ont d\u00e9velopp\u00e9 une infection", "PROBLEM", 6, 42], ["entre eux", "TEST", 64, 73], ["le virus", "PROBLEM", 75, 83], ["infection", "OBSERVATION", 33, 42], ["le virus", "ANATOMY", 75, 83]]], ["Le seul facteur de risque mis en \u00e9vidence par l'analyse multivari\u00e9e \u00e9tait l'existence d'un sepsis (Odds ratio : 4,62).", [["sepsis", "DISEASE", 91, 97], ["sepsis", "PROBLEM", 91, 97], ["sepsis", "OBSERVATION", 91, 97]]], ["D'autres publications avaient aussi retrouv\u00e9 le sepsis comme facteur favorisant d'une r\u00e9activation de l'infection \u00e0 CMV avec des pourcentages variant entre 45 et 97 % [10], [11].", [["sepsis", "DISEASE", 48, 54], ["le sepsis", "PROBLEM", 45, 54], ["sepsis", "OBSERVATION", 48, 54]]], ["Le m\u00e9canisme responsable de la r\u00e9activation d'une infection \u00e0 CMV latente impliquerait l'existence d'un d\u00e9s\u00e9quilibre de la r\u00e9ponse immune induit par une augmentation de production du TNF-\u03b1 [10].", [["infection", "DISEASE", 50, 59], ["TNF", "GENE_OR_GENE_PRODUCT", 183, 186], ["TNF", "PROTEIN", 183, 186], ["d'une infection", "PROBLEM", 44, 59], ["CMV latente", "TREATMENT", 62, 73], ["d\u00e9s\u00e9quilibre de la r\u00e9ponse immune induit par une augmentation", "TREATMENT", 104, 165]]], ["D'autres facteurs pourraient aussi \u00eatre mis en cause comme l'existence d'une chirurgie ou d'une anesth\u00e9sie qui ont toutes deux montr\u00e9 leur capacit\u00e9 \u00e0 alt\u00e9rer la r\u00e9ponse immunitaire [12], [13].", [["capacit\u00e9", "TEST", 139, 147]]], ["De la m\u00eame mani\u00e8re, la transfusion de produits sanguins contenant des leucocytes a \u00e9t\u00e9 impliqu\u00e9e [14].La culture virale ::: Signes cliniques et diagnostic positif ::: Le cytom\u00e9galovirus (CMV) ::: Les herp\u00e8s virusLe CMV est cultiv\u00e9 de fa\u00e7on traditionnelle sur culture de fibroblastes o\u00f9 il produit un effet cytopathog\u00e8ne caract\u00e9ristique confirm\u00e9 par technique de fluorescence.", [["Le cytom\u00e9galovirus", "ORGANISM", 167, 185], ["CMV", "ORGANISM", 187, 190], ["leucocytes", "CELL_TYPE", 70, 80], ["la transfusion", "TREATMENT", 20, 34], ["La culture", "TEST", 102, 112], ["Les herp\u00e8s virusLe", "TEST", 196, 214], ["CMV est cultiv\u00e9", "TEST", 215, 230], ["sur culture", "TEST", 255, 266]]], ["Sa sensibilit\u00e9 est inf\u00e9rieure \u00e0 celle de la PCR.", [["Sa sensibilit\u00e9 est inf\u00e9rieure", "TEST", 0, 29], ["celle de la PCR", "TEST", 32, 47]]], ["Une certaine am\u00e9lioration de la technique dite \u00ab rapide \u00bb a permis de diminuer la dur\u00e9e de culture \u00e0 48 heures en r\u00e9alisant une centrifugation des \u00e9chantillons sur une monocouche de fibroblastes avant la recherche de l'effet cytopathog\u00e8ne par anticorps monoclonaux [15].La d\u00e9tection des acides nucl\u00e9iques ::: Signes cliniques et diagnostic positif ::: Le cytom\u00e9galovirus (CMV) ::: Les herp\u00e8s virusLes m\u00e9thodes de type PCR sont utilis\u00e9es de fa\u00e7on de plus en plus syst\u00e9matique pour documenter une infection \u00e0 CMV.", [["infection", "DISEASE", 495, 504], ["Le cytom\u00e9galovirus", "ORGANISM", 352, 370], ["CMV", "ORGANISM", 372, 375], ["CMV", "ORGANISM", 507, 510], ["de culture", "TEST", 88, 98], ["heures en r\u00e9alisant une centrifugation des", "TREATMENT", 104, 146], ["Les herp\u00e8s virusLes", "TEST", 381, 400], ["une infection", "PROBLEM", 491, 504], ["CMV", "PROBLEM", 507, 510], ["une infection", "OBSERVATION", 491, 504]]], ["Les r\u00e9sultats sont cependant assez h\u00e9t\u00e9rog\u00e8nes d'une publication \u00e0 l'autre et en fonction du type d'\u00e9chantillon analys\u00e9.", [["du type d'\u00e9chantillon analys\u00e9", "TREATMENT", 90, 119]]], ["Dans une \u00e9tude regroupant 363 patients atteints de pneumonie interstitielle, la PCR CMV s'est av\u00e9r\u00e9e positive pour 58 des 882 \u00e9chantillons test\u00e9s [16].", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["la PCR", "TEST", 77, 83], ["CMV s", "TEST", 84, 89], ["\u00e9chantillons test\u00e9s", "TEST", 126, 145]]], ["En prenant l'histologie comme \u00ab gold standard \u00bb, les auteurs ont ainsi pu calculer une VPP et VPN de respectivement 100 et 98,8 % pour le LBA, la sensibilit\u00e9 et la sp\u00e9cificit\u00e9 \u00e9tant de 90,9 et 100 % pour ce m\u00eame pr\u00e9l\u00e8vement.", [["les", "TEST", 49, 52], ["et", "TEST", 120, 122], ["pour le LBA", "TEST", 130, 141], ["la sensibilit\u00e9", "TEST", 143, 157]]], ["Si l'analyse \u00e9tait r\u00e9alis\u00e9e sur un pr\u00e9l\u00e8vement non prot\u00e9g\u00e9, une l\u00e9g\u00e8re diminution de ces valeurs \u00e9tait observ\u00e9e, la VPN demeurant n\u00e9anmoins \u00e0 99,7 % et la sp\u00e9cificit\u00e9 \u00e0 99,7 %.", [["Si", "CHEMICAL", 0, 2], ["et la sp\u00e9cificit\u00e9", "TEST", 149, 166]]], ["Ces r\u00e9sultats particuli\u00e8rement int\u00e9ressants placent cette technique comme l'une des mieux adapt\u00e9es au diagnostic d'infection \u00e0 CMV.La d\u00e9tection d'antig\u00e8ne ::: Signes cliniques et diagnostic positif ::: Le cytom\u00e9galovirus (CMV) ::: Les herp\u00e8s virusD\u00e9velopp\u00e9e en 1988 chez l'immunod\u00e9prim\u00e9, la d\u00e9tection d'antig\u00e8ne pp65 dans les leucocytes a montr\u00e9 une meilleure sensibilit\u00e9 et une valeur pr\u00e9dictive plus int\u00e9ressante que la culture [17].", [["infection \u00e0 CMV", "DISEASE", 115, 130], ["CMV", "ORGANISM", 127, 130], ["Le cytom\u00e9galovirus", "ORGANISM", 202, 220], ["CMV", "ORGANISM", 222, 225], ["leucocytes", "ORGANISM_SUBSTANCE", 326, 336], ["leucocytes", "CELL_TYPE", 326, 336], ["CMV", "PROBLEM", 127, 130], ["chez l'immunod\u00e9prim\u00e9", "TEST", 266, 286], ["la d\u00e9tection", "TEST", 288, 300], ["dans les leucocytes", "TEST", 317, 336], ["a montr\u00e9 une meilleure", "TEST", 337, 359], ["et une valeur", "TEST", 372, 385], ["que la culture", "TEST", 415, 429]]], ["Son rendement est optimal sur le sang et le LCR, sa sensibilit\u00e9 initialement rapport\u00e9e \u00e0 100 % pour le LBA a \u00e9t\u00e9 depuis revue \u00e0 la baisse [15].L'histologie ::: Signes cliniques et diagnostic positif ::: Le cytom\u00e9galovirus (CMV) ::: Les herp\u00e8s virusLes inclusions intranucl\u00e9aires sont pathognomoniques d'infection \u00e0 CMV, elles peuvent \u00eatre retrouv\u00e9es au niveau du poumon, du c\u00f4lon, de l'\u0153sophage, ou du foie.", [["infection \u00e0 CMV", "DISEASE", 303, 318], ["Le cytom\u00e9galovirus", "ORGANISM", 203, 221], ["CMV", "ORGANISM", 223, 226], ["Les herp\u00e8s virusLes", "TEST", 232, 251], ["d'infection", "PROBLEM", 301, 312], ["CMV", "PROBLEM", 315, 318]]], ["La recherche de ces inclusions sur les cellules obtenues par un LBA a \u00e9t\u00e9 propos\u00e9e par Cordonnier et al., ces auteurs retrouvant une sup\u00e9riorit\u00e9 de cette analyse compar\u00e9e \u00e0 la biopsie pulmonaire [18].La s\u00e9rologie ::: Signes cliniques et diagnostic positif ::: Le cytom\u00e9galovirus (CMV) ::: Les herp\u00e8s virusD'un int\u00e9r\u00eat tr\u00e8s limit\u00e9, la s\u00e9rologie peut trouver une place dans la primo-infection.", [["Le cytom\u00e9galovirus", "ORGANISM", 260, 278], ["CMV", "ORGANISM", 280, 283], ["Les herp\u00e8s", "TEST", 289, 299], ["la s\u00e9rologie", "TEST", 331, 343]]], ["La pr\u00e9sence d'IgM peut aussi \u00eatre observ\u00e9e dans une r\u00e9activation, manquer chez l'immunod\u00e9prim\u00e9, ou enfin persister jusqu'\u00e0 une ann\u00e9e chez certains patients.", [["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 147, 155]]], ["L'ensemble de ces facteurs limite donc consid\u00e9rablement l'int\u00e9r\u00eat de cette technique.Traitement ::: Le cytom\u00e9galovirus (CMV) ::: Les herp\u00e8s virusLa prise en charge d'une infection \u00e0 CMV repose sur l'utilisation d'une chimioth\u00e9rapie sp\u00e9cifique, trois produits sont actuellement disponibles :\u2022le ganciclovir est un analogue nucl\u00e9osidique inhibiteur de l'HCMV DNA polym\u00e9rase.", [["infection", "DISEASE", 170, 179], ["ganciclovir", "CHEMICAL", 294, 305], ["Le cytom\u00e9galovirus", "ORGANISM", 100, 118], ["CMV", "ORGANISM", 120, 123], ["HCMV", "ORGANISM", 352, 356], ["HCMV", "SPECIES", 352, 356], ["Les herp\u00e8s virus", "PROBLEM", 129, 145], ["d'une infection", "PROBLEM", 164, 179], ["\u2022le ganciclovir", "TREATMENT", 290, 305], ["HCMV DNA polym\u00e9rase", "TREATMENT", 352, 371]]], ["Il est g\u00e9n\u00e9ralement administr\u00e9 \u00e0 la dose de 5 mg/kg par 12 heures en traitement d'attaque ;\u2022le foscarnet est un inhibiteur de la DNA polym\u00e9rase, il est administr\u00e9 \u00e0 la dose de 90 mg/kg par 12 heures en traitement d'attaque en intraveineux ;\u2022le cidofovir est un analogue nucl\u00e9osidique inhibant la DNA polym\u00e9rase virale.", [["cidofovir", "CHEMICAL", 244, 253], ["cidofovir", "CHEMICAL", 244, 253], ["Il est g\u00e9n\u00e9ralement", "TREATMENT", 0, 19], ["en traitement d'attaque", "TREATMENT", 66, 89], ["\u2022le foscarnet est un inhibiteur de la DNA polym\u00e9rase", "TREATMENT", 91, 143], ["en traitement d'attaque", "TREATMENT", 199, 222], ["en intraveineux", "TREATMENT", 223, 238], ["\u2022le cidofovir est un analogue", "TREATMENT", 240, 269]]]], "438a7c0ba9653dfc8079fc4334e0426d8426fc2f": [["In the age of Covid-19, surgeons are facing some challenges when deciding to perform or postpone elective operations.", [["postpone elective operations", "TREATMENT", 88, 116]]], ["They reported the overall hospital mortality following selective surgeries during the incubation period of COVID-19 as 20.5%.", [["selective surgeries", "TREATMENT", 55, 74], ["COVID", "TEST", 107, 112]]]], "PMC7220291": []}